<?xml version="1.0" encoding="UTF-8"?>
<aggregateKnowledgeResponse xmlns="http://www.w3.org/2005/Atom">
	<feed>
		<title>Management of persistent hyperglycemia in type 2 diabetes mellitus</title>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C1261381" scheme="gov.nih.nlm.semanticType.topp" label="destruction"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0643010" scheme="gov.nih.nlm.semanticType.phsu" label="ADA"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="add"/>
		<category term="C0017642" scheme="gov.nih.nlm.semanticType.phsu" label="glipizide"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
		<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
		<category term="C0246689" scheme="gov.nih.nlm.semanticType.phsu" label="repaglinide"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0023767" scheme="gov.nih.nlm.semanticType.imft" label="lipid"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0086466" scheme="gov.nih.nlm.semanticType.phsu" label="injectable"/>
		<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0014361" scheme="gov.nih.nlm.semanticType.horm" label="glucagon-like peptide"/>
		<category term="C0017687" scheme="gov.nih.nlm.semanticType.horm" label="glucagon"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0243192" scheme="gov.nih.nlm.semanticType.phsu" label="agonist"/>
		<category term="C0669693" scheme="gov.nih.nlm.semanticType.orch" label="DPP"/>
		<category term="C0763866" scheme="gov.nih.nlm.semanticType.aapp" label="GLP"/>
		<category term="C2354520" scheme="gov.nih.nlm.semanticType.aapp" label="peptide"/>
		<category term="C0631314" scheme="gov.nih.nlm.semanticType.phsu" label="CHF"/>
		<category term="C2605394" scheme="gov.nih.nlm.semanticType.orch" label="Thiazolidinediones"/>
		<category term="C0023767" scheme="gov.nih.nlm.semanticType.imft" label="lipid"/>
		<category term="C0289313" scheme="gov.nih.nlm.semanticType.phsu" label="rosiglitazone"/>
		<category term="C0071097" scheme="gov.nih.nlm.semanticType.phsu" label="pioglitazone"/>
		<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="add"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
		<category term="C0669693" scheme="gov.nih.nlm.semanticType.orch" label="DPP"/>
		<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
		<category term="C2605394" scheme="gov.nih.nlm.semanticType.orch" label="thiazolidinedione"/>
		<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="add"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0014361" scheme="gov.nih.nlm.semanticType.horm" label="glucagon-like peptide"/>
		<category term="C0017687" scheme="gov.nih.nlm.semanticType.horm" label="glucagon"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0669693" scheme="gov.nih.nlm.semanticType.orch" label="DPP"/>
		<category term="C0763866" scheme="gov.nih.nlm.semanticType.aapp" label="GLP"/>
		<category term="C1979844" scheme="gov.nih.nlm.semanticType.aapp" label="alpha"/>
		<category term="C2354520" scheme="gov.nih.nlm.semanticType.aapp" label="peptide"/>
		<category term="C2605394" scheme="gov.nih.nlm.semanticType.orch" label="thiazolidinediones"/>
		<category term="C3539108" scheme="gov.nih.nlm.semanticType.phsu" label="alpha-glucosidase inhibitors"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0432616" scheme="gov.nih.nlm.semanticType.imft" label="anti"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="Insulin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0907402" scheme="gov.nih.nlm.semanticType.horm" label="insulin glargine"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C1565750" scheme="gov.nih.nlm.semanticType.phsu" label="sitagliptin"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="Insulin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="Metformin"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
		<category term="C0017628" scheme="gov.nih.nlm.semanticType.phsu" label="glyburide"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0017642" scheme="gov.nih.nlm.semanticType.phsu" label="glipizide"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0071097" scheme="gov.nih.nlm.semanticType.phsu" label="pioglitazone"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0071097" scheme="gov.nih.nlm.semanticType.phsu" label="pioglitazone"/>
		<category term="C0023767" scheme="gov.nih.nlm.semanticType.imft" label="lipid"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
		<category term="C0071097" scheme="gov.nih.nlm.semanticType.phsu" label="pioglitazone"/>
		<category term="C0289313" scheme="gov.nih.nlm.semanticType.phsu" label="rosiglitazone"/>
		<category term="C0643010" scheme="gov.nih.nlm.semanticType.phsu" label="ADA"/>
		<category term="C1450229" scheme="gov.nih.nlm.semanticType.orch" label="TZD"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0017628" scheme="gov.nih.nlm.semanticType.phsu" label="glyburide"/>
		<category term="C0020616" scheme="gov.nih.nlm.semanticType.phsu" label="hypoglycemic"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimens"/>
		<category term="C0903898" scheme="gov.nih.nlm.semanticType.phsu" label="nateglinide"/>
		<category term="C0939773" scheme="gov.nih.nlm.semanticType.phsu" label="glyburide/metformin"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
		<category term="C0643010" scheme="gov.nih.nlm.semanticType.phsu" label="ADA"/>
		<category term="C0645690" scheme="gov.nih.nlm.semanticType.phsu" label="brand"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
		<category term="C0071097" scheme="gov.nih.nlm.semanticType.phsu" label="pioglitazone"/>
		<category term="C0071097" scheme="gov.nih.nlm.semanticType.phsu" label="pioglitazone"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0029151" scheme="gov.nih.nlm.semanticType.topp" label="pills"/>
		<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="Insulin"/>
		<category term="C0643010" scheme="gov.nih.nlm.semanticType.phsu" label="ADA"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="add"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0020616" scheme="gov.nih.nlm.semanticType.phsu" label="hypoglycemic"/>
		<category term="C0359086" scheme="gov.nih.nlm.semanticType.phsu" label="oral hypoglycemic"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0020616" scheme="gov.nih.nlm.semanticType.phsu" label="hypoglycemic"/>
		<category term="C0359086" scheme="gov.nih.nlm.semanticType.phsu" label="oral hypoglycemic"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C1445141" scheme="gov.nih.nlm.semanticType.phsu" label="combination oral hypoglycemic"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0199782" scheme="gov.nih.nlm.semanticType.topp" label="insulin injections"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="added"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0020616" scheme="gov.nih.nlm.semanticType.phsu" label="hypoglycemic"/>
		<category term="C0046449" scheme="gov.nih.nlm.semanticType.orch" label="NPH"/>
		<category term="C0304870" scheme="gov.nih.nlm.semanticType.horm" label="longer-acting insulins"/>
		<category term="C0359086" scheme="gov.nih.nlm.semanticType.phsu" label="oral hypoglycemic"/>
		<category term="C0907402" scheme="gov.nih.nlm.semanticType.horm" label="insulin glargine"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulins"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
		<category term="C0907402" scheme="gov.nih.nlm.semanticType.horm" label="glargine"/>
		<category term="C0907402" scheme="gov.nih.nlm.semanticType.horm" label="glargine"/>
		<category term="C2936643" scheme="gov.nih.nlm.semanticType.topp" label="standard care"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C1527374" scheme="gov.nih.nlm.semanticType.topp" label="therapy group"/>
		<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="angiotensin converting enzyme inhibitors"/>
		<category term="C0360714" scheme="gov.nih.nlm.semanticType.phsu" label="statins"/>
		<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
		<category term="C0020616" scheme="gov.nih.nlm.semanticType.phsu" label="hypoglycemic"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="Sulfonylureas"/>
		<category term="C0359086" scheme="gov.nih.nlm.semanticType.phsu" label="oral hypoglycemic"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
		<category term="C0199782" scheme="gov.nih.nlm.semanticType.topp" label="insulin injections"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0071097" scheme="gov.nih.nlm.semanticType.phsu" label="pioglitazone"/>
		<category term="C0289313" scheme="gov.nih.nlm.semanticType.phsu" label="rosiglitazone"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="adding"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C1450229" scheme="gov.nih.nlm.semanticType.orch" label="TZD"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
		<category term="C0289313" scheme="gov.nih.nlm.semanticType.phsu" label="rosiglitazone"/>
		<category term="C0907402" scheme="gov.nih.nlm.semanticType.horm" label="insulin glargine"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0628655" scheme="gov.nih.nlm.semanticType.phsu" label="meeting"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0023767" scheme="gov.nih.nlm.semanticType.imft" label="lipid"/>
		<category term="C0071097" scheme="gov.nih.nlm.semanticType.phsu" label="pioglitazone"/>
		<category term="C0289313" scheme="gov.nih.nlm.semanticType.phsu" label="rosiglitazone"/>
		<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="Insulin"/>
		<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
		<category term="C0650607" scheme="gov.nih.nlm.semanticType.phsu" label="basal insulin"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0014361" scheme="gov.nih.nlm.semanticType.horm" label="glucagon-like peptide"/>
		<category term="C0017687" scheme="gov.nih.nlm.semanticType.horm" label="glucagon"/>
		<category term="C0167117" scheme="gov.nih.nlm.semanticType.phsu" label="Exenatide"/>
		<category term="C0763866" scheme="gov.nih.nlm.semanticType.aapp" label="GLP"/>
		<category term="C2354520" scheme="gov.nih.nlm.semanticType.aapp" label="peptide"/>
		<category term="C0167117" scheme="gov.nih.nlm.semanticType.phsu" label="Exenatide"/>
		<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
		<category term="C0167117" scheme="gov.nih.nlm.semanticType.phsu" label="exenatide"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0167117" scheme="gov.nih.nlm.semanticType.phsu" label="Exenatide"/>
		<category term="C0023767" scheme="gov.nih.nlm.semanticType.imft" label="lipid"/>
		<category term="C0763866" scheme="gov.nih.nlm.semanticType.aapp" label="GLP"/>
		<category term="C1456408" scheme="gov.nih.nlm.semanticType.horm" label="Liraglutide"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
		<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C1456408" scheme="gov.nih.nlm.semanticType.horm" label="Liraglutide"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C1456408" scheme="gov.nih.nlm.semanticType.horm" label="liraglutide"/>
		<category term="C0019932" scheme="gov.nih.nlm.semanticType.horm" label="hormone"/>
		<category term="C0063684" scheme="gov.nih.nlm.semanticType.horm" label="Amylin"/>
		<category term="C0449838" scheme="gov.nih.nlm.semanticType.horm" label="hormone secreted"/>
		<category term="C0597192" scheme="gov.nih.nlm.semanticType.horm" label="peptide hormone"/>
		<category term="C0634858" scheme="gov.nih.nlm.semanticType.phsu" label="polypeptide"/>
		<category term="C0657027" scheme="gov.nih.nlm.semanticType.aapp" label="amyloid polypeptide"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C2354520" scheme="gov.nih.nlm.semanticType.aapp" label="peptide"/>
		<category term="C0063684" scheme="gov.nih.nlm.semanticType.horm" label="amylin"/>
		<category term="C0537551" scheme="gov.nih.nlm.semanticType.horm" label="Pramlintide"/>
		<category term="C0537551" scheme="gov.nih.nlm.semanticType.horm" label="Pramlintide"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C3542461" scheme="gov.nih.nlm.semanticType.phsu" label="SGLT2) inhibitors"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C3542461" scheme="gov.nih.nlm.semanticType.phsu" label="SGLT2 inhibitors"/>
		<category term="C3542461" scheme="gov.nih.nlm.semanticType.phsu" label="SGLT2 inhibitors"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0669693" scheme="gov.nih.nlm.semanticType.orch" label="DPP"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C3542461" scheme="gov.nih.nlm.semanticType.phsu" label="SGLT2 inhibitors"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
		<category term="C2353951" scheme="gov.nih.nlm.semanticType.phsu" label="dapagliflozin"/>
		<category term="C0017642" scheme="gov.nih.nlm.semanticType.phsu" label="glipizide"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C2353951" scheme="gov.nih.nlm.semanticType.phsu" label="dapagliflozin"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C2353951" scheme="gov.nih.nlm.semanticType.phsu" label="dapagliflozin"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
		<category term="C1565750" scheme="gov.nih.nlm.semanticType.phsu" label="sitagliptin"/>
		<category term="C2974540" scheme="gov.nih.nlm.semanticType.phsu" label="canagliflozin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
		<category term="C1565750" scheme="gov.nih.nlm.semanticType.phsu" label="sitagliptin"/>
		<category term="C2974540" scheme="gov.nih.nlm.semanticType.phsu" label="canagliflozin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0061323" scheme="gov.nih.nlm.semanticType.phsu" label="glimepiride"/>
		<category term="C2974540" scheme="gov.nih.nlm.semanticType.phsu" label="canagliflozin"/>
		<category term="C0061323" scheme="gov.nih.nlm.semanticType.phsu" label="glimepiride"/>
		<category term="C0124598" scheme="gov.nih.nlm.semanticType.phsu" label="kg"/>
		<category term="C2974540" scheme="gov.nih.nlm.semanticType.phsu" label="Canagliflozin"/>
		<category term="C2974540" scheme="gov.nih.nlm.semanticType.phsu" label="Canagliflozin"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0541155" scheme="gov.nih.nlm.semanticType.phsu" label="colesevelam"/>
		<category term="C0541155" scheme="gov.nih.nlm.semanticType.phsu" label="Colesevelam"/>
		<category term="C0625158" scheme="gov.nih.nlm.semanticType.phsu" label="cholesterol"/>
		<category term="C2917673" scheme="gov.nih.nlm.semanticType.phsu" label="bile acid"/>
		<category term="C3537227" scheme="gov.nih.nlm.semanticType.phsu" label="bile acid sequestrant"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0541155" scheme="gov.nih.nlm.semanticType.phsu" label="colesevelam"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C0541155" scheme="gov.nih.nlm.semanticType.phsu" label="colesevelam"/>
		<category term="C0625158" scheme="gov.nih.nlm.semanticType.phsu" label="cholesterol"/>
		<category term="C0006230" scheme="gov.nih.nlm.semanticType.phsu" label="bromocriptine"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C1311032" scheme="gov.nih.nlm.semanticType.orch" label="GI"/>
		<category term="C0006230" scheme="gov.nih.nlm.semanticType.phsu" label="Bromocriptine"/>
		<category term="C0243192" scheme="gov.nih.nlm.semanticType.phsu" label="agonist"/>
		<category term="C0304712" scheme="gov.nih.nlm.semanticType.phsu" label="ergot"/>
		<category term="C0006230" scheme="gov.nih.nlm.semanticType.phsu" label="bromocriptine"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="Drug"/>
		<category term="C3469597" scheme="gov.nih.nlm.semanticType.hlca" label="Drug Administration"/>
		<category term="C3540798" scheme="gov.nih.nlm.semanticType.imft" label="Food"/>
		<category term="C0006230" scheme="gov.nih.nlm.semanticType.phsu" label="bromocriptine"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="Surgical"/>
		<category term="C0418981" scheme="gov.nih.nlm.semanticType.topp" label="medical therapy"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgery"/>
		<category term="C1456587" scheme="gov.nih.nlm.semanticType.topp" label="bariatric surgery"/>
		<category term="C1433710" scheme="gov.nih.nlm.semanticType.orch" label="BMI"/>
		<category term="C0005435" scheme="gov.nih.nlm.semanticType.topp" label="bypass, biliopancreatic"/>
		<category term="C0017125" scheme="gov.nih.nlm.semanticType.topp" label="gastric bypass"/>
		<category term="C0185033" scheme="gov.nih.nlm.semanticType.topp" label="diversion"/>
		<category term="C0418981" scheme="gov.nih.nlm.semanticType.topp" label="medical therapy"/>
		<category term="C0741847" scheme="gov.nih.nlm.semanticType.topp" label="bypass"/>
		<category term="C1433710" scheme="gov.nih.nlm.semanticType.orch" label="BMI"/>
		<category term="C0005435" scheme="gov.nih.nlm.semanticType.topp" label="biliopancreatic diversion"/>
		<category term="C0185033" scheme="gov.nih.nlm.semanticType.topp" label="diversion"/>
		<category term="C0741847" scheme="gov.nih.nlm.semanticType.topp" label="bypass"/>
		<category term="C0017118" scheme="gov.nih.nlm.semanticType.topp" label="gastrectomy"/>
		<category term="C0017125" scheme="gov.nih.nlm.semanticType.topp" label="gastric bypass"/>
		<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
		<category term="C0418981" scheme="gov.nih.nlm.semanticType.topp" label="medical therapy"/>
		<category term="C0741847" scheme="gov.nih.nlm.semanticType.topp" label="bypass"/>
		<category term="C1433710" scheme="gov.nih.nlm.semanticType.orch" label="BMI"/>
		<category term="C3160799" scheme="gov.nih.nlm.semanticType.topp" label="sleeve gastrectomy"/>
		<category term="C0002804" scheme="gov.nih.nlm.semanticType.topp" label="Roux-en-Y"/>
		<category term="C0017125" scheme="gov.nih.nlm.semanticType.topp" label="gastric bypass"/>
		<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgery"/>
		<category term="C0585179" scheme="gov.nih.nlm.semanticType.topp" label="Roux-en-Y gastric bypass"/>
		<category term="C0741847" scheme="gov.nih.nlm.semanticType.topp" label="bypass"/>
		<category term="C0920298" scheme="gov.nih.nlm.semanticType.topp" label="weight control"/>
		<category term="C1121354" scheme="gov.nih.nlm.semanticType.orch" label="en"/>
		<category term="C1433710" scheme="gov.nih.nlm.semanticType.orch" label="BMI"/>
		<category term="C1444341" scheme="gov.nih.nlm.semanticType.hlca" label="managed weight control"/>
		<category term="C1536078" scheme="gov.nih.nlm.semanticType.topp" label="bypass surgery"/>
		<category term="C0017125" scheme="gov.nih.nlm.semanticType.topp" label="gastric bypass"/>
		<category term="C0625158" scheme="gov.nih.nlm.semanticType.phsu" label="cholesterol"/>
		<category term="C0741847" scheme="gov.nih.nlm.semanticType.topp" label="bypass"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C0002688" scheme="gov.nih.nlm.semanticType.topp" label="amputation"/>
		<category term="C0017125" scheme="gov.nih.nlm.semanticType.topp" label="gastric bypass"/>
		<category term="C0337308" scheme="gov.nih.nlm.semanticType.topp" label="leg amputation"/>
		<category term="C0741847" scheme="gov.nih.nlm.semanticType.topp" label="bypass"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
		<category term="C0278293" scheme="gov.nih.nlm.semanticType.topp" label="procedures"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgery"/>
		<category term="C1456587" scheme="gov.nih.nlm.semanticType.topp" label="bariatric surgery"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="adding"/>
		<category term="C0017642" scheme="gov.nih.nlm.semanticType.phsu" label="glipizide"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
		<category term="C0246689" scheme="gov.nih.nlm.semanticType.phsu" label="repaglinide"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
		<category term="C0071097" scheme="gov.nih.nlm.semanticType.phsu" label="pioglitazone"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="add"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
		<category term="C0071097" scheme="gov.nih.nlm.semanticType.phsu" label="pioglitazone"/>
		<category term="C0669693" scheme="gov.nih.nlm.semanticType.orch" label="DPP"/>
		<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
		<category term="C0071097" scheme="gov.nih.nlm.semanticType.phsu" label="pioglitazone"/>
		<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="add"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0014361" scheme="gov.nih.nlm.semanticType.horm" label="glucagon-like peptide"/>
		<category term="C0017687" scheme="gov.nih.nlm.semanticType.horm" label="glucagon"/>
		<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
		<category term="C0763866" scheme="gov.nih.nlm.semanticType.aapp" label="GLP"/>
		<category term="C2354520" scheme="gov.nih.nlm.semanticType.aapp" label="peptide"/>
		<id>1790</id>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H2"/>
			<id>172402</id>
			<summary>
				<section label="INDICATIONS FOR A SECOND AGENT" id="2">
					<fragment>After a successful initial response to oral therapy, patients fail to maintain target glycated hemoglobin (A1C) levels (&lt;7 percent) at a rate of 5 to 10 percent per year  . An analysis from the United Kingdom Prospective Diabetes Study (UKPDS) found that 50 percent of patients originally controlled with a single drug required the addition of a second drug after three years;</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H2"/>
			<id>172405</id>
			<summary>
				<section label="INDICATIONS FOR A SECOND AGENT" id="2">
					<fragment>An intercurrent illness or the ingestion of drugs that can increase insulin resistance, interfere with insulin release, or increase hepatic glucose production  . The latter factor is particularly important in elderly patients who are taking multiple drugs.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H2"/>
			<id>172407</id>
			<summary>
				<section label="INDICATIONS FOR A SECOND AGENT" id="2">
					<fragment>The patient may have type 1 diabetes with gradual destruction of the pancreatic beta-cells, sometimes referred to as "latent autoimmune diabetes in adults" (LADA).</fragment>
				</section>
			</summary>
			<category term="C1261381" scheme="gov.nih.nlm.semanticType.topp" label="destruction"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H2"/>
			<id>172409</id>
			<summary>
				<section label="INDICATIONS FOR A SECOND AGENT" id="2">
					<fragment>A population-based study of over 7200 patients with type 2 diabetes demonstrated that many patients remain with A1C levels higher than ideal for years because changes in therapy to improve glycemic control were not made or were only made slowly.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H2"/>
			<id>172411</id>
			<summary>
				<section label="INDICATIONS FOR A SECOND AGENT" id="2">
					<fragment>The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) consensus guideline for pharmacotherapy to control hyperglycemia in type 2 diabetes recommends testing A1C levels every three months and addition of a second medication when the treatment goal of A1C &lt;7 percent with metformin plus lifestyle intervention is not achieved within three months  . In order to achieve the A1C goal, the glucose goals below are usually necessary: Fasting glucose 70 to 130 mg/dL (3.89 to 7.22 mmol/L).</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="pharmacotherapy"/>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0643010" scheme="gov.nih.nlm.semanticType.phsu" label="ADA"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H3"/>
			<id>172414</id>
			<summary>
				<section label="TREATMENT OPTIONS" id="3">
					<fragment>We favor insulin or sulfonylurea as the second step, and insulin is preferred for patients whose glycated hemoglobin (A1C) is further from target (&gt;8.5 percent) or who have symptoms related to hyperglycemia.</fragment>
				</section>
			</summary>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H3"/>
			<id>172415</id>
			<summary>
				<section label="TREATMENT OPTIONS" id="3">
					<fragment>For those close to target, we prefer to add a shorter-duration sulfonylurea (such as glipizide, to reduce the risk of hypoglycemia compared with longer-acting sulfonylureas), rather than insulin.</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="add"/>
			<category term="C0017642" scheme="gov.nih.nlm.semanticType.phsu" label="glipizide"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
			<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H3"/>
			<id>172416</id>
			<summary>
				<section label="TREATMENT OPTIONS" id="3">
					<fragment>Another reasonable alternative is the addition of repaglinide, which can be considered in individuals who do not reach glycemic goals with metformin, if there are contraindications to sulfonylureas or patient preference limits the use of insulin.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
			<category term="C0246689" scheme="gov.nih.nlm.semanticType.phsu" label="repaglinide"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H3"/>
			<id>172419</id>
			<summary>
				<section label="TREATMENT OPTIONS" id="3">
					<fragment>This selection of drugs is based upon clinical trial evidence and clinical experience in achieving glycemic targets, with the recognition that there is a paucity of many high quality head-to-head drug comparison trials.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H3"/>
			<id>172420</id>
			<summary>
				<section label="TREATMENT OPTIONS" id="3">
					<fragment>In a meta-analysis of 140 trials and 26 observational studies evaluating the effects of oral or injectable diabetes medications as monotherapy and in combination with other oral agents or insulin on intermediate outcomes (A1C, body weight, lipid profiles), combination therapy decreased A1C levels more than monotherapy by approximately one percentage point.</fragment>
				</section>
			</summary>
			<category term="C0023767" scheme="gov.nih.nlm.semanticType.imft" label="lipid"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0086466" scheme="gov.nih.nlm.semanticType.phsu" label="injectable"/>
			<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H3"/>
			<id>172421</id>
			<summary>
				<section label="TREATMENT OPTIONS" id="3">
					<fragment>Most combinations similarly reduced A1C, but there was weak evidence favoring metformin plus a glucagon-like peptide-1 (GLP-1) agonist over metformin plus a dipeptidyl peptidase-4 (DPP-4) inhibitor for reducing A1C levels.</fragment>
				</section>
			</summary>
			<category term="C0014361" scheme="gov.nih.nlm.semanticType.horm" label="glucagon-like peptide"/>
			<category term="C0017687" scheme="gov.nih.nlm.semanticType.horm" label="glucagon"/>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0243192" scheme="gov.nih.nlm.semanticType.phsu" label="agonist"/>
			<category term="C0669693" scheme="gov.nih.nlm.semanticType.orch" label="DPP"/>
			<category term="C0763866" scheme="gov.nih.nlm.semanticType.aapp" label="GLP"/>
			<category term="C2354520" scheme="gov.nih.nlm.semanticType.aapp" label="peptide"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H3"/>
			<id>172422</id>
			<summary>
				<section label="TREATMENT OPTIONS" id="3">
					<fragment>Thiazolidinediones (TZDs) are not considered first choice agents due to the risk of congestive heart failure (CHF), fractures, and expense.</fragment>
				</section>
			</summary>
			<category term="C0631314" scheme="gov.nih.nlm.semanticType.phsu" label="CHF"/>
			<category term="C2605394" scheme="gov.nih.nlm.semanticType.orch" label="Thiazolidinediones"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H3"/>
			<id>172425</id>
			<summary>
				<section label="TREATMENT OPTIONS" id="3">
					<fragment>The use of rosiglitazone is not recommended because of the greater concern about its atherogenic lipid profiles and a potential increased risk for cardiovascular events.</fragment>
				</section>
			</summary>
			<category term="C0023767" scheme="gov.nih.nlm.semanticType.imft" label="lipid"/>
			<category term="C0289313" scheme="gov.nih.nlm.semanticType.phsu" label="rosiglitazone"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H3"/>
			<id>172427</id>
			<summary>
				<section label="TREATMENT OPTIONS" id="3">
					<fragment>Subsequently, in 2011, the French and German Medicines Agencies suspended the use of pioglitazone because of the potential increased risk of bladder cancer and the concern that the overall risks of pioglitazone exceed its benefits.</fragment>
				</section>
			</summary>
			<category term="C0071097" scheme="gov.nih.nlm.semanticType.phsu" label="pioglitazone"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H3"/>
			<id>172430</id>
			<summary>
				<section label="TREATMENT OPTIONS" id="3">
					<fragment>DPP-4 inhibitors can be considered as add-on drug therapy for patients who are inadequately controlled on metformin, a thiazolidinedione, or a sulfonylurea.</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="add"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
			<category term="C0669693" scheme="gov.nih.nlm.semanticType.orch" label="DPP"/>
			<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
			<category term="C2605394" scheme="gov.nih.nlm.semanticType.orch" label="thiazolidinedione"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H5"/>
			<id>172433</id>
			<summary>
				<section label="Combination with metformin" id="5">
					<fragment>In meta-analyses of placebo-controlled trials evaluating different drugs (sulfonylureas, thiazolidinediones [TZDs], meglitinides, alpha-glucosidase inhibitors, glucagon-like peptide-1 [GLP-1] analogs, dipeptidyl peptidase-4 [DPP-4] inhibitors) as add-on therapy to metformin, reductions in glycated hemoglobin (A1C) with different classes of drugs ranged from 0.42 to 1.0 percentage points.</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="add"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0014361" scheme="gov.nih.nlm.semanticType.horm" label="glucagon-like peptide"/>
			<category term="C0017687" scheme="gov.nih.nlm.semanticType.horm" label="glucagon"/>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0669693" scheme="gov.nih.nlm.semanticType.orch" label="DPP"/>
			<category term="C0763866" scheme="gov.nih.nlm.semanticType.aapp" label="GLP"/>
			<category term="C1979844" scheme="gov.nih.nlm.semanticType.aapp" label="alpha"/>
			<category term="C2354520" scheme="gov.nih.nlm.semanticType.aapp" label="peptide"/>
			<category term="C2605394" scheme="gov.nih.nlm.semanticType.orch" label="thiazolidinediones"/>
			<category term="C3539108" scheme="gov.nih.nlm.semanticType.phsu" label="alpha-glucosidase inhibitors"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H5"/>
			<id>172435</id>
			<summary>
				<section label="Combination with metformin" id="5">
					<fragment>However, these trials did not directly compare different agents in combination with metformin.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H5"/>
			<id>172438</id>
			<summary>
				<section label="Combination with metformin" id="5">
					<fragment>Insulin was not included in one meta-analysis, although it is clearly the most effective and one of the least expensive of the anti-diabetic medications available.</fragment>
				</section>
			</summary>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0432616" scheme="gov.nih.nlm.semanticType.imft" label="anti"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="Insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H5"/>
			<id>172439</id>
			<summary>
				<section label="Combination with metformin" id="5">
					<fragment>As an example, in a 24-week trial of insulin glargine versus sitagliptin in 515 patients with type 2 diabetes inadequately controlled with metformin monotherapy, there was a greater reduction in A1C in patients randomly assigned to glargine (-1.72 versus -1.13 percent).</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0907402" scheme="gov.nih.nlm.semanticType.horm" label="insulin glargine"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="C1565750" scheme="gov.nih.nlm.semanticType.phsu" label="sitagliptin"/>
			<category term="6" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H5"/>
			<id>172441</id>
			<summary>
				<section label="Combination with metformin" id="5">
					<fragment>Insulin or sulfonylureas are the preferred second-line agents because of efficacy, side effect profile, long-term safety, and relative cost.</fragment>
				</section>
			</summary>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="Insulin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H6"/>
			<id>172442</id>
			<summary>
				<section label="Metformin plus sulfonylureas" id="6">
					<fragment>Metformin has an additive glycemic effect when given in combination with a sulfonylurea.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="Metformin"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H6"/>
			<id>172444</id>
			<summary>
				<section label="Metformin plus sulfonylureas" id="6">
					<fragment>Treatment with metformin plus glyburide resulted in lower A1C levels than glyburide alone (7.1 versus 8.7 percent, respectively).</fragment>
				</section>
			</summary>
			<category term="C0017628" scheme="gov.nih.nlm.semanticType.phsu" label="glyburide"/>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H6"/>
			<id>172448</id>
			<summary>
				<section label="Metformin plus sulfonylureas" id="6">
					<fragment>Shorter-acting sulfonylureas, such as glipizide, are less likely to cause hypoglycemia than the older, long-acting sulfonylureas, and therefore are the preferred sulfonylureas, especially in older patients.</fragment>
				</section>
			</summary>
			<category term="C0017642" scheme="gov.nih.nlm.semanticType.phsu" label="glipizide"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H7"/>
			<id>172454</id>
			<summary>
				<section label="Metformin plus thiazolidinediones" id="7">
					<fragment>As an example, in a study of patients with inadequate glycemic control on metformin monotherapy, the addition of pioglitazone (30 mg daily) versus placebo resulted in significant improvement in A1C, fasting blood glucose values, and in measures of insulin sensitivity.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0071097" scheme="gov.nih.nlm.semanticType.phsu" label="pioglitazone"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H7"/>
			<id>172455</id>
			<summary>
				<section label="Metformin plus thiazolidinediones" id="7">
					<fragment>Specifically, the mean A1C values decreased by 0.6 percentage points in patients receiving metformin plus pioglitazone and increased by 0.2 percentage points in patients receiving metformin-placebo.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0071097" scheme="gov.nih.nlm.semanticType.phsu" label="pioglitazone"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H7"/>
			<id>172457</id>
			<summary>
				<section label="Metformin plus thiazolidinediones" id="7">
					<fragment>The early addition of a TZD to metformin to achieve glycemic goals is favored by some but not all, and is not included as a first tier option in the American Diabetes Association/European Association for the Study of Diabetes (ADA/EASD) consensus algorithm  . If a TZD is to be used in combination with metformin (or a sulfonylurea), pioglitazone is recommended because of the greater concern about atherogenic lipid profiles and a potential increased risk for cardiovascular events with rosiglitazone.</fragment>
				</section>
			</summary>
			<category term="C0023767" scheme="gov.nih.nlm.semanticType.imft" label="lipid"/>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
			<category term="C0071097" scheme="gov.nih.nlm.semanticType.phsu" label="pioglitazone"/>
			<category term="C0289313" scheme="gov.nih.nlm.semanticType.phsu" label="rosiglitazone"/>
			<category term="C0643010" scheme="gov.nih.nlm.semanticType.phsu" label="ADA"/>
			<category term="C1450229" scheme="gov.nih.nlm.semanticType.orch" label="TZD"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H8"/>
			<id>172458</id>
			<summary>
				<section label="Metformin plus meglitinides" id="8">
					<fragment>Meglitinides may also be given in combination with metformin, resulting in superior glycemic control than with either agent used as monotherapy.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H8"/>
			<id>172459</id>
			<summary>
				<section label="Metformin plus meglitinides" id="8">
					<fragment>A randomized two-year study of initial diabetic treatment comparing nateglinide/metformin or glyburide/metformin concluded that both regimens had similar efficacy in lowering A1C, but hypoglycemic events were more common in patients treated with glyburide/metformin (17.7 percent of patients versus 8.2 percent for nateglinide/metformin).</fragment>
				</section>
			</summary>
			<category term="C0017628" scheme="gov.nih.nlm.semanticType.phsu" label="glyburide"/>
			<category term="C0020616" scheme="gov.nih.nlm.semanticType.phsu" label="hypoglycemic"/>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimens"/>
			<category term="C0903898" scheme="gov.nih.nlm.semanticType.phsu" label="nateglinide"/>
			<category term="C0939773" scheme="gov.nih.nlm.semanticType.phsu" label="glyburide/metformin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H8"/>
			<id>172461</id>
			<summary>
				<section label="Metformin plus meglitinides" id="8">
					<fragment>Meglitinides were not recommended by the ADA/EASD guidelines because of higher costs (currently only available as brand name drugs) compared with sulfonylureas and more limited clinical data.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
			<category term="C0643010" scheme="gov.nih.nlm.semanticType.phsu" label="ADA"/>
			<category term="C0645690" scheme="gov.nih.nlm.semanticType.phsu" label="brand"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H8"/>
			<id>172463</id>
			<summary>
				<section label="Metformin plus meglitinides" id="8">
					<fragment>Thus, it can be used safely in patients with chronic kidney disease.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H10"/>
			<id>172468</id>
			<summary>
				<section label="Sulfonylureas and thiazolidinediones" id="10">
					<fragment>The glycemic efficacy of TZDs in combination with a sulfonylurea is illustrated by the findings from a 16-week study of 560 patients with type 2 diabetes who had A1C values &gt;8.0 percent despite sulfonylurea therapy.</fragment>
				</section>
			</summary>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H10"/>
			<id>172469</id>
			<summary>
				<section label="Sulfonylureas and thiazolidinediones" id="10">
					<fragment>Those receiving pioglitazone (15 or 30 mg) plus the sulfonylurea had significant decreases in A1C values compared with those receiving placebo plus the sulfonylurea (0.9 and 1.3 percentage points for the lower and higher dose of pioglitazone, respectively).</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
			<category term="C0071097" scheme="gov.nih.nlm.semanticType.phsu" label="pioglitazone"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H10"/>
			<id>172470</id>
			<summary>
				<section label="Sulfonylureas and thiazolidinediones" id="10">
					<fragment>Fasting plasma glucose concentrations also decreased significantly in the patients given pioglitazone.</fragment>
				</section>
			</summary>
			<category term="C0071097" scheme="gov.nih.nlm.semanticType.phsu" label="pioglitazone"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H10"/>
			<id>172472</id>
			<summary>
				<section label="Sulfonylureas and thiazolidinediones" id="10">
					<fragment>Although combination therapy may be more convenient than taking the drugs individually, the fixed-dose combinations offer less dosing flexibility and are generally more expensive than using generic agents, when available, as separate pills.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0029151" scheme="gov.nih.nlm.semanticType.topp" label="pills"/>
			<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H10"/>
			<id>172473</id>
			<summary>
				<section label="Sulfonylureas and thiazolidinediones" id="10">
					<fragment>While these combinations result in short-term improvements in glycemic control, long-term trials demonstrating improved outcomes are lacking.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H12"/>
			<id>172478</id>
			<summary>
				<section label="INSULIN" id="12">
					<fragment>Both patients and providers are often reluctant to initiate insulin therapy, despite its proven efficacy and cost advantage compared with many newer agents.</fragment>
				</section>
			</summary>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H12"/>
			<id>172483</id>
			<summary>
				<section label="INSULIN" id="12">
					<fragment>Insulin is a reasonable choice for initial therapy in patients who present with symptomatic or poorly controlled diabetes, and is the preferred second-line medication for patients with glycated hemoglobin (A1C) &gt;8.5 percent or with symptoms of hyperglycemia despite initial therapy with metformin and lifestyle intervention.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="Insulin"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H12"/>
			<id>172484</id>
			<summary>
				<section label="INSULIN" id="12">
					<fragment>The American Diabetes Association/European Association for the Study of Diabetes (ADA/EASD) have developed a flow diagram for initiating and titrating insulin in the management of type 2 diabetes  . The dose of insulin may be adjusted every three to four days, until glycemic targets are achieved.</fragment>
				</section>
			</summary>
			<category term="C0643010" scheme="gov.nih.nlm.semanticType.phsu" label="ADA"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H13"/>
			<id>172485</id>
			<summary>
				<section label="Combination oral and insulin therapy" id="13">
					<fragment>Patients with persistent hyperglycemia despite oral hypoglycemic therapy may add insulin to oral medication, or may stop the oral drug and begin insulin.</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="add"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0020616" scheme="gov.nih.nlm.semanticType.phsu" label="hypoglycemic"/>
			<category term="C0359086" scheme="gov.nih.nlm.semanticType.phsu" label="oral hypoglycemic"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H13"/>
			<id>172486</id>
			<summary>
				<section label="Combination oral and insulin therapy" id="13">
					<fragment>Part of the rationale for combination oral hypoglycemic drug and insulin therapy is that by suppressing hepatic glucose production, the patient can retain the convenience of oral agents while minimizing total insulin requirements and, therefore, the degree of hyperinsulinemia.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0020616" scheme="gov.nih.nlm.semanticType.phsu" label="hypoglycemic"/>
			<category term="C0359086" scheme="gov.nih.nlm.semanticType.phsu" label="oral hypoglycemic"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="C1445141" scheme="gov.nih.nlm.semanticType.phsu" label="combination oral hypoglycemic"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H13"/>
			<id>172487</id>
			<summary>
				<section label="Combination oral and insulin therapy" id="13">
					<fragment>In several studies of patients inadequately controlled with drugs alone, combination oral-insulin therapy resulted in equivalent glycemic control with less or no weight gain compared with several daily insulin injections.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0199782" scheme="gov.nih.nlm.semanticType.topp" label="insulin injections"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H13"/>
			<id>172488</id>
			<summary>
				<section label="Combination oral and insulin therapy" id="13">
					<fragment>While neutral protamine Hagedorn (NPH) has been used commonly at bedtime to supplement oral hypoglycemic drug therapy, longer-acting insulins, such as insulin glargine (once daily) and detemir (once or twice daily), added to oral agents are similarly effective for reducing A1C values and may cause less nocturnal hypoglycemia, with the important disadvantages of higher cost and fewer long-term safety data.</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="added"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0020616" scheme="gov.nih.nlm.semanticType.phsu" label="hypoglycemic"/>
			<category term="C0046449" scheme="gov.nih.nlm.semanticType.orch" label="NPH"/>
			<category term="C0304870" scheme="gov.nih.nlm.semanticType.horm" label="longer-acting insulins"/>
			<category term="C0359086" scheme="gov.nih.nlm.semanticType.phsu" label="oral hypoglycemic"/>
			<category term="C0907402" scheme="gov.nih.nlm.semanticType.horm" label="insulin glargine"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulins"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H13"/>
			<id>172489</id>
			<summary>
				<section label="Combination oral and insulin therapy" id="13">
					<fragment>Combination oral agent and glargine therapy does not appear to reduce or increase cardiovascular outcomes, compared with oral agent(s) only, as illustrated by the findings of the Outcome Reduction with Initial Glargine Intervention (ORIGIN) trial.</fragment>
				</section>
			</summary>
			<category term="C0907402" scheme="gov.nih.nlm.semanticType.horm" label="glargine"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H13"/>
			<id>172490</id>
			<summary>
				<section label="Combination oral and insulin therapy" id="13">
					<fragment>In this trial, over 12,500 patients with cardiovascular risk factors plus type 2 diabetes or prediabetes were randomly assigned to an evening dose of glargine or to standard care.</fragment>
				</section>
			</summary>
			<category term="C0907402" scheme="gov.nih.nlm.semanticType.horm" label="glargine"/>
			<category term="C2936643" scheme="gov.nih.nlm.semanticType.topp" label="standard care"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H13"/>
			<id>172491</id>
			<summary>
				<section label="Combination oral and insulin therapy" id="13">
					<fragment>Approximately 60 percent of the patients with prior diabetes were using oral glucose-lowering agents (predominantly metformin or sulfonylurea).</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H13"/>
			<id>172495</id>
			<summary>
				<section label="Combination oral and insulin therapy" id="13">
					<fragment>Only 11 percent of the patients in the standard therapy group received insulin.</fragment>
				</section>
			</summary>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="C1527374" scheme="gov.nih.nlm.semanticType.topp" label="therapy group"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H13"/>
			<id>172497</id>
			<summary>
				<section label="Combination oral and insulin therapy" id="13">
					<fragment>Approximately 60 percent of patients in both groups were treated with statins and 75 percent with angiotensin converting enzyme inhibitors or angiotensin II receptor blockers.</fragment>
				</section>
			</summary>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="angiotensin converting enzyme inhibitors"/>
			<category term="C0360714" scheme="gov.nih.nlm.semanticType.phsu" label="statins"/>
			<category term="C0619701" scheme="gov.nih.nlm.semanticType.horm" label="II"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H14"/>
			<id>172498</id>
			<summary>
				<section label="Sulfonylureas and insulin" id="14">
					<fragment>Sulfonylureas are the oldest class of oral hypoglycemic agents.</fragment>
				</section>
			</summary>
			<category term="C0020616" scheme="gov.nih.nlm.semanticType.phsu" label="hypoglycemic"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="Sulfonylureas"/>
			<category term="C0359086" scheme="gov.nih.nlm.semanticType.phsu" label="oral hypoglycemic"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H14"/>
			<id>172500</id>
			<summary>
				<section label="Sulfonylureas and insulin" id="14">
					<fragment>However, the combination of sulfonylurea and insulin is less efficacious and results in more weight gain than metformin and insulin.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H15"/>
			<id>172503</id>
			<summary>
				<section label="Metformin and insulin" id="15">
					<fragment>In several trials and a meta-analysis, glycemic control was better with metformin-insulin combinations than with insulin monotherapy or with sulfonylurea-insulin combinations.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H15"/>
			<id>172504</id>
			<summary>
				<section label="Metformin and insulin" id="15">
					<fragment>In the UKPDS, the combination of insulin with metformin was also associated with significantly less weight gain than seen with twice daily insulin injections or insulin combined with sulfonylureas.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
			<category term="C0199782" scheme="gov.nih.nlm.semanticType.topp" label="insulin injections"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H15"/>
			<id>172505</id>
			<summary>
				<section label="Metformin and insulin" id="15">
					<fragment>This is consistent with other observations that metformin alone does not usually produce hyperinsulinemia or weight gain.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H15"/>
			<id>172507</id>
			<summary>
				<section label="Metformin and insulin" id="15">
					<fragment>Based upon the available evidence, we prefer combination metformin-insulin therapy to sulfonylurea-insulin therapy in individuals without contraindications to metformin.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H16"/>
			<id>172509</id>
			<summary>
				<section label="Thiazolidinediones and insulin" id="16">
					<fragment>However, the combination of insulin plus either rosiglitazone or pioglitazone causes an increased incidence of heart failure and should be avoided in patients with heart failure.</fragment>
				</section>
			</summary>
			<category term="C0071097" scheme="gov.nih.nlm.semanticType.phsu" label="pioglitazone"/>
			<category term="C0289313" scheme="gov.nih.nlm.semanticType.phsu" label="rosiglitazone"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H17"/>
			<id>172512</id>
			<summary>
				<section label="Insulin versus triple oral therapy" id="17">
					<fragment>In patients who are not well-controlled on two oral agents, switching to insulin is usually less expensive than adding a third oral agent.</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="adding"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H17"/>
			<id>172513</id>
			<summary>
				<section label="Insulin versus triple oral therapy" id="17">
					<fragment>This was demonstrated in a study of 188 type 2 diabetic patients with inadequate glycemic control on two oral agents who were randomly assigned to receive a third oral agent or be switched to twice daily insulin along with metformin.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H17"/>
			<id>172514</id>
			<summary>
				<section label="Insulin versus triple oral therapy" id="17">
					<fragment>Patients on three oral agents (a sulfonylurea, metformin, and a TZD) had similar glycemic control, but more side effects, a more atherogenic profile, and substantially higher costs than patients on twice daily insulin along with metformin.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="C1450229" scheme="gov.nih.nlm.semanticType.orch" label="TZD"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H17"/>
			<id>172515</id>
			<summary>
				<section label="Insulin versus triple oral therapy" id="17">
					<fragment>Three oral agents can be considered in patients with A1C values that are not too far from goal.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H17"/>
			<id>172516</id>
			<summary>
				<section label="Insulin versus triple oral therapy" id="17">
					<fragment>This was illustrated in a study of 217 patients inadequately controlled on dual therapy with sulfonylureas and metformin, who were randomly assigned to receive either insulin glargine or rosiglitazone.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
			<category term="C0289313" scheme="gov.nih.nlm.semanticType.phsu" label="rosiglitazone"/>
			<category term="C0907402" scheme="gov.nih.nlm.semanticType.horm" label="insulin glargine"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H17"/>
			<id>172523</id>
			<summary>
				<section label="Insulin versus triple oral therapy" id="17">
					<fragment>In general this means the addition of insulin in patients who are not meeting goals with two oral agents.</fragment>
				</section>
			</summary>
			<category term="C0628655" scheme="gov.nih.nlm.semanticType.phsu" label="meeting"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H17"/>
			<id>172524</id>
			<summary>
				<section label="Insulin versus triple oral therapy" id="17">
					<fragment>However, it is reasonable to try a third oral agent before starting insulin in patients who are close to glycemic goals and who prefer not to start insulin.</fragment>
				</section>
			</summary>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H17"/>
			<id>172525</id>
			<summary>
				<section label="Insulin versus triple oral therapy" id="17">
					<fragment>In this situation, pioglitazone is preferred because of the greater concern about atherogenic lipid profiles and a potential increased risk for cardiovascular events with rosiglitazone.</fragment>
				</section>
			</summary>
			<category term="C0023767" scheme="gov.nih.nlm.semanticType.imft" label="lipid"/>
			<category term="C0071097" scheme="gov.nih.nlm.semanticType.phsu" label="pioglitazone"/>
			<category term="C0289313" scheme="gov.nih.nlm.semanticType.phsu" label="rosiglitazone"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H18"/>
			<id>172527</id>
			<summary>
				<section label="Insulin intensification" id="18">
					<fragment>Insulin doses should then be adjusted to achieve target glycemic control.</fragment>
				</section>
			</summary>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="Insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H18"/>
			<id>172529</id>
			<summary>
				<section label="Insulin intensification" id="18">
					<fragment>Daily insulin doses typically exceed 65 to 100 units per day, and may sometimes be much higher, for obese type 2 diabetic patients to achieve near-normal glycemia.</fragment>
				</section>
			</summary>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H18"/>
			<id>172531</id>
			<summary>
				<section label="Insulin intensification" id="18">
					<fragment>Use of an intensive insulin regimen (similar to that used in type 1 diabetes) results in higher serum insulin concentrations and better glycemic control than that achieved with either an oral drug or conventional insulin therapy (basal insulin only) alone.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
			<category term="C0650607" scheme="gov.nih.nlm.semanticType.phsu" label="basal insulin"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H18"/>
			<id>172533</id>
			<summary>
				<section label="Insulin intensification" id="18">
					<fragment>In addition to the directly deleterious effects of worsening obesity, it can also lead to partial noncompliance with therapy, particularly in women.)</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H21"/>
			<id>172535</id>
			<summary>
				<section label="Exenatide" id="21">
					<fragment>Exenatide is a glucagon-like peptide-1 (GLP-1) analog used as adjunctive therapy for patients with type 2 diabetes who are inadequately controlled on oral agents.</fragment>
				</section>
			</summary>
			<category term="C0014361" scheme="gov.nih.nlm.semanticType.horm" label="glucagon-like peptide"/>
			<category term="C0017687" scheme="gov.nih.nlm.semanticType.horm" label="glucagon"/>
			<category term="C0167117" scheme="gov.nih.nlm.semanticType.phsu" label="Exenatide"/>
			<category term="C0763866" scheme="gov.nih.nlm.semanticType.aapp" label="GLP"/>
			<category term="C2354520" scheme="gov.nih.nlm.semanticType.aapp" label="peptide"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H21"/>
			<id>172537</id>
			<summary>
				<section label="Exenatide" id="21">
					<fragment>Exenatide does not cause hypoglycemia unless it is administered with unadjusted doses of other diabetes medications.</fragment>
				</section>
			</summary>
			<category term="C0167117" scheme="gov.nih.nlm.semanticType.phsu" label="Exenatide"/>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H21"/>
			<id>172538</id>
			<summary>
				<section label="Exenatide" id="21">
					<fragment>Unlike insulin, exenatide promotes weight loss but has a high rate of gastrointestinal side effects including nausea, vomiting, and diarrhea.</fragment>
				</section>
			</summary>
			<category term="C0167117" scheme="gov.nih.nlm.semanticType.phsu" label="exenatide"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H21"/>
			<id>172540</id>
			<summary>
				<section label="Exenatide" id="21">
					<fragment>Exenatide use may be most appropriate for an overweight patient who is experiencing weight gain on oral agents.</fragment>
				</section>
			</summary>
			<category term="C0167117" scheme="gov.nih.nlm.semanticType.phsu" label="Exenatide"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H22"/>
			<id>172542</id>
			<summary>
				<section label="Liraglutide" id="22">
					<fragment>Liraglutide is a GLP-1 analog that has been modified to non-covalently bind to serum albumin through a lipid side chain, resulting in slower degradation and allowing for once-daily subcutaneous dosing.</fragment>
				</section>
			</summary>
			<category term="C0023767" scheme="gov.nih.nlm.semanticType.imft" label="lipid"/>
			<category term="C0763866" scheme="gov.nih.nlm.semanticType.aapp" label="GLP"/>
			<category term="C1456408" scheme="gov.nih.nlm.semanticType.horm" label="Liraglutide"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H22"/>
			<id>172543</id>
			<summary>
				<section label="Liraglutide" id="22">
					<fragment>It is available for use as monotherapy as an adjunct to diet and exercise or in combination with oral agents in adults with type 2 diabetes.</fragment>
				</section>
			</summary>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H22"/>
			<id>172545</id>
			<summary>
				<section label="Liraglutide" id="22">
					<fragment>Liraglutide does not cause hypoglycemia unless it is administered with unadjusted doses of other diabetes medications that can cause hypoglycemia, such as sulfonylureas or insulin.</fragment>
				</section>
			</summary>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="C1456408" scheme="gov.nih.nlm.semanticType.horm" label="Liraglutide"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H22"/>
			<id>172546</id>
			<summary>
				<section label="Liraglutide" id="22">
					<fragment>Unlike insulin, liraglutide promotes weight loss, in part probably because of its high rate of gastrointestinal side effects including nausea, vomiting, and diarrhea.</fragment>
				</section>
			</summary>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="C1456408" scheme="gov.nih.nlm.semanticType.horm" label="liraglutide"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H457895"/>
			<id>172554</id>
			<summary>
				<section label="Pramlintide" id="457895">
					<fragment>Amylin (also known as islet amyloid polypeptide) is a peptide hormone secreted by pancreatic beta cells in conjunction with insulin in response to nutrient stimuli.</fragment>
				</section>
			</summary>
			<category term="C0019932" scheme="gov.nih.nlm.semanticType.horm" label="hormone"/>
			<category term="C0063684" scheme="gov.nih.nlm.semanticType.horm" label="Amylin"/>
			<category term="C0449838" scheme="gov.nih.nlm.semanticType.horm" label="hormone secreted"/>
			<category term="C0597192" scheme="gov.nih.nlm.semanticType.horm" label="peptide hormone"/>
			<category term="C0634858" scheme="gov.nih.nlm.semanticType.phsu" label="polypeptide"/>
			<category term="C0657027" scheme="gov.nih.nlm.semanticType.aapp" label="amyloid polypeptide"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="C2354520" scheme="gov.nih.nlm.semanticType.aapp" label="peptide"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H457895"/>
			<id>172555</id>
			<summary>
				<section label="Pramlintide" id="457895">
					<fragment>Pramlintide is a synthetic analog of human amylin that slows gastric emptying, reduces postprandial rises in blood glucose concentrations, and modestly improves A1C concentrations in patients with type 1 and type 2 diabetes when injected subcutaneously three times per day.</fragment>
				</section>
			</summary>
			<category term="C0063684" scheme="gov.nih.nlm.semanticType.horm" label="amylin"/>
			<category term="C0537551" scheme="gov.nih.nlm.semanticType.horm" label="Pramlintide"/>
			<category term="7" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H457895"/>
			<id>172556</id>
			<summary>
				<section label="Pramlintide" id="457895">
					<fragment>Pramlintide is only approved for use in patients also taking insulin.</fragment>
				</section>
			</summary>
			<category term="C0537551" scheme="gov.nih.nlm.semanticType.horm" label="Pramlintide"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H457895"/>
			<id>172557</id>
			<summary>
				<section label="Pramlintide" id="457895">
					<fragment>It may be considered for patients with type 2 diabetes inadequately controlled on insulin who are overweight or experience weight gain refractory to lifestyle measures.</fragment>
				</section>
			</summary>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H457938"/>
			<id>172559</id>
			<summary>
				<section label="SGLT2 inhibitors" id="457938">
					<fragment>Given the absence of long-term efficacy and safety data, we do not recommend sodium-glucose co-transporter 2 (SGLT2) inhibitors for routine use in patients with type 2 diabetes.</fragment>
				</section>
			</summary>
			<category term="C3542461" scheme="gov.nih.nlm.semanticType.phsu" label="SGLT2) inhibitors"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H457938"/>
			<id>172560</id>
			<summary>
				<section label="SGLT2 inhibitors" id="457938">
					<fragment>SGLT2 inhibitors may play a role as a third-line agent in patients with inadequate glycemic control on two oral agents (eg, metformin and sulfonylurea) if for some reason combination metformin and insulin is not a therapeutic option.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="C3542461" scheme="gov.nih.nlm.semanticType.phsu" label="SGLT2 inhibitors"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H457938"/>
			<id>172561</id>
			<summary>
				<section label="SGLT2 inhibitors" id="457938">
					<fragment>The sodium-glucose co-transporter 2 (SGLT2) is expressed in the proximal tubule and mediates reabsorption of approximately 90 percent of the filtered glucose load.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H457938"/>
			<id>172562</id>
			<summary>
				<section label="SGLT2 inhibitors" id="457938">
					<fragment>SGLT2 inhibitors promote the renal excretion of glucose and thereby modestly lower elevated blood glucose levels in patients with type 2 diabetes.</fragment>
				</section>
			</summary>
			<category term="C3542461" scheme="gov.nih.nlm.semanticType.phsu" label="SGLT2 inhibitors"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H457938"/>
			<id>172567</id>
			<summary>
				<section label="SGLT2 inhibitors" id="457938">
					<fragment>In meta-analyses of clinical trials comparing SGLT2 inhibitors with placebo or active comparators (metformin, sulfonylurea, DPP-4 inhibitor, insulin), SGLT2 inhibitors reduced A1C by approximately 0.5 to 0.7 percentage points (mean difference versus active comparators -0.06 percent), making them relatively weak glucose-lowering agents, similar in potency to the DPP-4 inhibitors.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0669693" scheme="gov.nih.nlm.semanticType.orch" label="DPP"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="C3542461" scheme="gov.nih.nlm.semanticType.phsu" label="SGLT2 inhibitors"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H457938"/>
			<id>172568</id>
			<summary>
				<section label="SGLT2 inhibitors" id="457938">
					<fragment>As examples: In a 24-week double blind trial, 597 patients with type 2 diabetes inadequately controlled with sulfonylureas (A1C 7 to 10 percent) were randomly assigned to dapagliflozin (2.5, 5, or 10 mg) or placebo once daily.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
			<category term="C2353951" scheme="gov.nih.nlm.semanticType.phsu" label="dapagliflozin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H457938"/>
			<id>172571</id>
			<summary>
				<section label="SGLT2 inhibitors" id="457938">
					<fragment>In a 52-week double blind trial, 814 patients with type 2 diabetes inadequately controlled with metformin (mean A1C 7.7 percent) were randomly assigned to dapagliflozin or glipizide.</fragment>
				</section>
			</summary>
			<category term="C0017642" scheme="gov.nih.nlm.semanticType.phsu" label="glipizide"/>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C2353951" scheme="gov.nih.nlm.semanticType.phsu" label="dapagliflozin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H457938"/>
			<id>172574</id>
			<summary>
				<section label="SGLT2 inhibitors" id="457938">
					<fragment>In another trial, 808 patients with type 2 diabetes mellitus inadequately controlled with insulin and up to two oral agents were randomly assigned to dapagliflozin (2.5, 5, or 10 mg once daily) or placebo.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="C2353951" scheme="gov.nih.nlm.semanticType.phsu" label="dapagliflozin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H457938"/>
			<id>172579</id>
			<summary>
				<section label="SGLT2 inhibitors" id="457938">
					<fragment>In a double blind trial, 451 patients with type 2 diabetes were randomly assigned to canagliflozin (several doses), sitagliptin 100 mg daily, or placebo.</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="C1565750" scheme="gov.nih.nlm.semanticType.phsu" label="sitagliptin"/>
			<category term="C2974540" scheme="gov.nih.nlm.semanticType.phsu" label="canagliflozin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H457938"/>
			<id>172581</id>
			<summary>
				<section label="SGLT2 inhibitors" id="457938">
					<fragment>In another double blind trial, 755 patients with type 2 diabetes inadequately controlled with metformin plus a sulfonylurea (mean A1C 8.1 percent) were randomly assigned to canagliflozin (300 mg daily) or sitagliptin (100 mg daily).</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
			<category term="C1565750" scheme="gov.nih.nlm.semanticType.phsu" label="sitagliptin"/>
			<category term="C2974540" scheme="gov.nih.nlm.semanticType.phsu" label="canagliflozin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H457938"/>
			<id>172586</id>
			<summary>
				<section label="SGLT2 inhibitors" id="457938">
					<fragment>In a 52-week double blind trial, 1452 patients with type 2 diabetes inadequately controlled with metformin (mean A1C 7.8 percent) were randomly assigned to glimepiride (titrated based upon blood glucose, median dose 5.6 mg daily) or canagliflozin (100 or 300 mg daily).</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0061323" scheme="gov.nih.nlm.semanticType.phsu" label="glimepiride"/>
			<category term="C2974540" scheme="gov.nih.nlm.semanticType.phsu" label="canagliflozin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H457938"/>
			<id>172589</id>
			<summary>
				<section label="SGLT2 inhibitors" id="457938">
					<fragment>Canagliflozin reduced weight (-4.2 to 4.4 kg compared with +0.8 kg with glimepiride) and had less frequent severe hypoglycemia (&lt;1 compared with 3 percent), but was associated with more frequent genital yeast infections (women: 11 to 14 percent versus 2 percent with glimepiride).</fragment>
				</section>
			</summary>
			<category term="C0061323" scheme="gov.nih.nlm.semanticType.phsu" label="glimepiride"/>
			<category term="C0124598" scheme="gov.nih.nlm.semanticType.phsu" label="kg"/>
			<category term="C2974540" scheme="gov.nih.nlm.semanticType.phsu" label="Canagliflozin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H457938"/>
			<id>172598</id>
			<summary>
				<section label="SGLT2 inhibitors" id="457938">
					<fragment>There are no long-term safety data with regard to the effects of chronic glucosuria on the urinary tract.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H457938"/>
			<id>172602</id>
			<summary>
				<section label="SGLT2 inhibitors" id="457938">
					<fragment>In patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] 45 to 59 mL/min), the dose should not exceed 100 mg daily.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H457938"/>
			<id>172603</id>
			<summary>
				<section label="SGLT2 inhibitors" id="457938">
					<fragment>Canagliflozin should not be given to patients with eGFR &lt;45 mL/min or in patients with severe hepatic impairment.</fragment>
				</section>
			</summary>
			<category term="C2974540" scheme="gov.nih.nlm.semanticType.phsu" label="Canagliflozin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H457938"/>
			<id>172606</id>
			<summary>
				<section label="SGLT2 inhibitors" id="457938">
					<fragment>It is not recommended for use in patients with eGFR &lt;60 mL/min.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H457938"/>
			<id>172607</id>
			<summary>
				<section label="SGLT2 inhibitors" id="457938">
					<fragment>For patients with severely reduced liver function, a starting dose of 5 mg is recommended.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H457938"/>
			<id>172608</id>
			<summary>
				<section label="SGLT2 inhibitors" id="457938">
					<fragment>There is limited experience with either drug in patients with severe hepatic impairment.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H25"/>
			<id>172611</id>
			<summary>
				<section label="Colesevelam" id="25">
					<fragment>Given the modest glucose-lowering effectiveness, expense, and limited clinical experience, we typically do not recommend colesevelam to improve glycemic control in patients with type 2 diabetes.</fragment>
				</section>
			</summary>
			<category term="C0541155" scheme="gov.nih.nlm.semanticType.phsu" label="colesevelam"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H25"/>
			<id>172612</id>
			<summary>
				<section label="Colesevelam" id="25">
					<fragment>Colesevelam is a bile acid sequestrant that lowers low-density lipoprotein (LDL) cholesterol in patients with primary hypercholesterolemia.</fragment>
				</section>
			</summary>
			<category term="C0541155" scheme="gov.nih.nlm.semanticType.phsu" label="Colesevelam"/>
			<category term="C0625158" scheme="gov.nih.nlm.semanticType.phsu" label="cholesterol"/>
			<category term="C2917673" scheme="gov.nih.nlm.semanticType.phsu" label="bile acid"/>
			<category term="C3537227" scheme="gov.nih.nlm.semanticType.phsu" label="bile acid sequestrant"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H25"/>
			<id>172615</id>
			<summary>
				<section label="Colesevelam" id="25">
					<fragment>In a meta-analysis of five short-term trials (16 to 26 weeks) in patients with type 2 diabetes inadequately treated with oral agents or insulin, the addition of colesevelam compared with placebo modestly reduced A1C levels (mean difference 0.5 percentage points, 95% CI -0.6 to -0.4).</fragment>
				</section>
			</summary>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0541155" scheme="gov.nih.nlm.semanticType.phsu" label="colesevelam"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H25"/>
			<id>172618</id>
			<summary>
				<section label="Colesevelam" id="25">
					<fragment>In contrast to its effects on LDL cholesterol, colesevelam increases triglyceride concentrations by approximately 20 percent.</fragment>
				</section>
			</summary>
			<category term="C0541155" scheme="gov.nih.nlm.semanticType.phsu" label="colesevelam"/>
			<category term="C0625158" scheme="gov.nih.nlm.semanticType.phsu" label="cholesterol"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H24159710"/>
			<id>172620</id>
			<summary>
				<section label="Bromocriptine" id="24159710">
					<fragment>Given its modest glucose-lowering effect, very frequent gastrointestinal (GI) side effects, and the availability of more effective drugs, we do not recommend bromocriptine for the treatment of type 2 diabetes.</fragment>
				</section>
			</summary>
			<category term="C0006230" scheme="gov.nih.nlm.semanticType.phsu" label="bromocriptine"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C1311032" scheme="gov.nih.nlm.semanticType.orch" label="GI"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H24159710"/>
			<id>172621</id>
			<summary>
				<section label="Bromocriptine" id="24159710">
					<fragment>Bromocriptine is an ergot-derived dopamine agonist that has been used for over two decades for the treatment of hyperprolactinemia and Parkinson disease.</fragment>
				</section>
			</summary>
			<category term="C0006230" scheme="gov.nih.nlm.semanticType.phsu" label="Bromocriptine"/>
			<category term="C0243192" scheme="gov.nih.nlm.semanticType.phsu" label="agonist"/>
			<category term="C0304712" scheme="gov.nih.nlm.semanticType.phsu" label="ergot"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H24159710"/>
			<id>172622</id>
			<summary>
				<section label="Bromocriptine" id="24159710">
					<fragment>A new quick release formulation of bromocriptine (Cycloset) was approved by the US Food and Drug Administration for the treatment of type 2 diabetes mellitus.</fragment>
				</section>
			</summary>
			<category term="C0006230" scheme="gov.nih.nlm.semanticType.phsu" label="bromocriptine"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="Drug"/>
			<category term="C3469597" scheme="gov.nih.nlm.semanticType.hlca" label="Drug Administration"/>
			<category term="C3540798" scheme="gov.nih.nlm.semanticType.imft" label="Food"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H24159710"/>
			<id>172623</id>
			<summary>
				<section label="Bromocriptine" id="24159710">
					<fragment>In short-term clinical trials in patients with type 2 diabetes mellitus, bromocriptine (up to 4.8 mg daily) as monotherapy or as adjunctive therapy to sulfonylureas was minimally effective in reducing A1C compared with placebo (mean difference 0.4 to 0.5 percentage points).</fragment>
				</section>
			</summary>
			<category term="C0006230" scheme="gov.nih.nlm.semanticType.phsu" label="bromocriptine"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H1665282"/>
			<id>172626</id>
			<summary>
				<section label="SURGICAL TREATMENT OF OBESITY" id="1665282">
					<fragment>Surgical treatment of obese patients with diabetes results in the largest degree of sustained weight loss (20 to 30 percent after one to two years) and, in parallel, the largest improvements in blood glucose control.</fragment>
				</section>
			</summary>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="Surgical"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H1665282"/>
			<id>172627</id>
			<summary>
				<section label="SURGICAL TREATMENT OF OBESITY" id="1665282">
					<fragment>There are a growing number of unblinded trials comparing bariatric surgery with medical therapy for the treatment of type 2 diabetes.</fragment>
				</section>
			</summary>
			<category term="C0418981" scheme="gov.nih.nlm.semanticType.topp" label="medical therapy"/>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgery"/>
			<category term="C1456587" scheme="gov.nih.nlm.semanticType.topp" label="bariatric surgery"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H1665282"/>
			<id>172628</id>
			<summary>
				<section label="SURGICAL TREATMENT OF OBESITY" id="1665282">
					<fragment>As examples: In a two-year trial of 60 obese patients (body mass index [BMI] 30 to 40) with a history of type 2 diabetes diagnosed within the previous two years, subjects randomly assigned to laparoscopic banding with conventional therapy versus conventional therapy alone (education, lifestyle modification, pharmacologic therapy) experienced greater weight loss (20 versus 1.4 percent, respectively) and remission rates of diabetes (73 versus 13 percent, respectively).</fragment>
				</section>
			</summary>
			<category term="C1433710" scheme="gov.nih.nlm.semanticType.orch" label="BMI"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H1665282"/>
			<id>172629</id>
			<summary>
				<section label="SURGICAL TREATMENT OF OBESITY" id="1665282">
					<fragment>In another trial, 72 patients with obesity (BMI &gt;35) and type 2 diabetes for at least five years were randomly assigned to gastric bypass, biliopancreatic diversion, or medical therapy (pharmacologic therapy, education, lifestyle modification).</fragment>
				</section>
			</summary>
			<category term="C0005435" scheme="gov.nih.nlm.semanticType.topp" label="bypass, biliopancreatic"/>
			<category term="C0017125" scheme="gov.nih.nlm.semanticType.topp" label="gastric bypass"/>
			<category term="C0185033" scheme="gov.nih.nlm.semanticType.topp" label="diversion"/>
			<category term="C0418981" scheme="gov.nih.nlm.semanticType.topp" label="medical therapy"/>
			<category term="C0741847" scheme="gov.nih.nlm.semanticType.topp" label="bypass"/>
			<category term="C1433710" scheme="gov.nih.nlm.semanticType.orch" label="BMI"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H1665282"/>
			<id>172632</id>
			<summary>
				<section label="SURGICAL TREATMENT OF OBESITY" id="1665282">
					<fragment>The average time to normalization of fasting glucose and A1C levels for bypass and biliopancreatic diversion was 10 and 4 months respectively.</fragment>
				</section>
			</summary>
			<category term="C0005435" scheme="gov.nih.nlm.semanticType.topp" label="biliopancreatic diversion"/>
			<category term="C0185033" scheme="gov.nih.nlm.semanticType.topp" label="diversion"/>
			<category term="C0741847" scheme="gov.nih.nlm.semanticType.topp" label="bypass"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H1665282"/>
			<id>172635</id>
			<summary>
				<section label="SURGICAL TREATMENT OF OBESITY" id="1665282">
					<fragment>In a one-year trial, 150 obese (BMI 27 to 43) patients with type 2 diabetes (mean duration approximately eight years) were randomly assigned to gastric bypass, sleeve gastrectomy, or intensive medical therapy.</fragment>
				</section>
			</summary>
			<category term="C0017118" scheme="gov.nih.nlm.semanticType.topp" label="gastrectomy"/>
			<category term="C0017125" scheme="gov.nih.nlm.semanticType.topp" label="gastric bypass"/>
			<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
			<category term="C0418981" scheme="gov.nih.nlm.semanticType.topp" label="medical therapy"/>
			<category term="C0741847" scheme="gov.nih.nlm.semanticType.topp" label="bypass"/>
			<category term="C1433710" scheme="gov.nih.nlm.semanticType.orch" label="BMI"/>
			<category term="C3160799" scheme="gov.nih.nlm.semanticType.topp" label="sleeve gastrectomy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H1665282"/>
			<id>172638</id>
			<summary>
				<section label="SURGICAL TREATMENT OF OBESITY" id="1665282">
					<fragment>In another one-year trial, 120 obese patients (BMI 30 to 39.9) with type 2 diabetes (mean duration nine years) who were participating in an intensive lifestyle and medically-managed weight control program were randomly assigned to receive Roux-en-Y gastric bypass surgery while continuing the lifestyle program or to continue the lifestyle program alone.</fragment>
				</section>
			</summary>
			<category term="C0002804" scheme="gov.nih.nlm.semanticType.topp" label="Roux-en-Y"/>
			<category term="C0017125" scheme="gov.nih.nlm.semanticType.topp" label="gastric bypass"/>
			<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgery"/>
			<category term="C0585179" scheme="gov.nih.nlm.semanticType.topp" label="Roux-en-Y gastric bypass"/>
			<category term="C0741847" scheme="gov.nih.nlm.semanticType.topp" label="bypass"/>
			<category term="C0920298" scheme="gov.nih.nlm.semanticType.topp" label="weight control"/>
			<category term="C1121354" scheme="gov.nih.nlm.semanticType.orch" label="en"/>
			<category term="C1433710" scheme="gov.nih.nlm.semanticType.orch" label="BMI"/>
			<category term="C1444341" scheme="gov.nih.nlm.semanticType.hlca" label="managed weight control"/>
			<category term="C1536078" scheme="gov.nih.nlm.semanticType.topp" label="bypass surgery"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H1665282"/>
			<id>172640</id>
			<summary>
				<section label="SURGICAL TREATMENT OF OBESITY" id="1665282">
					<fragment>Medications were administered to achieve maximum control of glycemia and cardiovascular risk factors.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H1665282"/>
			<id>172641</id>
			<summary>
				<section label="SURGICAL TREATMENT OF OBESITY" id="1665282">
					<fragment>After one year, a greater proportion of patients in the gastric bypass group achieved the composite outcome (A1C &lt;7 percent, low-density lipoprotein [LDL] cholesterol &lt;100 mg/dL, and systolic blood pressure less than 130 mmHg, 49 verus 19 percent, odds ratio [OR] 4.8, 95% CI 1.9-11.7).</fragment>
				</section>
			</summary>
			<category term="C0017125" scheme="gov.nih.nlm.semanticType.topp" label="gastric bypass"/>
			<category term="C0625158" scheme="gov.nih.nlm.semanticType.phsu" label="cholesterol"/>
			<category term="C0741847" scheme="gov.nih.nlm.semanticType.topp" label="bypass"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H1665282"/>
			<id>172644</id>
			<summary>
				<section label="SURGICAL TREATMENT OF OBESITY" id="1665282">
					<fragment>Serious adverse events were more frequent in the gastric bypass group (22 versus 15 events), one of which involved a postoperative complication resulting in sepsis, stroke, leg amputation, and renal failure.</fragment>
				</section>
			</summary>
			<category term="C0002688" scheme="gov.nih.nlm.semanticType.topp" label="amputation"/>
			<category term="C0017125" scheme="gov.nih.nlm.semanticType.topp" label="gastric bypass"/>
			<category term="C0337308" scheme="gov.nih.nlm.semanticType.topp" label="leg amputation"/>
			<category term="C0741847" scheme="gov.nih.nlm.semanticType.topp" label="bypass"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H1665282"/>
			<id>172645</id>
			<summary>
				<section label="SURGICAL TREATMENT OF OBESITY" id="1665282">
					<fragment>Despite these impressive results, concerns remain about long-term success rates in maintaining weight loss and reproducibility of the results in patients with an extensive history of diabetes or with a different surgical team.</fragment>
				</section>
			</summary>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H1665282"/>
			<id>172647</id>
			<summary>
				<section label="SURGICAL TREATMENT OF OBESITY" id="1665282">
					<fragment>Longer-term follow-up of clinically important endpoints, such as effects on microvascular and macrovascular complications and mortality, are required before laparoscopic banding or other bariatric surgery procedures can be routinely recommended for the treatment of persistent hyperglycemia, resistant to multiple medications, in obesity-related type 2 diabetes.</fragment>
				</section>
			</summary>
			<category term="C0278293" scheme="gov.nih.nlm.semanticType.topp" label="procedures"/>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgery"/>
			<category term="C1456587" scheme="gov.nih.nlm.semanticType.topp" label="bariatric surgery"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H28"/>
			<id>172658</id>
			<summary>
				<section label="Glycemic goals" id="28">
					<fragment>In the absence of contraindications, metformin is usually the initial therapy for most patients with type 2 diabetes.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H28"/>
			<id>172663</id>
			<summary>
				<section label="Glycemic goals" id="28">
					<fragment>We are aware that this goal is not appropriate for all patients, especially the elderly and those with comorbid conditions.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H29"/>
			<id>172666</id>
			<summary>
				<section label="Metformin monotherapy failure" id="29">
					<fragment>In patients with inadequate glycemic control on metformin (A1C &gt;7.0 percent), with A1C close to target (&lt;=8.5 percent), we suggest adding a short-acting sulfonylurea, such as glipizide . The addition of repaglinide is an alternative option, which can be considered in individuals who do not reach glycemic goals with metformin, if there are contraindications to sulfonylureas or patient preference limits the use of insulin.</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="adding"/>
			<category term="C0017642" scheme="gov.nih.nlm.semanticType.phsu" label="glipizide"/>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
			<category term="C0246689" scheme="gov.nih.nlm.semanticType.phsu" label="repaglinide"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H29"/>
			<id>172667</id>
			<summary>
				<section label="Metformin monotherapy failure" id="29">
					<fragment>The addition of pioglitazone is also an option in individuals without risk factors for heart failure or fracture, who do not reach glycemic goals with metformin alone, if there are contraindications to sulfonylureas or patient preference limits the use of sulfonylureas or insulin.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
			<category term="C0071097" scheme="gov.nih.nlm.semanticType.phsu" label="pioglitazone"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H30"/>
			<id>172672</id>
			<summary>
				<section label="Contraindications to metformin and sulfonylurea monotherapy failure" id="30">
					<fragment>Dipeptidyl peptidase-4 (DPP-4) inhibitors can be considered as add-on drug therapy to sulfonylureas in patients who have contraindications to metformin and pioglitazone.</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="add"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
			<category term="C0071097" scheme="gov.nih.nlm.semanticType.phsu" label="pioglitazone"/>
			<category term="C0669693" scheme="gov.nih.nlm.semanticType.orch" label="DPP"/>
			<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H31"/>
			<id>172674</id>
			<summary>
				<section label="Dual oral agent failure" id="31">
					<fragment>In individuals with inadequate glycemic control (A1C &gt;7 percent) on two oral agents (usually metformin and sulfonylurea), we suggest switching to insulin (discontinue sulfonylurea and continue metformin).</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H31"/>
			<id>172675</id>
			<summary>
				<section label="Dual oral agent failure" id="31">
					<fragment>However, three oral agents (metformin, sulfonylurea, pioglitazone) can be considered in patients with A1C values that are not too far from goal (A1C &lt;=8.5 percent).</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
			<category term="C0071097" scheme="gov.nih.nlm.semanticType.phsu" label="pioglitazone"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1790#H31"/>
			<id>172676</id>
			<summary>
				<section label="Dual oral agent failure" id="31">
					<fragment>A glucagon-like peptide-1 (GLP-1) analog could also be considered as an add-on drug for overweight patients who are poorly controlled on maximal doses of two oral agents.</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="add"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0014361" scheme="gov.nih.nlm.semanticType.horm" label="glucagon-like peptide"/>
			<category term="C0017687" scheme="gov.nih.nlm.semanticType.horm" label="glucagon"/>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="C0763866" scheme="gov.nih.nlm.semanticType.aapp" label="GLP"/>
			<category term="C2354520" scheme="gov.nih.nlm.semanticType.aapp" label="peptide"/>
			<category term="7" scheme="org.openInfobutton.score"/>
		</entry>
	</feed>
	<feed>
		<title>Initial management of blood glucose in adults with type 2 diabetes mellitus</title>
		<category term="C0308403" scheme="gov.nih.nlm.semanticType.phsu" label="balancing"/>
		<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
		<category term="C0023767" scheme="gov.nih.nlm.semanticType.imft" label="lipids"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0012167" scheme="gov.nih.nlm.semanticType.topp" label="Weight reduction, diet"/>
		<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="Pharmacotherapy"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
		<category term="C0278293" scheme="gov.nih.nlm.semanticType.topp" label="procedures"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgery"/>
		<category term="C1456587" scheme="gov.nih.nlm.semanticType.topp" label="bariatric surgery"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
		<category term="C0124598" scheme="gov.nih.nlm.semanticType.phsu" label="kg"/>
		<category term="C1433710" scheme="gov.nih.nlm.semanticType.orch" label="BMI"/>
		<category term="C0622644" scheme="gov.nih.nlm.semanticType.orch" label="fat"/>
		<category term="C1135809" scheme="gov.nih.nlm.semanticType.topp" label="caloric restriction"/>
		<category term="C3540798" scheme="gov.nih.nlm.semanticType.imft" label="food"/>
		<category term="C0076275" scheme="gov.nih.nlm.semanticType.phsu" label="orlistat"/>
		<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
		<category term="C0625158" scheme="gov.nih.nlm.semanticType.phsu" label="cholesterol"/>
		<category term="C0003364" scheme="gov.nih.nlm.semanticType.phsu" label="antihypertensives"/>
		<category term="C0360714" scheme="gov.nih.nlm.semanticType.phsu" label="statins"/>
		<category term="C0418981" scheme="gov.nih.nlm.semanticType.topp" label="medical therapy"/>
		<category term="C0588436" scheme="gov.nih.nlm.semanticType.topp" label="self-monitoring"/>
		<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="Psychotherapy"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="Insulin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
		<category term="C0246689" scheme="gov.nih.nlm.semanticType.phsu" label="repaglinide"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
		<category term="C0071097" scheme="gov.nih.nlm.semanticType.phsu" label="Pioglitazone"/>
		<category term="C0071097" scheme="gov.nih.nlm.semanticType.phsu" label="pioglitazone"/>
		<category term="C0086466" scheme="gov.nih.nlm.semanticType.phsu" label="injectable"/>
		<category term="C0243192" scheme="gov.nih.nlm.semanticType.phsu" label="agonists"/>
		<category term="C0669693" scheme="gov.nih.nlm.semanticType.orch" label="DPP"/>
		<category term="C0763866" scheme="gov.nih.nlm.semanticType.aapp" label="GLP"/>
		<category term="C1979844" scheme="gov.nih.nlm.semanticType.aapp" label="alpha"/>
		<category term="C3539108" scheme="gov.nih.nlm.semanticType.phsu" label="alpha-glucosidase inhibitors"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0020616" scheme="gov.nih.nlm.semanticType.phsu" label="hypoglycemic"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0643010" scheme="gov.nih.nlm.semanticType.phsu" label="ADA"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0150600" scheme="gov.nih.nlm.semanticType.hlca" label="guidance"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0643010" scheme="gov.nih.nlm.semanticType.phsu" label="ADA"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0643010" scheme="gov.nih.nlm.semanticType.phsu" label="ADA"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0935929" scheme="gov.nih.nlm.semanticType.phsu" label="antidiabetic"/>
		<category term="C1293130" scheme="gov.nih.nlm.semanticType.topp" label="stabilization"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0017642" scheme="gov.nih.nlm.semanticType.phsu" label="glipizide"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0017642" scheme="gov.nih.nlm.semanticType.phsu" label="glipizide"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="Metformin"/>
		<category term="C0001975" scheme="gov.nih.nlm.semanticType.phsu" label="alcohol"/>
		<category term="C0031001" scheme="gov.nih.nlm.semanticType.topp" label="perfusion"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0031809" scheme="gov.nih.nlm.semanticType.hlca" label="physical exam"/>
		<category term="C0278293" scheme="gov.nih.nlm.semanticType.topp" label="procedure"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
		<category term="C0020616" scheme="gov.nih.nlm.semanticType.phsu" label="hypoglycemic"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="Sulfonylureas"/>
		<category term="C0359086" scheme="gov.nih.nlm.semanticType.phsu" label="oral hypoglycemic"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C0017631" scheme="gov.nih.nlm.semanticType.phsu" label="gliclazide"/>
		<category term="C0017642" scheme="gov.nih.nlm.semanticType.phsu" label="glipizide"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
		<category term="C0246689" scheme="gov.nih.nlm.semanticType.phsu" label="Repaglinide"/>
		<category term="C0903898" scheme="gov.nih.nlm.semanticType.phsu" label="nateglinide"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
		<category term="C0246689" scheme="gov.nih.nlm.semanticType.phsu" label="repaglinide"/>
		<category term="C0903898" scheme="gov.nih.nlm.semanticType.phsu" label="nateglinide"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
		<category term="C0246689" scheme="gov.nih.nlm.semanticType.phsu" label="repaglinide"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0289313" scheme="gov.nih.nlm.semanticType.phsu" label="rosiglitazone"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="Drug"/>
		<category term="C0071097" scheme="gov.nih.nlm.semanticType.phsu" label="pioglitazone"/>
		<category term="C3469597" scheme="gov.nih.nlm.semanticType.hlca" label="Drug Administration"/>
		<category term="C3540798" scheme="gov.nih.nlm.semanticType.imft" label="Food"/>
		<category term="C0071097" scheme="gov.nih.nlm.semanticType.phsu" label="pioglitazone"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C2605394" scheme="gov.nih.nlm.semanticType.orch" label="thiazolidinediones"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="Drugs"/>
		<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
		<category term="C0023767" scheme="gov.nih.nlm.semanticType.imft" label="lipid"/>
		<category term="C0071097" scheme="gov.nih.nlm.semanticType.phsu" label="pioglitazone"/>
		<category term="C0289313" scheme="gov.nih.nlm.semanticType.phsu" label="rosiglitazone"/>
		<category term="C2605394" scheme="gov.nih.nlm.semanticType.orch" label="thiazolidinedione"/>
		<category term="C0669693" scheme="gov.nih.nlm.semanticType.orch" label="DPP"/>
		<category term="C1565750" scheme="gov.nih.nlm.semanticType.phsu" label="Sitagliptin"/>
		<category term="C1611934" scheme="gov.nih.nlm.semanticType.phsu" label="saxagliptin"/>
		<category term="C1958126" scheme="gov.nih.nlm.semanticType.phsu" label="alogliptin"/>
		<category term="C2746078" scheme="gov.nih.nlm.semanticType.phsu" label="linagliptin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
		<category term="C0669693" scheme="gov.nih.nlm.semanticType.orch" label="DPP"/>
		<category term="C2605394" scheme="gov.nih.nlm.semanticType.orch" label="thiazolidinedione"/>
		<category term="C2746078" scheme="gov.nih.nlm.semanticType.phsu" label="linagliptin"/>
		<category term="C0014361" scheme="gov.nih.nlm.semanticType.horm" label="glucagon-like peptide"/>
		<category term="C0017687" scheme="gov.nih.nlm.semanticType.horm" label="glucagon"/>
		<category term="C0167117" scheme="gov.nih.nlm.semanticType.phsu" label="Exenatide"/>
		<category term="C0763866" scheme="gov.nih.nlm.semanticType.aapp" label="GLP"/>
		<category term="C1456408" scheme="gov.nih.nlm.semanticType.horm" label="liraglutide"/>
		<category term="C2354520" scheme="gov.nih.nlm.semanticType.aapp" label="peptide"/>
		<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="add"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0167117" scheme="gov.nih.nlm.semanticType.phsu" label="Exenatide"/>
		<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
		<category term="C1456408" scheme="gov.nih.nlm.semanticType.horm" label="liraglutide"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0020616" scheme="gov.nih.nlm.semanticType.phsu" label="hypoglycemics"/>
		<category term="C0359086" scheme="gov.nih.nlm.semanticType.phsu" label="oral hypoglycemics"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="Insulin"/>
		<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0017628" scheme="gov.nih.nlm.semanticType.phsu" label="glyburide"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0289313" scheme="gov.nih.nlm.semanticType.phsu" label="rosiglitazone"/>
		<category term="C1620263" scheme="gov.nih.nlm.semanticType.phsu" label="rosiglitazone, metformin"/>
		<category term="C0289313" scheme="gov.nih.nlm.semanticType.phsu" label="rosiglitazone"/>
		<category term="C0023767" scheme="gov.nih.nlm.semanticType.imft" label="lipid"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0086466" scheme="gov.nih.nlm.semanticType.phsu" label="injectable"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0023767" scheme="gov.nih.nlm.semanticType.imft" label="lipids"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
		<category term="C0243192" scheme="gov.nih.nlm.semanticType.phsu" label="agonists"/>
		<category term="C0763866" scheme="gov.nih.nlm.semanticType.aapp" label="GLP"/>
		<category term="C1300198" scheme="gov.nih.nlm.semanticType.phsu" label="second generation sulfonylureas"/>
		<category term="C2605394" scheme="gov.nih.nlm.semanticType.orch" label="thiazolidinediones"/>
		<category term="C2917359" scheme="gov.nih.nlm.semanticType.phsu" label="GLP-1 receptor agonists"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
		<category term="C2605394" scheme="gov.nih.nlm.semanticType.orch" label="thiazolidinediones"/>
		<category term="C0012167" scheme="gov.nih.nlm.semanticType.topp" label="Weight reduction, diet"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="Metformin"/>
		<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="added"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
		<category term="C0246689" scheme="gov.nih.nlm.semanticType.phsu" label="repaglinide"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
		<category term="C2605394" scheme="gov.nih.nlm.semanticType.orch" label="thiazolidinedione"/>
		<category term="C0023767" scheme="gov.nih.nlm.semanticType.imft" label="lipid"/>
		<category term="C0071097" scheme="gov.nih.nlm.semanticType.phsu" label="pioglitazone"/>
		<category term="C0289313" scheme="gov.nih.nlm.semanticType.phsu" label="rosiglitazone"/>
		<category term="C2605394" scheme="gov.nih.nlm.semanticType.orch" label="thiazolidinedione"/>
		<category term="C2746078" scheme="gov.nih.nlm.semanticType.phsu" label="linagliptin"/>
		<category term="C0246689" scheme="gov.nih.nlm.semanticType.phsu" label="repaglinide"/>
		<category term="C3537178" scheme="gov.nih.nlm.semanticType.phsu" label="glinides"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0308403" scheme="gov.nih.nlm.semanticType.phsu" label="balancing"/>
		<id>1779</id>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H3"/>
			<id>172115</id>
			<summary>
				<section label="Degree of glycemic control" id="3">
					<fragment>Achieving near normal blood glucose concentrations markedly reduces the risk of microvascular and macrovascular complications in type 1 diabetes.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H3"/>
			<id>172116</id>
			<summary>
				<section label="Degree of glycemic control" id="3">
					<fragment>Improved glycemic control also improves the risk of microvascular complications in patients with type 2 diabetes  . Every 1 percent drop in A1C is associated with improved outcomes with no threshold effect.</fragment>
				</section>
			</summary>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H3"/>
			<id>172117</id>
			<summary>
				<section label="Degree of glycemic control" id="3">
					<fragment>To date, no randomized clinical trial has convincingly demonstrated a beneficial effect of intensive therapy on macrovascular outcomes in type 2 diabetes.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H3"/>
			<id>172118</id>
			<summary>
				<section label="Degree of glycemic control" id="3">
					<fragment>Target A1C goals in patients with type 2 diabetes should be tailored to the individual, balancing the improvement in microvascular complications with the risk of hypoglycemia.</fragment>
				</section>
			</summary>
			<category term="C0308403" scheme="gov.nih.nlm.semanticType.phsu" label="balancing"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H4"/>
			<id>172121</id>
			<summary>
				<section label="Cardiovascular risk factor management" id="4">
					<fragment>In addition to glycemic control, vigorous cardiac risk reduction (smoking cessation, aspirin, blood pressure control, reduction in serum lipids, diet, and exercise) should be a top priority for all patients with type 2 diabetes.)</fragment>
				</section>
			</summary>
			<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
			<category term="C0023767" scheme="gov.nih.nlm.semanticType.imft" label="lipids"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H4"/>
			<id>172122</id>
			<summary>
				<section label="Cardiovascular risk factor management" id="4">
					<fragment>However, in spite of evidence that aggressive risk factor reduction lowers the risk of both micro- and macrovascular complications in patients with diabetes, the vast majority of patients do not achieve recommended goals for A1C, blood pressure control, and management of dyslipidemia.</fragment>
				</section>
			</summary>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H5"/>
			<id>172123</id>
			<summary>
				<section label="NONPHARMACOLOGIC THERAPY" id="5">
					<fragment>Besides contributing to microvascular and macrovascular disease, hyperglycemia adversely and reversibly affects both insulin resistance and insulin secretion.</fragment>
				</section>
			</summary>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H5"/>
			<id>172124</id>
			<summary>
				<section label="NONPHARMACOLOGIC THERAPY" id="5">
					<fragment>Weight reduction, diet, and exercise can all be used to improve glycemic control, although the majority of patients with type 2 diabetes will require medication over the course of their diabetes.</fragment>
				</section>
			</summary>
			<category term="C0012167" scheme="gov.nih.nlm.semanticType.topp" label="Weight reduction, diet"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H6"/>
			<id>172130</id>
			<summary>
				<section label="Diet" id="6">
					<fragment>Several studies have evaluated the long-term efficacy of diet (alone or with exercise) in patients with newly diagnosed type 2 diabetes.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H6"/>
			<id>172137</id>
			<summary>
				<section label="Diet" id="6">
					<fragment>Despite the clear benefit of weight loss, only a small percentage of patients with type 2 diabetes are able to attain and maintain substantial weight loss.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H1667087"/>
			<id>172140</id>
			<summary>
				<section label="Pharmacologic therapy" id="1667087">
					<fragment>Pharmacotherapy for weight loss may be effective in patients with type 2 diabetes, but generally is associated with high dropout rates due to medication side effects and is not recommended as primary therapy for diabetes.</fragment>
				</section>
			</summary>
			<category term="C0013216" scheme="gov.nih.nlm.semanticType.topp" label="Pharmacotherapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H1667108"/>
			<id>172141</id>
			<summary>
				<section label="Surgical therapy" id="1667108">
					<fragment>The surgical treatment of obese patients with diabetes results in the largest degree of sustained weight loss and, in parallel, improvements in blood glucose control.</fragment>
				</section>
			</summary>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H1667108"/>
			<id>172142</id>
			<summary>
				<section label="Surgical therapy" id="1667108">
					<fragment>However, longer-term follow-up is required before bariatric surgery procedures can be routinely recommended for the treatment of recent onset, obesity-related type 2 diabetes.</fragment>
				</section>
			</summary>
			<category term="C0278293" scheme="gov.nih.nlm.semanticType.topp" label="procedures"/>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgery"/>
			<category term="C1456587" scheme="gov.nih.nlm.semanticType.topp" label="bariatric surgery"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H8"/>
			<id>172144</id>
			<summary>
				<section label="Exercise" id="8">
					<fragment>Regular exercise is also beneficial in type 2 diabetes, independent of weight loss.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H8"/>
			<id>172148</id>
			<summary>
				<section label="Exercise" id="8">
					<fragment>However, only a fraction of patients with type 2 diabetes are able to maintain a regular exercise regimen.</fragment>
				</section>
			</summary>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H9"/>
			<id>172151</id>
			<summary>
				<section label="Intensive lifestyle modification" id="9">
					<fragment>In the Look AHEAD trial, 5145 individuals with type 2 diabetes and BMI &gt;25 kg/m2 were randomly assigned to an intensive lifestyle intervention or standard diabetes education.</fragment>
				</section>
			</summary>
			<category term="C0124598" scheme="gov.nih.nlm.semanticType.phsu" label="kg"/>
			<category term="C1433710" scheme="gov.nih.nlm.semanticType.orch" label="BMI"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H9"/>
			<id>172152</id>
			<summary>
				<section label="Intensive lifestyle modification" id="9">
					<fragment>The intensive intervention included caloric restriction (maximum 30 percent calories from fat, minimum 15 percent protein, and the remainder from carbohydrates, in the form of liquid meal replacements, frozen food entrees, or structured meal plans), moderate-intensity physical activity (goal 175 minutes weekly), and weekly group or individual sessions with registered dietitians, behavioral psychologists, and exercise specialists.</fragment>
				</section>
			</summary>
			<category term="C0622644" scheme="gov.nih.nlm.semanticType.orch" label="fat"/>
			<category term="C1135809" scheme="gov.nih.nlm.semanticType.topp" label="caloric restriction"/>
			<category term="C3540798" scheme="gov.nih.nlm.semanticType.imft" label="food"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H9"/>
			<id>172153</id>
			<summary>
				<section label="Intensive lifestyle modification" id="9">
					<fragment>If weight loss goals were not achieved in the first six months, a weight loss medication (orlistat) and/or advanced behavioral strategies were initiated.</fragment>
				</section>
			</summary>
			<category term="C0076275" scheme="gov.nih.nlm.semanticType.phsu" label="orlistat"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H9"/>
			<id>172154</id>
			<summary>
				<section label="Intensive lifestyle modification" id="9">
					<fragment>The primary outcome was a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, and hospitalization for angina.</fragment>
				</section>
			</summary>
			<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H9"/>
			<id>172162</id>
			<summary>
				<section label="Intensive lifestyle modification" id="9">
					<fragment>LDL cholesterol was lower in the control group than in the intervention group (mean difference 1.6 mg/dL [0.04 mmol/L]).</fragment>
				</section>
			</summary>
			<category term="C0625158" scheme="gov.nih.nlm.semanticType.phsu" label="cholesterol"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H9"/>
			<id>172165</id>
			<summary>
				<section label="Intensive lifestyle modification" id="9">
					<fragment>Thus, the improvement in weight and glycemia did not reduce the occurrence of cardiovascular events.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H9"/>
			<id>172166</id>
			<summary>
				<section label="Intensive lifestyle modification" id="9">
					<fragment>Possible reasons for this finding include the lower than expected rates of cardiovascular events in both groups, improved overall cardiovascular risk factor treatment with medical therapy (antihypertensives, statins), enrollment of a relatively healthy patient population, and gradual weight loss in the control group such that the differential weight loss between the two groups was only 2.5 percent at study end.</fragment>
				</section>
			</summary>
			<category term="C0003364" scheme="gov.nih.nlm.semanticType.phsu" label="antihypertensives"/>
			<category term="C0360714" scheme="gov.nih.nlm.semanticType.phsu" label="statins"/>
			<category term="C0418981" scheme="gov.nih.nlm.semanticType.topp" label="medical therapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H9"/>
			<id>172167</id>
			<summary>
				<section label="Intensive lifestyle modification" id="9">
					<fragment>A sustained weight loss of greater than that achieved in the trial may be required to reduce the risk of cardiovascular disease.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H9"/>
			<id>172169</id>
			<summary>
				<section label="Intensive lifestyle modification" id="9">
					<fragment>The intensive lifestyle intervention appears to reduce microvascular complications, although final analysis is pending.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H9"/>
			<id>172170</id>
			<summary>
				<section label="Intensive lifestyle modification" id="9">
					<fragment>Weight loss and exercise remain an important component of diabetes management due to overall health benefits.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H10"/>
			<id>172171</id>
			<summary>
				<section label="Psychological interventions" id="10">
					<fragment>Patients with type 2 diabetes often experience significant stress related to the many self-care responsibilities to optimize glycemic control (lifestyle modifications, medication, and self-monitoring of blood glucose).</fragment>
				</section>
			</summary>
			<category term="C0588436" scheme="gov.nih.nlm.semanticType.topp" label="self-monitoring"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H10"/>
			<id>172173</id>
			<summary>
				<section label="Psychological interventions" id="10">
					<fragment>Psychotherapy reduces psychological distress and improves glycemic control in some, but not all, studies.</fragment>
				</section>
			</summary>
			<category term="C0033968" scheme="gov.nih.nlm.semanticType.topp" label="Psychotherapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H10"/>
			<id>172174</id>
			<summary>
				<section label="Psychological interventions" id="10">
					<fragment>In a meta-analysis of 12 trials of patients with type 2 diabetes randomly assigned to psychological intervention or usual care, mean A1C was lower in the intervention group (pooled mean difference -0.32, 95% CI -0.57 to -0.07; absolute decrease in A1C was 0.76 percent [-1.32 to -0.18]).</fragment>
				</section>
			</summary>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H26275125"/>
			<id>172177</id>
			<summary>
				<section label="Our approach" id="26275125">
					<fragment>Early institution of treatment for diabetes, at a time when the A1C is not significantly elevated, is associated with improved glycemic control over time and decreased long-term complications.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H26275125"/>
			<id>172179</id>
			<summary>
				<section label="Our approach" id="26275125">
					<fragment>In the absence of specific contraindications, we suggest metformin as initial therapy in most patients.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H26275125"/>
			<id>172180</id>
			<summary>
				<section label="Our approach" id="26275125">
					<fragment>We suggest initiating metformin at the time of diabetes diagnosis, along with consultation for lifestyle intervention.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H26275125"/>
			<id>172188</id>
			<summary>
				<section label="Our approach" id="26275125">
					<fragment>Insulin is also a reasonable option for initial therapy in patients who present with symptomatic or poorly controlled diabetes or in patients in whom it is difficult to distinguish type 1 from type 2 diabetes.</fragment>
				</section>
			</summary>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="Insulin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H26275125"/>
			<id>172189</id>
			<summary>
				<section label="Our approach" id="26275125">
					<fragment>In patients who are intolerant of or are not candidates for metformin or sulfonylureas, repaglinide is a reasonable alternative, particularly in a patient with chronic kidney disease at risk for hypoglycemia.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
			<category term="C0246689" scheme="gov.nih.nlm.semanticType.phsu" label="repaglinide"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H26275125"/>
			<id>172190</id>
			<summary>
				<section label="Our approach" id="26275125">
					<fragment>Pioglitazone may also be considered in patients with specific contraindications to metformin and sulfonylureas.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
			<category term="C0071097" scheme="gov.nih.nlm.semanticType.phsu" label="Pioglitazone"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H26275125"/>
			<id>172191</id>
			<summary>
				<section label="Our approach" id="26275125">
					<fragment>However, the risk of heart failure, fractures, and the potential increased risk of bladder cancer raises the concern that the overall risks and cost of pioglitazone may exceed its benefits.</fragment>
				</section>
			</summary>
			<category term="C0071097" scheme="gov.nih.nlm.semanticType.phsu" label="pioglitazone"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H26275125"/>
			<id>172192</id>
			<summary>
				<section label="Our approach" id="26275125">
					<fragment>Other oral and injectable agents, such as GLP-1 agonists, alpha-glucosidase inhibitors, or DPP-4 inhibitors may be appropriate initial therapy for some patients.</fragment>
				</section>
			</summary>
			<category term="C0086466" scheme="gov.nih.nlm.semanticType.phsu" label="injectable"/>
			<category term="C0243192" scheme="gov.nih.nlm.semanticType.phsu" label="agonists"/>
			<category term="C0669693" scheme="gov.nih.nlm.semanticType.orch" label="DPP"/>
			<category term="C0763866" scheme="gov.nih.nlm.semanticType.aapp" label="GLP"/>
			<category term="C1979844" scheme="gov.nih.nlm.semanticType.aapp" label="alpha"/>
			<category term="C3539108" scheme="gov.nih.nlm.semanticType.phsu" label="alpha-glucosidase inhibitors"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H26275125"/>
			<id>172193</id>
			<summary>
				<section label="Our approach" id="26275125">
					<fragment>However, limited clinical experience, lower or overall equivalent effectiveness compared with metformin, insulin, and sulfonylureas, higher cost, and/or side effects reduce their appeal as initial agents.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H26275125"/>
			<id>172196</id>
			<summary>
				<section label="Our approach" id="26275125">
					<fragment>Avoiding insulin, the most potent of all hypoglycemic medications, at the expense of poorer glucose control and greater side effects and cost, is not likely to benefit the patient in the long-term.</fragment>
				</section>
			</summary>
			<category term="C0020616" scheme="gov.nih.nlm.semanticType.phsu" label="hypoglycemic"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H26275125"/>
			<id>172198</id>
			<summary>
				<section label="Our approach" id="26275125">
					<fragment>A consensus statement regarding the management of hyperglycemia in type 2 diabetes by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) was developed in 2006 and has been updated regularly.</fragment>
				</section>
			</summary>
			<category term="C0643010" scheme="gov.nih.nlm.semanticType.phsu" label="ADA"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H26275125"/>
			<id>172199</id>
			<summary>
				<section label="Our approach" id="26275125">
					<fragment>The 2006 and 2009 consensus guidelines were developed with the intent of providing guidance ("guidelines") for clinicians to select from the increasing number of classes and drugs within classes.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0150600" scheme="gov.nih.nlm.semanticType.hlca" label="guidance"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H26275125"/>
			<id>172202</id>
			<summary>
				<section label="Our approach" id="26275125">
					<fragment>The selection of drugs in the 2009 ADA/EASD consensus guideline was based upon clinical trial evidence and clinical experience in achieving glycemic targets, with the recognition that there is a paucity of many high-quality head to head drug comparison trials and trials with important clinical endpoints, such as effects on complications.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0643010" scheme="gov.nih.nlm.semanticType.phsu" label="ADA"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H26275125"/>
			<id>172206</id>
			<summary>
				<section label="Our approach" id="26275125">
					<fragment>The ADA/EASD recommends metformin (in the absence of contraindications) as initial therapy in most patients.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0643010" scheme="gov.nih.nlm.semanticType.phsu" label="ADA"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H12"/>
			<id>172209</id>
			<summary>
				<section label="Metformin" id="12">
					<fragment>In the absence of contraindications, metformin is the first choice for oral treatment of type 2 diabetes.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H12"/>
			<id>172211</id>
			<summary>
				<section label="Metformin" id="12">
					<fragment>In contrast with most other antidiabetic drugs, metformin often leads to modest weight reduction or weight stabilization.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0935929" scheme="gov.nih.nlm.semanticType.phsu" label="antidiabetic"/>
			<category term="C1293130" scheme="gov.nih.nlm.semanticType.topp" label="stabilization"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H12"/>
			<id>172212</id>
			<summary>
				<section label="Metformin" id="12">
					<fragment>Furthermore, obese patients in the UKPDS who were assigned initially to receive metformin rather than sulfonylurea or insulin therapy had a decreased risk of the aggregate diabetes-related endpoint and all-cause mortality.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H12"/>
			<id>172214</id>
			<summary>
				<section label="Metformin" id="12">
					<fragment>The cardiovascular benefits of metformin in the UKPDS are supported by the findings of a randomized trial comparing metformin and glipizide in 304 Chinese patients with established coronary heart disease and type 2 diabetes.</fragment>
				</section>
			</summary>
			<category term="C0017642" scheme="gov.nih.nlm.semanticType.phsu" label="glipizide"/>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="8" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H12"/>
			<id>172218</id>
			<summary>
				<section label="Metformin" id="12">
					<fragment>Lifestyle intervention and other treatment for coronary heart disease were similar in both groups.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H12"/>
			<id>172221</id>
			<summary>
				<section label="Metformin" id="12">
					<fragment>A similar proportion of patients in each group received insulin (30 and 25 patients in metformin and glipizide groups, respectively).</fragment>
				</section>
			</summary>
			<category term="C0017642" scheme="gov.nih.nlm.semanticType.phsu" label="glipizide"/>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H12"/>
			<id>172224</id>
			<summary>
				<section label="Metformin" id="12">
					<fragment>However, the results support the use of metformin, particularly in patients with coronary heart disease.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H12"/>
			<id>172226</id>
			<summary>
				<section label="Metformin" id="12">
					<fragment>Metformin can rarely cause lactic acidosis, and because of the potentially fatal outcome of this side effect, metformin should not be administered when conditions predisposing to lactic acidosis are present.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="Metformin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H12"/>
			<id>172227</id>
			<summary>
				<section label="Metformin" id="12">
					<fragment>Such conditions include impaired renal function (plasma creatinine above 1.4 mg/dL [124 micromol/L] in women and 1.5 mg/dL [133 micromol/L] in men), decreased tissue perfusion or hemodynamic instability due to infection or other causes, concurrent liver disease or alcohol abuse, and heart failure.</fragment>
				</section>
			</summary>
			<category term="C0001975" scheme="gov.nih.nlm.semanticType.phsu" label="alcohol"/>
			<category term="C0031001" scheme="gov.nih.nlm.semanticType.topp" label="perfusion"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H12"/>
			<id>172229</id>
			<summary>
				<section label="Metformin" id="12">
					<fragment>Patients who are about to receive intravenous iodinated contrast material (with potential for contrast-induced renal failure) or undergo a surgical procedure (with potential compromise of circulation) should have metformin held until renal function and circulation can be established (normal urine output, normal serum creatinine, and no physical exam evidence of fluid overload or circulatory compromise).</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0031809" scheme="gov.nih.nlm.semanticType.hlca" label="physical exam"/>
			<category term="C0278293" scheme="gov.nih.nlm.semanticType.topp" label="procedure"/>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H13"/>
			<id>172231</id>
			<summary>
				<section label="Sulfonylureas" id="13">
					<fragment>Sulfonylureas are the oldest class of oral hypoglycemic agents.</fragment>
				</section>
			</summary>
			<category term="C0020616" scheme="gov.nih.nlm.semanticType.phsu" label="hypoglycemic"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="Sulfonylureas"/>
			<category term="C0359086" scheme="gov.nih.nlm.semanticType.phsu" label="oral hypoglycemic"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H13"/>
			<id>172234</id>
			<summary>
				<section label="Sulfonylureas" id="13">
					<fragment>The major adverse effect of sulfonylureas is hypoglycemia.</fragment>
				</section>
			</summary>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H13"/>
			<id>172236</id>
			<summary>
				<section label="Sulfonylureas" id="13">
					<fragment>Hypoglycemia induced by long-acting sulfonylureas may be severe and is often prolonged in the absence of appropriate therapy.</fragment>
				</section>
			</summary>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H13"/>
			<id>172238</id>
			<summary>
				<section label="Sulfonylureas" id="13">
					<fragment>Shorter acting sulfonylureas, such as glipizide and gliclazide, are less likely to cause hypoglycemia than the older, long-acting sulfonylureas ), and therefore are the preferred sulfonylureas, especially in older patients.</fragment>
				</section>
			</summary>
			<category term="C0017631" scheme="gov.nih.nlm.semanticType.phsu" label="gliclazide"/>
			<category term="C0017642" scheme="gov.nih.nlm.semanticType.phsu" label="glipizide"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="6" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H13"/>
			<id>172240</id>
			<summary>
				<section label="Sulfonylureas" id="13">
					<fragment>The choice of sulfonylurea is primarily dependent upon cost, risk of hypoglycemia, and local availability, since the efficacy of the available drugs is similar.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H14"/>
			<id>172242</id>
			<summary>
				<section label="Meglitinides" id="14">
					<fragment>Repaglinide and nateglinide are short-acting glucose-lowering drugs that act similarly to the sulfonylureas and have similar or slightly less efficacy in decreasing glycemia.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
			<category term="C0246689" scheme="gov.nih.nlm.semanticType.phsu" label="Repaglinide"/>
			<category term="C0903898" scheme="gov.nih.nlm.semanticType.phsu" label="nateglinide"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H14"/>
			<id>172243</id>
			<summary>
				<section label="Meglitinides" id="14">
					<fragment>Meglitinides are pharmacologically distinct from sulfonylureas and may be used in patients who have allergy to sulfonylurea medications.</fragment>
				</section>
			</summary>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H14"/>
			<id>172250</id>
			<summary>
				<section label="Meglitinides" id="14">
					<fragment>Dose adjustments with this agent do not appear to be necessary in patients with renal insufficiency.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H14"/>
			<id>172251</id>
			<summary>
				<section label="Meglitinides" id="14">
					<fragment>In addition, repaglinide is somewhat more effective in lowering A1C than nateglinide.</fragment>
				</section>
			</summary>
			<category term="C0246689" scheme="gov.nih.nlm.semanticType.phsu" label="repaglinide"/>
			<category term="C0903898" scheme="gov.nih.nlm.semanticType.phsu" label="nateglinide"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H14"/>
			<id>172252</id>
			<summary>
				<section label="Meglitinides" id="14">
					<fragment>Thus, repaglinide could be considered as initial therapy in a patient with chronic kidney disease who is intolerant of sulfonylureas.</fragment>
				</section>
			</summary>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
			<category term="C0246689" scheme="gov.nih.nlm.semanticType.phsu" label="repaglinide"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H15"/>
			<id>172256</id>
			<summary>
				<section label="Thiazolidinediones" id="15">
					<fragment>However, some meta-analyses have questioned the safety of rosiglitazone with regard to the risk of myocardial infarction.</fragment>
				</section>
			</summary>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0289313" scheme="gov.nih.nlm.semanticType.phsu" label="rosiglitazone"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H15"/>
			<id>172258</id>
			<summary>
				<section label="Thiazolidinediones" id="15">
					<fragment>At the same time, the US Food and Drug Administration restricted its use to patients with type 2 diabetes who cannot achieve adequate glycemic control with other medications, including pioglitazone.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="Drug"/>
			<category term="C0071097" scheme="gov.nih.nlm.semanticType.phsu" label="pioglitazone"/>
			<category term="C3469597" scheme="gov.nih.nlm.semanticType.hlca" label="Drug Administration"/>
			<category term="C3540798" scheme="gov.nih.nlm.semanticType.imft" label="Food"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H15"/>
			<id>172259</id>
			<summary>
				<section label="Thiazolidinediones" id="15">
					<fragment>Subsequently, in 2011, the French and German Medicines Agencies suspended the use of pioglitazone because of the potential increased risk of bladder cancer and the concern that the overall risks of pioglitazone exceed its benefits.</fragment>
				</section>
			</summary>
			<category term="C0071097" scheme="gov.nih.nlm.semanticType.phsu" label="pioglitazone"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H15"/>
			<id>172261</id>
			<summary>
				<section label="Thiazolidinediones" id="15">
					<fragment>As monotherapy, thiazolidinediones are probably somewhat less effective in lowering glycemia than metformin, lowering A1C by 0.5 to 1.4 percentage points.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C2605394" scheme="gov.nih.nlm.semanticType.orch" label="thiazolidinediones"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H15"/>
			<id>172262</id>
			<summary>
				<section label="Thiazolidinediones" id="15">
					<fragment>They are also associated with more weight gain and fluid retention than metformin, and are considerably more expensive than generic sulfonylureas and metformin.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H15"/>
			<id>172263</id>
			<summary>
				<section label="Thiazolidinediones" id="15">
					<fragment>Drugs in this class are not recommended in patients with symptomatic heart failure and are contraindicated in patients with New York Heart Association class III or IV heart failure.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="Drugs"/>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H15"/>
			<id>172265</id>
			<summary>
				<section label="Thiazolidinediones" id="15">
					<fragment>If a thiazolidinedione is used, pioglitazone is recommended because of the greater concern about atherogenic lipid profiles and a potential increased risk for cardiovascular events with rosiglitazone.</fragment>
				</section>
			</summary>
			<category term="C0023767" scheme="gov.nih.nlm.semanticType.imft" label="lipid"/>
			<category term="C0071097" scheme="gov.nih.nlm.semanticType.phsu" label="pioglitazone"/>
			<category term="C0289313" scheme="gov.nih.nlm.semanticType.phsu" label="rosiglitazone"/>
			<category term="C2605394" scheme="gov.nih.nlm.semanticType.orch" label="thiazolidinedione"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H16"/>
			<id>172266</id>
			<summary>
				<section label="4 inhibitors" id="16">
					<fragment>Sitagliptin, saxagliptin, linagliptin, and alogliptin are the DPP-4 inhibitors available for the treatment of type 2 diabetes in the United States and many other countries.</fragment>
				</section>
			</summary>
			<category term="C0669693" scheme="gov.nih.nlm.semanticType.orch" label="DPP"/>
			<category term="C1565750" scheme="gov.nih.nlm.semanticType.phsu" label="Sitagliptin"/>
			<category term="C1611934" scheme="gov.nih.nlm.semanticType.phsu" label="saxagliptin"/>
			<category term="C1958126" scheme="gov.nih.nlm.semanticType.phsu" label="alogliptin"/>
			<category term="C2746078" scheme="gov.nih.nlm.semanticType.phsu" label="linagliptin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H16"/>
			<id>172268</id>
			<summary>
				<section label="4 inhibitors" id="16">
					<fragment>Because of modest glucose lowering effectiveness, expense, and limited clinical experience, DPP-4 inhibitors are more commonly used as a second agent in those who do not respond to a single agent (such as a sulfonylurea, metformin or a thiazolidinedione), or as a third agent when dual therapy with metformin and a sulfonylurea does not provide adequate glycemic control.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
			<category term="C0669693" scheme="gov.nih.nlm.semanticType.orch" label="DPP"/>
			<category term="C2605394" scheme="gov.nih.nlm.semanticType.orch" label="thiazolidinedione"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H16"/>
			<id>172270</id>
			<summary>
				<section label="4 inhibitors" id="16">
					<fragment>As an example, linagliptin might be a good choice as initial therapy in a patient with chronic kidney disease at risk for hypoglycemia.</fragment>
				</section>
			</summary>
			<category term="C2746078" scheme="gov.nih.nlm.semanticType.phsu" label="linagliptin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H17"/>
			<id>172272</id>
			<summary>
				<section label="like peptide 1 agonists" id="17">
					<fragment>Exenatide and liraglutide are glucagon-like peptide 1 (GLP-1) analogs that are administered subcutaneously.</fragment>
				</section>
			</summary>
			<category term="C0014361" scheme="gov.nih.nlm.semanticType.horm" label="glucagon-like peptide"/>
			<category term="C0017687" scheme="gov.nih.nlm.semanticType.horm" label="glucagon"/>
			<category term="C0167117" scheme="gov.nih.nlm.semanticType.phsu" label="Exenatide"/>
			<category term="C0763866" scheme="gov.nih.nlm.semanticType.aapp" label="GLP"/>
			<category term="C1456408" scheme="gov.nih.nlm.semanticType.horm" label="liraglutide"/>
			<category term="C2354520" scheme="gov.nih.nlm.semanticType.aapp" label="peptide"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H17"/>
			<id>172273</id>
			<summary>
				<section label="like peptide 1 agonists" id="17">
					<fragment>They are approved in the United States by the FDA for the treatment of type 2 diabetes in patients not sufficiently controlled with diet, exercise, or oral agents.</fragment>
				</section>
			</summary>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H17"/>
			<id>172274</id>
			<summary>
				<section label="like peptide 1 agonists" id="17">
					<fragment>Exenatide (requires two daily injections or a once weekly injection) or liraglutide (one daily injection) could be considered as add-on drugs for patients with type 2 diabetes who are poorly controlled on maximal doses of one or two oral agents.</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="add"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0167117" scheme="gov.nih.nlm.semanticType.phsu" label="Exenatide"/>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="C1456408" scheme="gov.nih.nlm.semanticType.horm" label="liraglutide"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H18"/>
			<id>172277</id>
			<summary>
				<section label="glucosidase inhibitors" id="18">
					<fragment>This class of drugs is less potent than the sulfonylureas or metformin, lowering A1C by only 0.5 to 0.8 percentage points.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H19"/>
			<id>172280</id>
			<summary>
				<section label="Insulin" id="19">
					<fragment>Although historically insulin has been used for type 2 diabetes only when inadequate glycemic control persists despite oral agents and lifestyle intervention, there are increasing data to support using insulin earlier and more aggressively in type 2 diabetes.</fragment>
				</section>
			</summary>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H19"/>
			<id>172282</id>
			<summary>
				<section label="Insulin" id="19">
					<fragment>this results in better glycemic control, which can then be maintained with diet, exercise, and oral hypoglycemics for many months thereafter.</fragment>
				</section>
			</summary>
			<category term="C0020616" scheme="gov.nih.nlm.semanticType.phsu" label="hypoglycemics"/>
			<category term="C0359086" scheme="gov.nih.nlm.semanticType.phsu" label="oral hypoglycemics"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H19"/>
			<id>172283</id>
			<summary>
				<section label="Insulin" id="19">
					<fragment>Insulin may cause weight gain and hypoglycemia.</fragment>
				</section>
			</summary>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="Insulin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H19"/>
			<id>172285</id>
			<summary>
				<section label="Insulin" id="19">
					<fragment>Patients with type 2 diabetes require relatively large doses of insulin, compared with those needed for type 1 diabetes.</fragment>
				</section>
			</summary>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H20"/>
			<id>172288</id>
			<summary>
				<section label="Comparison of initial therapies" id="20">
					<fragment>In A Diabetes Outcome Progression Trial (ADOPT), 4360 recently diagnosed patients with type 2 diabetes were randomly assigned to monotherapy with rosiglitazone, metformin, or glyburide.</fragment>
				</section>
			</summary>
			<category term="C0017628" scheme="gov.nih.nlm.semanticType.phsu" label="glyburide"/>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0289313" scheme="gov.nih.nlm.semanticType.phsu" label="rosiglitazone"/>
			<category term="C1620263" scheme="gov.nih.nlm.semanticType.phsu" label="rosiglitazone, metformin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H20"/>
			<id>172292</id>
			<summary>
				<section label="Comparison of initial therapies" id="20">
					<fragment>There was also an unexpected increase in fractures in women taking rosiglitazone.</fragment>
				</section>
			</summary>
			<category term="C0289313" scheme="gov.nih.nlm.semanticType.phsu" label="rosiglitazone"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H20"/>
			<id>172296</id>
			<summary>
				<section label="Comparison of initial therapies" id="20">
					<fragment>The use of metformin as initial therapy is supported by a meta-analysis of 140 trials and 26 observational studies evaluating the effects of oral or injectable diabetes medications as monotherapy and in combination with other oral agents or insulin on intermediate outcomes (A1C, body weight, lipid profiles) and adverse events.</fragment>
				</section>
			</summary>
			<category term="C0023767" scheme="gov.nih.nlm.semanticType.imft" label="lipid"/>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0086466" scheme="gov.nih.nlm.semanticType.phsu" label="injectable"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H20"/>
			<id>172297</id>
			<summary>
				<section label="Comparison of initial therapies" id="20">
					<fragment>Older agents (metformin and second generation sulfonylureas) had similar efficacy in reducing A1C values (approximately one percentage point) and other cardiovascular risk factors (blood pressure, lipids, body weight) compared with newer agents (thiazolidinediones, meglitinides, and GLP-1 receptor agonists).</fragment>
				</section>
			</summary>
			<category term="C0023767" scheme="gov.nih.nlm.semanticType.imft" label="lipids"/>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
			<category term="C0243192" scheme="gov.nih.nlm.semanticType.phsu" label="agonists"/>
			<category term="C0763866" scheme="gov.nih.nlm.semanticType.aapp" label="GLP"/>
			<category term="C1300198" scheme="gov.nih.nlm.semanticType.phsu" label="second generation sulfonylureas"/>
			<category term="C2605394" scheme="gov.nih.nlm.semanticType.orch" label="thiazolidinediones"/>
			<category term="C2917359" scheme="gov.nih.nlm.semanticType.phsu" label="GLP-1 receptor agonists"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H20"/>
			<id>172299</id>
			<summary>
				<section label="Comparison of initial therapies" id="20">
					<fragment>Although each diabetes medication is associated with adverse events, metformin was associated with fewer episodes of hypoglycemia compared with sulfonylureas and less edema, congestive heart failure, and weight gain compared with thiazolidinediones.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
			<category term="C2605394" scheme="gov.nih.nlm.semanticType.orch" label="thiazolidinediones"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H22"/>
			<id>172312</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="22">
					<fragment>Weight reduction, diet, and exercise can all be used to improve glycemic control, although the majority of patients with type 2 diabetes will require medication over the course of their diabetes.</fragment>
				</section>
			</summary>
			<category term="C0012167" scheme="gov.nih.nlm.semanticType.topp" label="Weight reduction, diet"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H22"/>
			<id>172313</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="22">
					<fragment>In the absence of specific contraindications, we suggest metformin as initial therapy in most patients.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H22"/>
			<id>172314</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="22">
					<fragment>We suggest initiating metformin at the time of diabetes diagnosis, along with consultation for lifestyle intervention.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H22"/>
			<id>172316</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="22">
					<fragment>Metformin should not be administered when conditions predisposing to lactic acidosis are present.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="Metformin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H22"/>
			<id>172319</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="22">
					<fragment>However, if lifestyle intervention has not produced a significant reduction in symptoms of hyperglycemia or in glucose values after one or two weeks, then the sulfonylurea should be added.</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="added"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H22"/>
			<id>172320</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="22">
					<fragment>In patients who are intolerant of or are not candidates for metformin or sulfonylureas, repaglinide is a reasonable alternative, particularly in a patient with chronic kidney disease at risk for hypoglycemia.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
			<category term="C0246689" scheme="gov.nih.nlm.semanticType.phsu" label="repaglinide"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H22"/>
			<id>172321</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="22">
					<fragment>Another alternative is a thiazolidinedione, which may be considered in patients with lower initial A1C values or if there are specific contraindications to sulfonylureas.</fragment>
				</section>
			</summary>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
			<category term="C2605394" scheme="gov.nih.nlm.semanticType.orch" label="thiazolidinedione"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H22"/>
			<id>172322</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="22">
					<fragment>If a thiazolidinedione is to be used as initial therapy, pioglitazone is preferred because of the greater concern about atherogenic lipid profiles and a potential increased risk for cardiovascular events with rosiglitazone.</fragment>
				</section>
			</summary>
			<category term="C0023767" scheme="gov.nih.nlm.semanticType.imft" label="lipid"/>
			<category term="C0071097" scheme="gov.nih.nlm.semanticType.phsu" label="pioglitazone"/>
			<category term="C0289313" scheme="gov.nih.nlm.semanticType.phsu" label="rosiglitazone"/>
			<category term="C2605394" scheme="gov.nih.nlm.semanticType.orch" label="thiazolidinedione"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H22"/>
			<id>172324</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="22">
					<fragment>As an example, linagliptin might be a good choice as initial therapy in a patient with chronic kidney disease at risk for hypoglycemia.</fragment>
				</section>
			</summary>
			<category term="C2746078" scheme="gov.nih.nlm.semanticType.phsu" label="linagliptin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H22"/>
			<id>172325</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="22">
					<fragment>They are, however, more expensive and less potent in lowering glycemia than the glinides, such as repaglinide, which can also be used safely in patients with chronic kidney disease.</fragment>
				</section>
			</summary>
			<category term="C0246689" scheme="gov.nih.nlm.semanticType.phsu" label="repaglinide"/>
			<category term="C3537178" scheme="gov.nih.nlm.semanticType.phsu" label="glinides"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H22"/>
			<id>172326</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="22">
					<fragment>A potential problem is that patients who are initially thought to have type 2 diabetes may actually have type 1 diabetes, and therefore require insulin as initial therapy.</fragment>
				</section>
			</summary>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H22"/>
			<id>172327</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="22">
					<fragment>In patients in whom it is difficult to distinguish type 1 from type 2 diabetes, initial treatment with insulin is required.</fragment>
				</section>
			</summary>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H22"/>
			<id>172329</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="22">
					<fragment>Target A1C levels in patients with type 2 diabetes should be tailored to the individual, balancing the improvement in microvascular complications with the risk of hypoglycemia.</fragment>
				</section>
			</summary>
			<category term="C0308403" scheme="gov.nih.nlm.semanticType.phsu" label="balancing"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1779#H22"/>
			<id>172330</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="22">
					<fragment>A reasonable goal of therapy might be an A1C value of &lt;=7.0 percent for most patients.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
	</feed>
	<feed>
		<title>Insulin therapy in type 2 diabetes mellitus</title>
		<category term="C0650607" scheme="gov.nih.nlm.semanticType.phsu" label="Basal insulin"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimens"/>
		<category term="C0009574" scheme="gov.nih.nlm.semanticType.phsu" label="preparation"/>
		<category term="C0046449" scheme="gov.nih.nlm.semanticType.orch" label="NPH"/>
		<category term="C0293359" scheme="gov.nih.nlm.semanticType.horm" label="lispro"/>
		<category term="C0670129" scheme="gov.nih.nlm.semanticType.horm" label="neutral protamine lispro"/>
		<category term="C0907402" scheme="gov.nih.nlm.semanticType.horm" label="glargine"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0961398" scheme="gov.nih.nlm.semanticType.phsu" label="ways"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C3491971" scheme="gov.nih.nlm.semanticType.horm" label="degludec"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0009574" scheme="gov.nih.nlm.semanticType.phsu" label="preparations"/>
		<category term="C0021641" scheme="gov.nih.nlm.semanticType.horm" label="insulin preparations"/>
		<category term="C0021658" scheme="gov.nih.nlm.semanticType.horm" label="NPH insulin"/>
		<category term="C0046449" scheme="gov.nih.nlm.semanticType.orch" label="NPH"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0304870" scheme="gov.nih.nlm.semanticType.horm" label="insulin, long-acting"/>
		<category term="C0658010" scheme="gov.nih.nlm.semanticType.orch" label="premixed"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0009574" scheme="gov.nih.nlm.semanticType.phsu" label="preparations"/>
		<category term="C0021641" scheme="gov.nih.nlm.semanticType.horm" label="insulin preparations"/>
		<category term="C0046449" scheme="gov.nih.nlm.semanticType.orch" label="NPH"/>
		<category term="C0356365" scheme="gov.nih.nlm.semanticType.horm" label="rapid-acting insulin"/>
		<category term="C0658010" scheme="gov.nih.nlm.semanticType.orch" label="premixed"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C0009574" scheme="gov.nih.nlm.semanticType.phsu" label="preparations"/>
		<category term="C0021641" scheme="gov.nih.nlm.semanticType.horm" label="insulin preparations"/>
		<category term="C0658010" scheme="gov.nih.nlm.semanticType.orch" label="Premixed"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0199782" scheme="gov.nih.nlm.semanticType.topp" label="insulin injections"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="add"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0020616" scheme="gov.nih.nlm.semanticType.phsu" label="hypoglycemic"/>
		<category term="C0359086" scheme="gov.nih.nlm.semanticType.phsu" label="oral hypoglycemic"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0020616" scheme="gov.nih.nlm.semanticType.phsu" label="hypoglycemic"/>
		<category term="C0359086" scheme="gov.nih.nlm.semanticType.phsu" label="oral hypoglycemic"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C1445141" scheme="gov.nih.nlm.semanticType.phsu" label="combination oral hypoglycemic"/>
		<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="added"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0020616" scheme="gov.nih.nlm.semanticType.phsu" label="hypoglycemic"/>
		<category term="C0021658" scheme="gov.nih.nlm.semanticType.horm" label="NPH insulin"/>
		<category term="C0046449" scheme="gov.nih.nlm.semanticType.orch" label="NPH"/>
		<category term="C0304870" scheme="gov.nih.nlm.semanticType.horm" label="longer acting insulins"/>
		<category term="C0359086" scheme="gov.nih.nlm.semanticType.phsu" label="oral hypoglycemic"/>
		<category term="C0907402" scheme="gov.nih.nlm.semanticType.horm" label="insulin glargine"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
		<category term="C0304870" scheme="gov.nih.nlm.semanticType.horm" label="long-acting insulin"/>
		<category term="C0537270" scheme="gov.nih.nlm.semanticType.horm" label="Insulin detemir"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="Insulin"/>
		<category term="C1305435" scheme="gov.nih.nlm.semanticType.horm" label="insulin analog"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C0907402" scheme="gov.nih.nlm.semanticType.horm" label="insulin glargine"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0046449" scheme="gov.nih.nlm.semanticType.orch" label="NPH"/>
		<category term="C0650607" scheme="gov.nih.nlm.semanticType.phsu" label="basal insulin"/>
		<category term="C0907402" scheme="gov.nih.nlm.semanticType.horm" label="insulin glargine"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0907402" scheme="gov.nih.nlm.semanticType.horm" label="insulin glargine"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C3491971" scheme="gov.nih.nlm.semanticType.horm" label="insulin degludec"/>
		<category term="C0020616" scheme="gov.nih.nlm.semanticType.phsu" label="hypoglycemic"/>
		<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="added"/>
		<category term="C0020616" scheme="gov.nih.nlm.semanticType.phsu" label="hypoglycemic"/>
		<category term="C0021658" scheme="gov.nih.nlm.semanticType.horm" label="insulin NPH"/>
		<category term="C0046449" scheme="gov.nih.nlm.semanticType.orch" label="NPH"/>
		<category term="C0359086" scheme="gov.nih.nlm.semanticType.phsu" label="oral hypoglycemic"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
		<category term="C0907402" scheme="gov.nih.nlm.semanticType.horm" label="insulin glargine"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0046449" scheme="gov.nih.nlm.semanticType.orch" label="NPH"/>
		<category term="C0907402" scheme="gov.nih.nlm.semanticType.horm" label="insulin glargine"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0021641" scheme="gov.nih.nlm.semanticType.horm" label="regular) insulin"/>
		<category term="C0356365" scheme="gov.nih.nlm.semanticType.horm" label="rapid-acting insulins"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulins"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C0021641" scheme="gov.nih.nlm.semanticType.horm" label="regular insulin"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0356365" scheme="gov.nih.nlm.semanticType.horm" label="rapid-acting insulin"/>
		<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C1305435" scheme="gov.nih.nlm.semanticType.horm" label="insulin analogues"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C0356365" scheme="gov.nih.nlm.semanticType.horm" label="rapid-acting insulins"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulins"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C0356365" scheme="gov.nih.nlm.semanticType.horm" label="rapid-acting insulin"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimens"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimens"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
		<category term="C0293359" scheme="gov.nih.nlm.semanticType.horm" label="insulin lispro"/>
		<category term="C0907402" scheme="gov.nih.nlm.semanticType.horm" label="insulin glargine"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0046449" scheme="gov.nih.nlm.semanticType.orch" label="NPH"/>
		<category term="C0293359" scheme="gov.nih.nlm.semanticType.horm" label="lispro"/>
		<category term="C0907402" scheme="gov.nih.nlm.semanticType.horm" label="insulin glargine"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
		<category term="C0083439" scheme="gov.nih.nlm.semanticType.phsu" label="MI"/>
		<category term="C0581603" scheme="gov.nih.nlm.semanticType.topp" label="revascularization"/>
		<category term="C0877341" scheme="gov.nih.nlm.semanticType.topp" label="coronary revascularization"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
		<category term="C0650607" scheme="gov.nih.nlm.semanticType.phsu" label="basal insulin"/>
		<category term="C0658010" scheme="gov.nih.nlm.semanticType.orch" label="premixed"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
		<category term="C0123677" scheme="gov.nih.nlm.semanticType.horm" label="insulin aspart"/>
		<category term="C0356369" scheme="gov.nih.nlm.semanticType.horm" label="biphasic insulin"/>
		<category term="C0537270" scheme="gov.nih.nlm.semanticType.horm" label="basal insulin detemir"/>
		<category term="C0650607" scheme="gov.nih.nlm.semanticType.phsu" label="basal insulin"/>
		<category term="C0658010" scheme="gov.nih.nlm.semanticType.orch" label="premixed"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C1273270" scheme="gov.nih.nlm.semanticType.horm" label="biphasic insulin aspart"/>
		<category term="C0650607" scheme="gov.nih.nlm.semanticType.phsu" label="basal insulin"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C1562940" scheme="gov.nih.nlm.semanticType.hlca" label="carbohydrate counting"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C1562940" scheme="gov.nih.nlm.semanticType.hlca" label="carbohydrate counting"/>
		<category term="C0020616" scheme="gov.nih.nlm.semanticType.phsu" label="hypoglycemics"/>
		<category term="C0359086" scheme="gov.nih.nlm.semanticType.phsu" label="oral hypoglycemics"/>
		<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0020616" scheme="gov.nih.nlm.semanticType.phsu" label="hypoglycemic"/>
		<category term="C0021641" scheme="gov.nih.nlm.semanticType.horm" label="regular insulin"/>
		<category term="C0021658" scheme="gov.nih.nlm.semanticType.horm" label="NPH insulin"/>
		<category term="C0046449" scheme="gov.nih.nlm.semanticType.orch" label="NPH"/>
		<category term="C0359086" scheme="gov.nih.nlm.semanticType.phsu" label="oral hypoglycemic"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimens"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0020616" scheme="gov.nih.nlm.semanticType.phsu" label="hypoglycemic"/>
		<category term="C0199782" scheme="gov.nih.nlm.semanticType.topp" label="insulin injections"/>
		<category term="C0359086" scheme="gov.nih.nlm.semanticType.phsu" label="oral hypoglycemic"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0907402" scheme="gov.nih.nlm.semanticType.horm" label="insulin glargine"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0020616" scheme="gov.nih.nlm.semanticType.phsu" label="hypoglycemic"/>
		<category term="C0046449" scheme="gov.nih.nlm.semanticType.orch" label="NPH"/>
		<category term="C0359086" scheme="gov.nih.nlm.semanticType.phsu" label="oral hypoglycemic"/>
		<category term="C0907402" scheme="gov.nih.nlm.semanticType.horm" label="insulin glargine"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0020616" scheme="gov.nih.nlm.semanticType.phsu" label="hypoglycemic"/>
		<category term="C0359086" scheme="gov.nih.nlm.semanticType.phsu" label="oral hypoglycemic"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0033972" scheme="gov.nih.nlm.semanticType.topp" label="combined therapy"/>
		<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="adding"/>
		<category term="C0020616" scheme="gov.nih.nlm.semanticType.phsu" label="hypoglycemic"/>
		<category term="C0359086" scheme="gov.nih.nlm.semanticType.phsu" label="oral hypoglycemic"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="Insulin"/>
		<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0046449" scheme="gov.nih.nlm.semanticType.orch" label="NPH"/>
		<category term="C0907402" scheme="gov.nih.nlm.semanticType.horm" label="insulin glargine"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0009574" scheme="gov.nih.nlm.semanticType.phsu" label="preparation"/>
		<category term="C0021641" scheme="gov.nih.nlm.semanticType.horm" label="insulin preparation"/>
		<category term="C0046449" scheme="gov.nih.nlm.semanticType.orch" label="NPH"/>
		<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0021658" scheme="gov.nih.nlm.semanticType.horm" label="NPH insulin"/>
		<category term="C0046449" scheme="gov.nih.nlm.semanticType.orch" label="NPH"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0021658" scheme="gov.nih.nlm.semanticType.horm" label="NPH insulin"/>
		<category term="C0046449" scheme="gov.nih.nlm.semanticType.orch" label="NPH"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0017631" scheme="gov.nih.nlm.semanticType.phsu" label="gliclazide"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="Insulin"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C1504665" scheme="gov.nih.nlm.semanticType.phsu" label="Diabetic ketoacidosis"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0004358" scheme="gov.nih.nlm.semanticType.imft" label="autoantibodies"/>
		<category term="C0047145" scheme="gov.nih.nlm.semanticType.phsu" label="glutamic acid"/>
		<category term="C0368582" scheme="gov.nih.nlm.semanticType.imft" label="antibodies"/>
		<category term="C0443891" scheme="gov.nih.nlm.semanticType.imft" label="glutamic acid decarboxylase antibodies"/>
		<category term="C0012167" scheme="gov.nih.nlm.semanticType.topp" label="diet, weight reduction"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="added"/>
		<category term="C0020616" scheme="gov.nih.nlm.semanticType.phsu" label="hypoglycemic"/>
		<category term="C0021658" scheme="gov.nih.nlm.semanticType.horm" label="insulin NPH"/>
		<category term="C0046449" scheme="gov.nih.nlm.semanticType.orch" label="NPH"/>
		<category term="C0359086" scheme="gov.nih.nlm.semanticType.phsu" label="oral hypoglycemic"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
		<category term="C0907402" scheme="gov.nih.nlm.semanticType.horm" label="insulin glargine"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="Insulin"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0658010" scheme="gov.nih.nlm.semanticType.orch" label="premixed"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="adding"/>
		<category term="C0356365" scheme="gov.nih.nlm.semanticType.horm" label="rapid-acting insulin"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimens"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<id>1801</id>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H2"/>
			<id>172696</id>
			<summary>
				<section label="NORMAL PATTERNS OF INSULIN SECRETION" id="2">
					<fragment>Basal insulin secretion represents approximately 50 percent of 24-hour insulin production, with the remainder accounted for by prandial (mealtime) excursions.</fragment>
				</section>
			</summary>
			<category term="C0650607" scheme="gov.nih.nlm.semanticType.phsu" label="Basal insulin"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H2"/>
			<id>172698</id>
			<summary>
				<section label="NORMAL PATTERNS OF INSULIN SECRETION" id="2">
					<fragment>While intensive regimens were initially used for patients with type 1 diabetes, they are used for patients with type 2 diabetes as well.</fragment>
				</section>
			</summary>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimens"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H3"/>
			<id>172699</id>
			<summary>
				<section label="INSULIN PREPARATIONS" id="3">
					<fragment>In type 2 diabetes, insulin is generally provided in two ways: As a basal supplement with an intermediate to long-acting preparation (NPH, neutral protamine lispro [NPL], glargine, detemir, or degludec) to suppress hepatic glucose production and maintain near normoglycemia in the fasting state.</fragment>
				</section>
			</summary>
			<category term="C0009574" scheme="gov.nih.nlm.semanticType.phsu" label="preparation"/>
			<category term="C0046449" scheme="gov.nih.nlm.semanticType.orch" label="NPH"/>
			<category term="C0293359" scheme="gov.nih.nlm.semanticType.horm" label="lispro"/>
			<category term="C0670129" scheme="gov.nih.nlm.semanticType.horm" label="neutral protamine lispro"/>
			<category term="C0907402" scheme="gov.nih.nlm.semanticType.horm" label="glargine"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="C0961398" scheme="gov.nih.nlm.semanticType.phsu" label="ways"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="C3491971" scheme="gov.nih.nlm.semanticType.horm" label="degludec"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H3"/>
			<id>172702</id>
			<summary>
				<section label="INSULIN PREPARATIONS" id="3">
					<fragment>For many patients with type 2 diabetes, a basal supplement is often adequate for good glycemic control as endogenous insulin secretion will control the post-prandial excursions.</fragment>
				</section>
			</summary>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H3"/>
			<id>172703</id>
			<summary>
				<section label="INSULIN PREPARATIONS" id="3">
					<fragment>Some patients with type 2 diabetes will require additional premeal boluses, similar to treatment for type 1.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H4"/>
			<id>172708</id>
			<summary>
				<section label="Premixed insulin preparations" id="4">
					<fragment>In a meta-analysis of trials comparing rapid-acting/intermediate premixed insulin preparations with other treatments (premixed regular/NPH insulin, long-acting insulin, and non-insulin agents), premixed rapid-acting preparations were similarly effective in reducing A1C levels as premixed regular insulin preparations.</fragment>
				</section>
			</summary>
			<category term="C0009574" scheme="gov.nih.nlm.semanticType.phsu" label="preparations"/>
			<category term="C0021641" scheme="gov.nih.nlm.semanticType.horm" label="insulin preparations"/>
			<category term="C0021658" scheme="gov.nih.nlm.semanticType.horm" label="NPH insulin"/>
			<category term="C0046449" scheme="gov.nih.nlm.semanticType.orch" label="NPH"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0304870" scheme="gov.nih.nlm.semanticType.horm" label="insulin, long-acting"/>
			<category term="C0658010" scheme="gov.nih.nlm.semanticType.orch" label="premixed"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H4"/>
			<id>172710</id>
			<summary>
				<section label="Premixed insulin preparations" id="4">
					<fragment>However, in many of the trials included in the meta-analysis, the dose of insulin or oral agent in the control group was not aggressively titrated to achieve optimal glycemic control.</fragment>
				</section>
			</summary>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H4"/>
			<id>172711</id>
			<summary>
				<section label="Premixed insulin preparations" id="4">
					<fragment>Compared with other insulin therapy (long-acting or regular/NPH mix), premixed rapid-acting insulin preparations were more effective in reducing postprandial blood glucose levels but less effective in reducing fasting blood glucose.</fragment>
				</section>
			</summary>
			<category term="C0009574" scheme="gov.nih.nlm.semanticType.phsu" label="preparations"/>
			<category term="C0021641" scheme="gov.nih.nlm.semanticType.horm" label="insulin preparations"/>
			<category term="C0046449" scheme="gov.nih.nlm.semanticType.orch" label="NPH"/>
			<category term="C0356365" scheme="gov.nih.nlm.semanticType.horm" label="rapid-acting insulin"/>
			<category term="C0658010" scheme="gov.nih.nlm.semanticType.orch" label="premixed"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H4"/>
			<id>172713</id>
			<summary>
				<section label="Premixed insulin preparations" id="4">
					<fragment>Premixed insulin preparations are sometimes used in type 2 diabetics, but we almost never use them in patients with type 1 diabetes.</fragment>
				</section>
			</summary>
			<category term="C0009574" scheme="gov.nih.nlm.semanticType.phsu" label="preparations"/>
			<category term="C0021641" scheme="gov.nih.nlm.semanticType.horm" label="insulin preparations"/>
			<category term="C0658010" scheme="gov.nih.nlm.semanticType.orch" label="Premixed"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H4"/>
			<id>172714</id>
			<summary>
				<section label="Premixed insulin preparations" id="4">
					<fragment>For patients with type 2 diabetes who require prandial insulin, the goal is to adjust the dose of fast-acting insulin immediately prior to a meal and, therefore, we prefer to keep basal and premeal insulin injections separate and adjust them independently.</fragment>
				</section>
			</summary>
			<category term="C0199782" scheme="gov.nih.nlm.semanticType.topp" label="insulin injections"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H5"/>
			<id>172715</id>
			<summary>
				<section label="COMBINATION ORAL AGENT AND INSULIN THERAPY" id="5">
					<fragment>Patients with persistent hyperglycemia despite oral hypoglycemic therapy may add insulin to oral medication or may stop the oral drug(s) and begin insulin.</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="add"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0020616" scheme="gov.nih.nlm.semanticType.phsu" label="hypoglycemic"/>
			<category term="C0359086" scheme="gov.nih.nlm.semanticType.phsu" label="oral hypoglycemic"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H5"/>
			<id>172716</id>
			<summary>
				<section label="COMBINATION ORAL AGENT AND INSULIN THERAPY" id="5">
					<fragment>The rationale for combination oral hypoglycemic drug and insulin therapy is that, by suppressing hepatic glucose production, the patient can retain the convenience of oral agents, while minimizing total insulin requirements and therefore the degree of hyperinsulinemia.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0020616" scheme="gov.nih.nlm.semanticType.phsu" label="hypoglycemic"/>
			<category term="C0359086" scheme="gov.nih.nlm.semanticType.phsu" label="oral hypoglycemic"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="C1445141" scheme="gov.nih.nlm.semanticType.phsu" label="combination oral hypoglycemic"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H5"/>
			<id>172717</id>
			<summary>
				<section label="COMBINATION ORAL AGENT AND INSULIN THERAPY" id="5">
					<fragment>Many studies have shown that glycemia improves with insulin combination therapy.</fragment>
				</section>
			</summary>
			<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H6"/>
			<id>172720</id>
			<summary>
				<section label="Choice of insulin" id="6">
					<fragment>When insulin is combined with oral agents, a basal (long- or intermediate-acting) rather than a short-acting premeal (prandial) insulin is a reasonable first choice.</fragment>
				</section>
			</summary>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H7"/>
			<id>172723</id>
			<summary>
				<section label="Basal insulin" id="7">
					<fragment>While intermediate-acting NPH insulin has been used commonly at bedtime to supplement oral hypoglycemic drug therapy, longer acting insulins, such as insulin glargine (once daily) and detemir (once or twice daily), added to oral agents are equally effective for reducing A1C values and may cause less nocturnal hypoglycemia, albeit at greater cost.</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="added"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0020616" scheme="gov.nih.nlm.semanticType.phsu" label="hypoglycemic"/>
			<category term="C0021658" scheme="gov.nih.nlm.semanticType.horm" label="NPH insulin"/>
			<category term="C0046449" scheme="gov.nih.nlm.semanticType.orch" label="NPH"/>
			<category term="C0304870" scheme="gov.nih.nlm.semanticType.horm" label="longer acting insulins"/>
			<category term="C0359086" scheme="gov.nih.nlm.semanticType.phsu" label="oral hypoglycemic"/>
			<category term="C0907402" scheme="gov.nih.nlm.semanticType.horm" label="insulin glargine"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H7"/>
			<id>172725</id>
			<summary>
				<section label="Basal insulin" id="7">
					<fragment>Insulin detemir is another available long-acting insulin analog;</fragment>
				</section>
			</summary>
			<category term="C0304870" scheme="gov.nih.nlm.semanticType.horm" label="long-acting insulin"/>
			<category term="C0537270" scheme="gov.nih.nlm.semanticType.horm" label="Insulin detemir"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="Insulin"/>
			<category term="C1305435" scheme="gov.nih.nlm.semanticType.horm" label="insulin analog"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H7"/>
			<id>172728</id>
			<summary>
				<section label="Basal insulin" id="7">
					<fragment>As an example, in a 52-week study of supplementation of oral therapy with insulin glargine or detemir, there were similar improvements in glycemic control (mean A1C 7.1 and 7.2 percent, respectively), but over half of the participants (55 percent) required twice daily dosing with detemir, as opposed to once daily dosing with glargine.</fragment>
				</section>
			</summary>
			<category term="C0907402" scheme="gov.nih.nlm.semanticType.horm" label="insulin glargine"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H7"/>
			<id>172730</id>
			<summary>
				<section label="Basal insulin" id="7">
					<fragment>However, the rates of symptomatic overall and nocturnal hypoglycemia, while relatively infrequent with either basal insulin, were lower in patients treated with either insulin glargine or detemir compared with NPH.</fragment>
				</section>
			</summary>
			<category term="C0046449" scheme="gov.nih.nlm.semanticType.orch" label="NPH"/>
			<category term="C0650607" scheme="gov.nih.nlm.semanticType.phsu" label="basal insulin"/>
			<category term="C0907402" scheme="gov.nih.nlm.semanticType.horm" label="insulin glargine"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H7"/>
			<id>172741</id>
			<summary>
				<section label="Basal insulin" id="7">
					<fragment>It appears to have similar glycemic efficacy as that of insulin glargine, as illustrated by the findings of a one year, open-label, non-inferiority trial comparing insulin glargine with insulin degludec (both administered once daily) in 1030 patients with type 2 diabetes treated with metformin.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0907402" scheme="gov.nih.nlm.semanticType.horm" label="insulin glargine"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="C3491971" scheme="gov.nih.nlm.semanticType.horm" label="insulin degludec"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H7"/>
			<id>172742</id>
			<summary>
				<section label="Basal insulin" id="7">
					<fragment>The reduction in A1C (1.19 versus 1.06 percent) and rates of overall confirmed hypoglycemic episodes were similar in the two groups.</fragment>
				</section>
			</summary>
			<category term="C0020616" scheme="gov.nih.nlm.semanticType.phsu" label="hypoglycemic"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H7"/>
			<id>172746</id>
			<summary>
				<section label="Basal insulin" id="7">
					<fragment>If once daily insulin is added to oral hypoglycemic therapy in patients with type 2 diabetes, a single daily dose of either insulin NPH, or detemir given at bedtime or insulin glargine given in the morning or at bedtime is a reasonable initial regimen.</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="added"/>
			<category term="C0020616" scheme="gov.nih.nlm.semanticType.phsu" label="hypoglycemic"/>
			<category term="C0021658" scheme="gov.nih.nlm.semanticType.horm" label="insulin NPH"/>
			<category term="C0046449" scheme="gov.nih.nlm.semanticType.orch" label="NPH"/>
			<category term="C0359086" scheme="gov.nih.nlm.semanticType.phsu" label="oral hypoglycemic"/>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
			<category term="C0907402" scheme="gov.nih.nlm.semanticType.horm" label="insulin glargine"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H7"/>
			<id>172747</id>
			<summary>
				<section label="Basal insulin" id="7">
					<fragment>If nocturnal hypoglycemia or symptomatic hypoglycemia occurs in patients taking bedtime NPH, we adjust the dose or switch to insulin glargine.</fragment>
				</section>
			</summary>
			<category term="C0046449" scheme="gov.nih.nlm.semanticType.orch" label="NPH"/>
			<category term="C0907402" scheme="gov.nih.nlm.semanticType.horm" label="insulin glargine"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H8"/>
			<id>172748</id>
			<summary>
				<section label="Premeal (prandial) bolus insulin" id="8">
					<fragment>For patients with type 2 diabetes, a basal supplement is often adequate for good glycemic control, but for others, premeal (prandial or preprandial) boluses are necessary as they are in type 1 diabetes.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H8"/>
			<id>172749</id>
			<summary>
				<section label="Premeal (prandial) bolus insulin" id="8">
					<fragment>The newer rapid-acting insulins may have a minor glycemic advantage over short-acting (regular) insulin in patients with type 1 diabetes, but they do not have a clinically significant advantage in patients with type 2 diabetes.</fragment>
				</section>
			</summary>
			<category term="C0021641" scheme="gov.nih.nlm.semanticType.horm" label="regular) insulin"/>
			<category term="C0356365" scheme="gov.nih.nlm.semanticType.horm" label="rapid-acting insulins"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulins"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H8"/>
			<id>172750</id>
			<summary>
				<section label="Premeal (prandial) bolus insulin" id="8">
					<fragment>This was illustrated in a meta-analysis of 5 randomized, controlled trials (involving 2028 patients with type 2 diabetes) that compared rapid-acting insulin analogues to regular insulin as premeal bolus doses.</fragment>
				</section>
			</summary>
			<category term="C0021641" scheme="gov.nih.nlm.semanticType.horm" label="regular insulin"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0356365" scheme="gov.nih.nlm.semanticType.horm" label="rapid-acting insulin"/>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="C1305435" scheme="gov.nih.nlm.semanticType.horm" label="insulin analogues"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H8"/>
			<id>172752</id>
			<summary>
				<section label="Premeal (prandial) bolus insulin" id="8">
					<fragment>However, the ability to inject the rapid-acting insulins immediately before meals, as opposed to the 30 to 45 minutes before the meal recommended for short-acting insulins, may provide improved convenience for patients.</fragment>
				</section>
			</summary>
			<category term="C0356365" scheme="gov.nih.nlm.semanticType.horm" label="rapid-acting insulins"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulins"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H8"/>
			<id>172753</id>
			<summary>
				<section label="Premeal (prandial) bolus insulin" id="8">
					<fragment>There are also several trials in patients with type 2 diabetes comparing inhaled insulin to subcutaneous rapid-acting insulin, which report similar improvements in A1C in the inhaled and subcutaneous insulin groups.</fragment>
				</section>
			</summary>
			<category term="C0356365" scheme="gov.nih.nlm.semanticType.horm" label="rapid-acting insulin"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H8"/>
			<id>172754</id>
			<summary>
				<section label="Premeal (prandial) bolus insulin" id="8">
					<fragment>However, in these studies, neither the inhaled insulin nor the control arms achieved optimal glycemic efficacy that has been achieved with injection regimens in previous trials with insulin.</fragment>
				</section>
			</summary>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimens"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H9"/>
			<id>172757</id>
			<summary>
				<section label="Comparison of insulin regimens" id="9">
					<fragment>A number of randomized trials have evaluated different insulin regimens in patients with type 2 diabetes, almost all of whom were also treated with oral agents.</fragment>
				</section>
			</summary>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimens"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H9"/>
			<id>172759</id>
			<summary>
				<section label="Comparison of insulin regimens" id="9">
					<fragment>data are more limited on cardiovascular outcomes.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H10"/>
			<id>172761</id>
			<summary>
				<section label="Basal versus prandial" id="10">
					<fragment>This was illustrated by a randomized trial of once daily insulin glargine versus prandial insulin lispro in 415 patients who were inadequately controlled with metformin and a sulfonylurea.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
			<category term="C0293359" scheme="gov.nih.nlm.semanticType.horm" label="insulin lispro"/>
			<category term="C0907402" scheme="gov.nih.nlm.semanticType.horm" label="insulin glargine"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H10"/>
			<id>172764</id>
			<summary>
				<section label="Basal versus prandial" id="10">
					<fragment>Similar findings were noted in the HEART2D trial, which was designed to evaluate the effects of prandial (lispro) or basal (NPH twice daily or insulin glargine once daily) insulin on cardiovascular outcomes in 1115 patients after myocardial infarction.</fragment>
				</section>
			</summary>
			<category term="C0046449" scheme="gov.nih.nlm.semanticType.orch" label="NPH"/>
			<category term="C0293359" scheme="gov.nih.nlm.semanticType.horm" label="lispro"/>
			<category term="C0907402" scheme="gov.nih.nlm.semanticType.horm" label="insulin glargine"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H10"/>
			<id>172767</id>
			<summary>
				<section label="Basal versus prandial" id="10">
					<fragment>There was no difference between the prandial and basal groups in both A1C (7.7 versus 7.8 percent) and the time to a subsequent cardiovascular event (cardiovascular death, nonfatal MI, nonfatal stroke, coronary revascularization, or hospitalization for an acute coronary syndrome).</fragment>
				</section>
			</summary>
			<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
			<category term="C0083439" scheme="gov.nih.nlm.semanticType.phsu" label="MI"/>
			<category term="C0581603" scheme="gov.nih.nlm.semanticType.topp" label="revascularization"/>
			<category term="C0877341" scheme="gov.nih.nlm.semanticType.topp" label="coronary revascularization"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H11"/>
			<id>172770</id>
			<summary>
				<section label="Basal or prandial versus premixed" id="11">
					<fragment>In contrast, in a trial comparing a combined oral agent-basal insulin regimen with premixed insulin without oral agents, the oral agent-basal regimen was more effective in reducing A1C.</fragment>
				</section>
			</summary>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
			<category term="C0650607" scheme="gov.nih.nlm.semanticType.phsu" label="basal insulin"/>
			<category term="C0658010" scheme="gov.nih.nlm.semanticType.orch" label="premixed"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H11"/>
			<id>172773</id>
			<summary>
				<section label="Basal or prandial versus premixed" id="11">
					<fragment>In a three-year trial, 708 patients with type 2 diabetes who were suboptimally controlled with metformin and a sulfonylurea were randomly assigned to premixed biphasic insulin aspart (twice daily), prandial insulin aspart (three times daily), or basal insulin detemir (once or twice daily).</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
			<category term="C0123677" scheme="gov.nih.nlm.semanticType.horm" label="insulin aspart"/>
			<category term="C0356369" scheme="gov.nih.nlm.semanticType.horm" label="biphasic insulin"/>
			<category term="C0537270" scheme="gov.nih.nlm.semanticType.horm" label="basal insulin detemir"/>
			<category term="C0650607" scheme="gov.nih.nlm.semanticType.phsu" label="basal insulin"/>
			<category term="C0658010" scheme="gov.nih.nlm.semanticType.orch" label="premixed"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="C1273270" scheme="gov.nih.nlm.semanticType.horm" label="biphasic insulin aspart"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H11"/>
			<id>172776</id>
			<summary>
				<section label="Basal or prandial versus premixed" id="11">
					<fragment>Patients in the basal group had the fewest episodes of hypoglycemia.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H12"/>
			<id>172778</id>
			<summary>
				<section label="Conclusion" id="12">
					<fragment>In the absence of such data, we prefer initiating basal insulin, rather than prandial insulin, in patients who are poorly controlled on oral agents.</fragment>
				</section>
			</summary>
			<category term="C0650607" scheme="gov.nih.nlm.semanticType.phsu" label="basal insulin"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H15"/>
			<id>172794</id>
			<summary>
				<section label="Bolus" id="15">
					<fragment>Furthermore, it is uncertain if there is a glycemic advantage of carbohydrate counting in patients with type 2 diabetes.</fragment>
				</section>
			</summary>
			<category term="C1562940" scheme="gov.nih.nlm.semanticType.hlca" label="carbohydrate counting"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H15"/>
			<id>172795</id>
			<summary>
				<section label="Bolus" id="15">
					<fragment>As an example, in a 24-week randomized trial in 277 adults with type 2 diabetes, there was no difference in A1C values when mealtime insulin adjustments were based upon a simple algorithm (according to previous weeks blood glucose monitoring results) or carbohydrate counting, using an insulin-to-carbohydrate ratio for each meal.</fragment>
				</section>
			</summary>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="C1562940" scheme="gov.nih.nlm.semanticType.hlca" label="carbohydrate counting"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H16"/>
			<id>172797</id>
			<summary>
				<section label="Optimal timing of insulin dose" id="16">
					<fragment>For patients with type 2 diabetes on combination therapy (oral hypoglycemics and once-daily insulin), the optimal timing of the insulin dose depends in part upon the type of insulin.</fragment>
				</section>
			</summary>
			<category term="C0020616" scheme="gov.nih.nlm.semanticType.phsu" label="hypoglycemics"/>
			<category term="C0359086" scheme="gov.nih.nlm.semanticType.phsu" label="oral hypoglycemics"/>
			<category term="C0556895" scheme="gov.nih.nlm.semanticType.topp" label="combination therapy"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H16"/>
			<id>172799</id>
			<summary>
				<section label="Optimal timing of insulin dose" id="16">
					<fragment>The advantages of bedtime NPH administration were best illustrated in a trial of 153 patients with type 2 diabetes receiving oral hypoglycemic therapy who were randomly assigned to oral therapy alone or oral therapy plus one of four NPH insulin regimens (single morning dose, single bedtime dose, or one of two multiple injection regimens combining NPH and regular insulin.</fragment>
				</section>
			</summary>
			<category term="C0020616" scheme="gov.nih.nlm.semanticType.phsu" label="hypoglycemic"/>
			<category term="C0021641" scheme="gov.nih.nlm.semanticType.horm" label="regular insulin"/>
			<category term="C0021658" scheme="gov.nih.nlm.semanticType.horm" label="NPH insulin"/>
			<category term="C0046449" scheme="gov.nih.nlm.semanticType.orch" label="NPH"/>
			<category term="C0359086" scheme="gov.nih.nlm.semanticType.phsu" label="oral hypoglycemic"/>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimens"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H16"/>
			<id>172802</id>
			<summary>
				<section label="Optimal timing of insulin dose" id="16">
					<fragment>Thus, patients with type 2 diabetes on oral hypoglycemic therapy did not do better with multiple insulin injections and bedtime insulin appeared to be preferable to morning administration.</fragment>
				</section>
			</summary>
			<category term="C0020616" scheme="gov.nih.nlm.semanticType.phsu" label="hypoglycemic"/>
			<category term="C0199782" scheme="gov.nih.nlm.semanticType.topp" label="insulin injections"/>
			<category term="C0359086" scheme="gov.nih.nlm.semanticType.phsu" label="oral hypoglycemic"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H16"/>
			<id>172803</id>
			<summary>
				<section label="Optimal timing of insulin dose" id="16">
					<fragment>In contrast, a morning rather than a bedtime dose of insulin glargine may provide better glycemic control in patients with type 2 diabetes who are also treated with an oral agent.</fragment>
				</section>
			</summary>
			<category term="C0907402" scheme="gov.nih.nlm.semanticType.horm" label="insulin glargine"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H16"/>
			<id>172804</id>
			<summary>
				<section label="Optimal timing of insulin dose" id="16">
					<fragment>This issue was addressed in a randomized, controlled trial of 695 patients with type 2 diabetes previously treated with oral agents.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H16"/>
			<id>172807</id>
			<summary>
				<section label="Optimal timing of insulin dose" id="16">
					<fragment>In summary, for patients with type 2 diabetes taking an oral hypoglycemic agent, the optimal timing is once-daily NPH or detemir at bedtime or once-daily insulin glargine in the morning or bedtime.</fragment>
				</section>
			</summary>
			<category term="C0020616" scheme="gov.nih.nlm.semanticType.phsu" label="hypoglycemic"/>
			<category term="C0046449" scheme="gov.nih.nlm.semanticType.orch" label="NPH"/>
			<category term="C0359086" scheme="gov.nih.nlm.semanticType.phsu" label="oral hypoglycemic"/>
			<category term="C0907402" scheme="gov.nih.nlm.semanticType.horm" label="insulin glargine"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H17"/>
			<id>172808</id>
			<summary>
				<section label="SWITCHING TO INSULIN MONOTHERAPY" id="17">
					<fragment>Patients with persistent hyperglycemia despite oral hypoglycemic therapy may stop the oral drug and begin insulin monotherapy.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0020616" scheme="gov.nih.nlm.semanticType.phsu" label="hypoglycemic"/>
			<category term="C0359086" scheme="gov.nih.nlm.semanticType.phsu" label="oral hypoglycemic"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H17"/>
			<id>172809</id>
			<summary>
				<section label="SWITCHING TO INSULIN MONOTHERAPY" id="17">
					<fragment>This approach is cheaper than combined therapy (although generic metformin is relatively inexpensive), but results in more weight gain and more episodes of hypoglycemia, few of which are severe.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0033972" scheme="gov.nih.nlm.semanticType.topp" label="combined therapy"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H18"/>
			<id>172811</id>
			<summary>
				<section label="Starting dose" id="18">
					<fragment>The initial dose of insulin in patients with type 2 diabetes switching to monotherapy is similar to the starting dose described above for patients adding insulin to oral hypoglycemic therapy.</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="adding"/>
			<category term="C0020616" scheme="gov.nih.nlm.semanticType.phsu" label="hypoglycemic"/>
			<category term="C0359086" scheme="gov.nih.nlm.semanticType.phsu" label="oral hypoglycemic"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H18"/>
			<id>172813</id>
			<summary>
				<section label="Starting dose" id="18">
					<fragment>Insulin doses should then be adjusted to achieve target levels of glycemia.</fragment>
				</section>
			</summary>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="Insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H18"/>
			<id>172816</id>
			<summary>
				<section label="Starting dose" id="18">
					<fragment>Daily insulin doses typically exceed 65 to 100 units per day, and may sometimes be much higher, before obese type 2 diabetic patients can achieve near-normal glycemia.</fragment>
				</section>
			</summary>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H19"/>
			<id>172818</id>
			<summary>
				<section label="daily regimens" id="19">
					<fragment>As an example, insulin glargine is effective when used alone for once-daily therapy in patients with type 2 diabetes and may be associated with less nocturnal hypoglycemia and less weight gain than NPH.</fragment>
				</section>
			</summary>
			<category term="C0046449" scheme="gov.nih.nlm.semanticType.orch" label="NPH"/>
			<category term="C0907402" scheme="gov.nih.nlm.semanticType.horm" label="insulin glargine"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H19"/>
			<id>172819</id>
			<summary>
				<section label="daily regimens" id="19">
					<fragment>However, serum insulin concentrations over a 24-hour period may be more stable in patients taking two doses daily, when the insulin preparation is NPH or detemir.</fragment>
				</section>
			</summary>
			<category term="C0009574" scheme="gov.nih.nlm.semanticType.phsu" label="preparation"/>
			<category term="C0021641" scheme="gov.nih.nlm.semanticType.horm" label="insulin preparation"/>
			<category term="C0046449" scheme="gov.nih.nlm.semanticType.orch" label="NPH"/>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H20"/>
			<id>172820</id>
			<summary>
				<section label="daily regimens" id="20">
					<fragment>If the goal is control of persistent hyperglycemia with a regimen that is simple, then twice-daily NPH insulin will be effective in many patients.</fragment>
				</section>
			</summary>
			<category term="C0021658" scheme="gov.nih.nlm.semanticType.horm" label="NPH insulin"/>
			<category term="C0046449" scheme="gov.nih.nlm.semanticType.orch" label="NPH"/>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H20"/>
			<id>172822</id>
			<summary>
				<section label="daily regimens" id="20">
					<fragment>Injection of regular plus NPH insulin before breakfast and before dinner results in four peaks of insulin action, covering the morning, afternoon, evening, and overnight ).</fragment>
				</section>
			</summary>
			<category term="C0021658" scheme="gov.nih.nlm.semanticType.horm" label="NPH insulin"/>
			<category term="C0046449" scheme="gov.nih.nlm.semanticType.orch" label="NPH"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H21"/>
			<id>172825</id>
			<summary>
				<section label="Intensive insulin" id="21">
					<fragment>Use of an intensive insulin regimen (similar to that used in type 1 diabetes) results in higher serum insulin concentrations and better glycemic control than that achieved with either an oral drug or conventional insulin therapy alone.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H21"/>
			<id>172827</id>
			<summary>
				<section label="Intensive insulin" id="21">
					<fragment>This weight gain may in some instances result in partial noncompliance with therapy, particularly in women.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H21"/>
			<id>172828</id>
			<summary>
				<section label="Intensive insulin" id="21">
					<fragment>If intensive insulin therapy is chosen in a patient with type 2 diabetes, the pretreatment considerations, choice of regimen, and management issues are similar to those for patients with type 1 diabetes.</fragment>
				</section>
			</summary>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H22"/>
			<id>172832</id>
			<summary>
				<section label="INSULIN AS INITIAL THERAPY" id="22">
					<fragment>The improvement in insulin secretion is presumably due to the elimination of the deleterious effects of hyperglycemia on beta cell secretory function, and in some patients, it results in better glycemic control that can then be maintained with diet and exercise for many months thereafter.</fragment>
				</section>
			</summary>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H22"/>
			<id>172833</id>
			<summary>
				<section label="INSULIN AS INITIAL THERAPY" id="22">
					<fragment>This was illustrated in a randomized trial of short-term (two to five weeks) intensive insulin therapy versus oral agents (gliclazide and/or metformin) in 410 Chinese patients with newly diagnosed type 2 diabetes (mean fasting glucose 202 mg/dL [11.2 mmol/L]).</fragment>
				</section>
			</summary>
			<category term="C0017631" scheme="gov.nih.nlm.semanticType.phsu" label="gliclazide"/>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="7" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H22"/>
			<id>172838</id>
			<summary>
				<section label="INSULIN AS INITIAL THERAPY" id="22">
					<fragment>A greater proportion of patients receiving insulin achieved glycemic goals in less time than those assigned to oral agents (over 90 percent within 4.0 to 5.6 days versus 84 percent in 9.3 days).</fragment>
				</section>
			</summary>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H22"/>
			<id>172840</id>
			<summary>
				<section label="INSULIN AS INITIAL THERAPY" id="22">
					<fragment>Patients in remission had lower initial fasting glucose and A1C, and achieved glycemic goals more quickly than those with recurrent hyperglycemia.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H22"/>
			<id>172841</id>
			<summary>
				<section label="INSULIN AS INITIAL THERAPY" id="22">
					<fragment>Thus, insulin can be considered as initial therapy for all patients with type 2 diabetes, and can result in remission for one year or longer.</fragment>
				</section>
			</summary>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H22"/>
			<id>172843</id>
			<summary>
				<section label="INSULIN AS INITIAL THERAPY" id="22">
					<fragment>Insulin should be particularly considered for patients presenting with A1C &gt;10 percent, fasting plasma glucose &gt;250 mg/dL (13.9 mmol/L), random glucose consistently &gt;300 mg/dL (16.7 mmol/L), ketonuria, or with unplanned weight loss in association with hyperglycemia.</fragment>
				</section>
			</summary>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="Insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H23"/>
			<id>172844</id>
			<summary>
				<section label="onset type 1 diabetes" id="23">
					<fragment>A potential problem is that patients who are initially thought to have type 2 diabetes may actually have type 1 diabetes and therefore require insulin as initial therapy.</fragment>
				</section>
			</summary>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H23"/>
			<id>172848</id>
			<summary>
				<section label="onset type 1 diabetes" id="23">
					<fragment>Diabetic ketoacidosis at first presentation suggests that the patient has type 1 diabetes and will require lifelong insulin treatment, although there are exceptions to this general rule.</fragment>
				</section>
			</summary>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="C1504665" scheme="gov.nih.nlm.semanticType.phsu" label="Diabetic ketoacidosis"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H23"/>
			<id>172849</id>
			<summary>
				<section label="onset type 1 diabetes" id="23">
					<fragment>Some individuals with adult-onset type 1 diabetes may slowly progress to insulin dependence and at presentation may be indistinguishable from a patient with type 2 diabetes.</fragment>
				</section>
			</summary>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H23"/>
			<id>172851</id>
			<summary>
				<section label="onset type 1 diabetes" id="23">
					<fragment>LADA can be distinguished from type 2 diabetes by the presence of pancreatic autoantibodies, such as glutamic acid decarboxylase antibodies.</fragment>
				</section>
			</summary>
			<category term="C0004358" scheme="gov.nih.nlm.semanticType.imft" label="autoantibodies"/>
			<category term="C0047145" scheme="gov.nih.nlm.semanticType.phsu" label="glutamic acid"/>
			<category term="C0368582" scheme="gov.nih.nlm.semanticType.imft" label="antibodies"/>
			<category term="C0443891" scheme="gov.nih.nlm.semanticType.imft" label="glutamic acid decarboxylase antibodies"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H24"/>
			<id>172865</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="24">
					<fragment>Initial therapy in most patients with type 2 diabetes should begin with diet, weight reduction, exercise, and metformin therapy (in the absence of contraindications), which may induce normoglycemia if compliance is optimal.</fragment>
				</section>
			</summary>
			<category term="C0012167" scheme="gov.nih.nlm.semanticType.topp" label="diet, weight reduction"/>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H24"/>
			<id>172867</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="24">
					<fragment>If once per day insulin is added to oral hypoglycemic therapy in patients with type 2 diabetes, either insulin NPH or detemir given at bedtime or insulin glargine given in the morning or at bedtime is a reasonable initial regimen.</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="added"/>
			<category term="C0020616" scheme="gov.nih.nlm.semanticType.phsu" label="hypoglycemic"/>
			<category term="C0021658" scheme="gov.nih.nlm.semanticType.horm" label="insulin NPH"/>
			<category term="C0046449" scheme="gov.nih.nlm.semanticType.orch" label="NPH"/>
			<category term="C0359086" scheme="gov.nih.nlm.semanticType.phsu" label="oral hypoglycemic"/>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimen"/>
			<category term="C0907402" scheme="gov.nih.nlm.semanticType.horm" label="insulin glargine"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H24"/>
			<id>172869</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="24">
					<fragment>Insulin can be considered initial therapy for all patients with type 2 diabetes, particularly patients presenting with A1C &gt;10 percent, fasting plasma glucose &gt;250 mg/dL (13.9 mmol/L), random glucose consistently &gt;300 mg/dL (16.7 mmol/L), or ketonuria.</fragment>
				</section>
			</summary>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="Insulin"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H24"/>
			<id>172870</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="24">
					<fragment>A potential problem is that patients who are initially thought to have type 2 diabetes may actually have type 1 diabetes and therefore require insulin as initial therapy.</fragment>
				</section>
			</summary>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H24"/>
			<id>172871</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="24">
					<fragment>In patients in whom it is difficult to distinguish type 1 from type 2 diabetes (patients who are underweight, are losing weight, or are ketotic), initial treatment with insulin is required.</fragment>
				</section>
			</summary>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H24"/>
			<id>172872</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="24">
					<fragment>Although we do not recommend premixed insulin for the treatment of type 1 diabetes, it is a reasonable option for patients with type 2 diabetes who are doing well on a stable, fixed ratio.</fragment>
				</section>
			</summary>
			<category term="C0658010" scheme="gov.nih.nlm.semanticType.orch" label="premixed"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1801#H24"/>
			<id>172873</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="24">
					<fragment>More complex insulin regimens can be used in patients with type 2 diabetes in an attempt to achieve near normoglycemia by adding short- or rapid-acting insulin before meals.</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="adding"/>
			<category term="C0356365" scheme="gov.nih.nlm.semanticType.horm" label="rapid-acting insulin"/>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimens"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
	</feed>
	<feed>
		<title>Metformin in the treatment of adults with type 2 diabetes mellitus</title>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="Metformin"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="Metformin"/>
		<category term="C0022924" scheme="gov.nih.nlm.semanticType.orch" label="lactate"/>
		<category term="C0023767" scheme="gov.nih.nlm.semanticType.imft" label="lipid"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="Metformin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="Metformin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="Metformin"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C1293130" scheme="gov.nih.nlm.semanticType.topp" label="stabilization"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0008287" scheme="gov.nih.nlm.semanticType.phsu" label="chlorpropamide"/>
		<category term="C0017628" scheme="gov.nih.nlm.semanticType.phsu" label="glyburide"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0124598" scheme="gov.nih.nlm.semanticType.phsu" label="kg"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="Metformin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0023767" scheme="gov.nih.nlm.semanticType.imft" label="lipid"/>
		<category term="C0625158" scheme="gov.nih.nlm.semanticType.phsu" label="cholesterol"/>
		<category term="C2002735" scheme="gov.nih.nlm.semanticType.orch" label="HDL"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C2605394" scheme="gov.nih.nlm.semanticType.orch" label="thiazolidinediones"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0017642" scheme="gov.nih.nlm.semanticType.phsu" label="glipizide"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="Metformin"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
		<category term="C0167117" scheme="gov.nih.nlm.semanticType.phsu" label="exenatide"/>
		<category term="C0669693" scheme="gov.nih.nlm.semanticType.orch" label="DPP"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C1979844" scheme="gov.nih.nlm.semanticType.aapp" label="alpha"/>
		<category term="C2605394" scheme="gov.nih.nlm.semanticType.orch" label="thiazolidinediones"/>
		<category term="C3537178" scheme="gov.nih.nlm.semanticType.phsu" label="glinides"/>
		<category term="C3539108" scheme="gov.nih.nlm.semanticType.phsu" label="alpha-glucosidase inhibitors"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="Metformin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0080448" scheme="gov.nih.nlm.semanticType.orch" label="Biguanide"/>
		<category term="C0022924" scheme="gov.nih.nlm.semanticType.orch" label="lactate"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="Metformin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0031001" scheme="gov.nih.nlm.semanticType.topp" label="perfusion"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="Metformin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0031809" scheme="gov.nih.nlm.semanticType.hlca" label="physical exam"/>
		<category term="C0278293" scheme="gov.nih.nlm.semanticType.topp" label="procedure"/>
		<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0008783" scheme="gov.nih.nlm.semanticType.phsu" label="cimetidine"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C3252015" scheme="gov.nih.nlm.semanticType.phsu" label="RR"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
		<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
		<category term="C0669693" scheme="gov.nih.nlm.semanticType.orch" label="DPP"/>
		<category term="C2605394" scheme="gov.nih.nlm.semanticType.orch" label="thiazolidinedione"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="Metformin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
		<category term="C0669693" scheme="gov.nih.nlm.semanticType.orch" label="DPP"/>
		<category term="C2605394" scheme="gov.nih.nlm.semanticType.orch" label="thiazolidinediones"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="Metformin"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="Insulin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<id>1809</id>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H2"/>
			<id>173063</id>
			<summary>
				<section label="MECHANISM OF ACTION" id="2">
					<fragment>Metformin is effective only in the presence of insulin, and its major effect is to decrease hepatic glucose output.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="Metformin"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H2"/>
			<id>173064</id>
			<summary>
				<section label="MECHANISM OF ACTION" id="2">
					<fragment>In addition, metformin increases insulin-mediated glucose utilization in peripheral tissues (such as muscle and liver), particularly after meals, and has an antilipolytic effect that lowers serum free fatty acid concentrations, thereby reducing substrate availability for gluconeogenesis.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H2"/>
			<id>173065</id>
			<summary>
				<section label="MECHANISM OF ACTION" id="2">
					<fragment>As a result of the improvement in glycemic control, serum insulin concentrations decline slightly.</fragment>
				</section>
			</summary>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H2"/>
			<id>173066</id>
			<summary>
				<section label="MECHANISM OF ACTION" id="2">
					<fragment>Metformin also increases intestinal glucose utilization via nonoxidative metabolism, at least in experimental animals.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="Metformin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H2"/>
			<id>173067</id>
			<summary>
				<section label="MECHANISM OF ACTION" id="2">
					<fragment>The lactate produced by this process is largely metabolized in the liver as a substrate for gluconeogenesis.</fragment>
				</section>
			</summary>
			<category term="C0022924" scheme="gov.nih.nlm.semanticType.orch" label="lactate"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H2"/>
			<id>173070</id>
			<summary>
				<section label="MECHANISM OF ACTION" id="2">
					<fragment>Activation of the enzyme AMP-activated protein kinase (AMK) appears to be the mechanism by which metformin lowers serum lipid and blood glucose concentrations.</fragment>
				</section>
			</summary>
			<category term="C0023767" scheme="gov.nih.nlm.semanticType.imft" label="lipid"/>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H2"/>
			<id>173071</id>
			<summary>
				<section label="MECHANISM OF ACTION" id="2">
					<fragment>Metformin works through the Peutz-Jeghers protein, LKB1, to regulate AMPK.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="Metformin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H2"/>
			<id>173072</id>
			<summary>
				<section label="MECHANISM OF ACTION" id="2">
					<fragment>LKB1 is a tumor suppressor and activation of AMPK through LKB1 may play a role in inhibiting cell growth.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H2"/>
			<id>173073</id>
			<summary>
				<section label="MECHANISM OF ACTION" id="2">
					<fragment>Metformin may also inhibit hepatic glucose production via a mechanism independent of AMK and LKB1.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="Metformin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H2"/>
			<id>173074</id>
			<summary>
				<section label="MECHANISM OF ACTION" id="2">
					<fragment>In mice deficient in AMK or LKB1, metformin successfully inhibited glucose production.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H2"/>
			<id>173076</id>
			<summary>
				<section label="MECHANISM OF ACTION" id="2">
					<fragment>Thus, alternative pathways are likely to be involved in the inhibition of gluconeogenesis by metformin.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H4"/>
			<id>173078</id>
			<summary>
				<section label="Monotherapy" id="4">
					<fragment>The US Multicenter Metformin Study Group, for example, randomly assigned obese patients with type 2 diabetes who were inadequately controlled on diet alone to either metformin or placebo.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="Metformin"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H4"/>
			<id>173080</id>
			<summary>
				<section label="Monotherapy" id="4">
					<fragment>In those who are obese, metformin promotes modest weight reduction or at least weight stabilization.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C1293130" scheme="gov.nih.nlm.semanticType.topp" label="stabilization"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H4"/>
			<id>173081</id>
			<summary>
				<section label="Monotherapy" id="4">
					<fragment>This is in contrast to the weight gain often associated with insulin or sulfonylurea treatment.</fragment>
				</section>
			</summary>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H4"/>
			<id>173082</id>
			<summary>
				<section label="Monotherapy" id="4">
					<fragment>In one large study, for example, patients treated with glyburide, chlorpropamide, or insulin gained an average of 3.5 to 4.8 kg, whereas those receiving metformin had no change.</fragment>
				</section>
			</summary>
			<category term="C0008287" scheme="gov.nih.nlm.semanticType.phsu" label="chlorpropamide"/>
			<category term="C0017628" scheme="gov.nih.nlm.semanticType.phsu" label="glyburide"/>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0124598" scheme="gov.nih.nlm.semanticType.phsu" label="kg"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H4"/>
			<id>173083</id>
			<summary>
				<section label="Monotherapy" id="4">
					<fragment>In addition to causing modest weight loss, metformin has other advantages as compared with other oral agents.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H4"/>
			<id>173084</id>
			<summary>
				<section label="Monotherapy" id="4">
					<fragment>Metformin may be less likely to cause hypoglycemia.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="Metformin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H4"/>
			<id>173085</id>
			<summary>
				<section label="Monotherapy" id="4">
					<fragment>Careful blood glucose monitoring is still needed during the first weeks or months of treatment with metformin to avoid this problem.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H4"/>
			<id>173086</id>
			<summary>
				<section label="Monotherapy" id="4">
					<fragment>It has lipid-lowering activity, resulting in a decrease in serum triglyceride and free fatty acid concentrations, a small decrease in serum low-density-lipoprotein (LDL) cholesterol concentrations, and a very modest increase in serum high-density-lipoprotein (HDL) cholesterol concentrations.</fragment>
				</section>
			</summary>
			<category term="C0023767" scheme="gov.nih.nlm.semanticType.imft" label="lipid"/>
			<category term="C0625158" scheme="gov.nih.nlm.semanticType.phsu" label="cholesterol"/>
			<category term="C2002735" scheme="gov.nih.nlm.semanticType.orch" label="HDL"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H4"/>
			<id>173087</id>
			<summary>
				<section label="Monotherapy" id="4">
					<fragment>It appears to decrease cardiovascular events and all-cause mortality as illustrated by the findings of a systematic review of 29 trials of metformin as monotherapy compared with other oral agents (sulfonylureas, thiazolidinediones, meglitinides, glucosidase inhibitors), insulin, diet, or placebo.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="C2605394" scheme="gov.nih.nlm.semanticType.orch" label="thiazolidinediones"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H4"/>
			<id>173088</id>
			<summary>
				<section label="Monotherapy" id="4">
					<fragment>In overweight and obese patients with diabetes, metformin resulted in decreased all-cause mortality and a decreased rate of myocardial infarction.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H4"/>
			<id>173089</id>
			<summary>
				<section label="Monotherapy" id="4">
					<fragment>In a subsequent randomized trial of metformin versus glipizide in Chinese patients with established coronary heart disease and type 2 diabetes, there were fewer cardiovascular events in the metformin group (total events 43 versus 60, HR 0.54, 95% CI 0.3-0.9).</fragment>
				</section>
			</summary>
			<category term="C0017642" scheme="gov.nih.nlm.semanticType.phsu" label="glipizide"/>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="9" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H4"/>
			<id>173090</id>
			<summary>
				<section label="Monotherapy" id="4">
					<fragment>A comparison of metformin and other oral agents is reviewed in more detail separately.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H5"/>
			<id>173091</id>
			<summary>
				<section label="Combination therapy" id="5">
					<fragment>Combinations of drugs are often necessary to achieve optimal glycemic control.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H5"/>
			<id>173092</id>
			<summary>
				<section label="Combination therapy" id="5">
					<fragment>Metformin can be given in combination with sulfonylureas, insulin, glinides, alpha-glucosidase inhibitors, thiazolidinediones, exenatide, and DPP-IV inhibitors.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="Metformin"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
			<category term="C0167117" scheme="gov.nih.nlm.semanticType.phsu" label="exenatide"/>
			<category term="C0669693" scheme="gov.nih.nlm.semanticType.orch" label="DPP"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="C1979844" scheme="gov.nih.nlm.semanticType.aapp" label="alpha"/>
			<category term="C2605394" scheme="gov.nih.nlm.semanticType.orch" label="thiazolidinediones"/>
			<category term="C3537178" scheme="gov.nih.nlm.semanticType.phsu" label="glinides"/>
			<category term="C3539108" scheme="gov.nih.nlm.semanticType.phsu" label="alpha-glucosidase inhibitors"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H6"/>
			<id>173097</id>
			<summary>
				<section label="SIDE EFFECTS" id="6">
					<fragment>Metformin reduces intestinal absorption of vitamin B12 in up to 30 percent of patients, and lowers serum vitamin B12 concentrations in 5 to 10 percent, but only rarely causes megaloblastic anemia.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="Metformin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H6"/>
			<id>173098</id>
			<summary>
				<section label="SIDE EFFECTS" id="6">
					<fragment>In some patients with vitamin B12 deficiency, peripheral neuropathy may precede the development of megaloblastic anemia.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H6"/>
			<id>173099</id>
			<summary>
				<section label="SIDE EFFECTS" id="6">
					<fragment>The dose and duration of use of metformin correlates with the risk of vitamin B12 deficiency.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H6"/>
			<id>173100</id>
			<summary>
				<section label="SIDE EFFECTS" id="6">
					<fragment>In one study, this reduction appeared to be due to poor absorption of B12 in the ileum and was corrected by administration of oral calcium carbonate (1.2 g daily).</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H7"/>
			<id>173102</id>
			<summary>
				<section label="Lactic acidosis" id="7">
					<fragment>Biguanide therapy in type 2 diabetes with phenformin in the past or currently with metformin can lead to lactic acidosis.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0080448" scheme="gov.nih.nlm.semanticType.orch" label="Biguanide"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H7"/>
			<id>173104</id>
			<summary>
				<section label="Lactic acidosis" id="7">
					<fragment>Serum lactate concentrations are usually less than 2 mmol/L in patients taking metformin, values that are not clinically important.</fragment>
				</section>
			</summary>
			<category term="C0022924" scheme="gov.nih.nlm.semanticType.orch" label="lactate"/>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H7"/>
			<id>173106</id>
			<summary>
				<section label="Lactic acidosis" id="7">
					<fragment>Metformin-induced lactic acidosis can occur in patients with normal renal and hepatic function.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="Metformin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H7"/>
			<id>173108</id>
			<summary>
				<section label="Lactic acidosis" id="7">
					<fragment>In addition, patients with the genetic diabetes syndrome, maternally inherited diabetes and deafness (MIDD), are at increased risk of developing lactic acidosis with metformin therapy.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H8"/>
			<id>173110</id>
			<summary>
				<section label="Incidence" id="8">
					<fragment>In a review of 11,800 patients treated with metformin for a mean of about two years, only two patients developed lactic acidosis (incidence nine cases per 100,000 person-years of exposure).</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H8"/>
			<id>173114</id>
			<summary>
				<section label="Incidence" id="8">
					<fragment>Almost one-half of the studies allowed inclusion of patients with a serum creatinine above 1.5 mg/dL [133 micromol/L], and almost all allowed inclusion of patients with at least one contraindication to metformin therapy.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H9"/>
			<id>173117</id>
			<summary>
				<section label="Predisposing factors" id="9">
					<fragment>Most cases have occurred in patients with shock or tissue hypoxia or in the presence of several other predisposing conditions;</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H9"/>
			<id>173124</id>
			<summary>
				<section label="Predisposing factors" id="9">
					<fragment>however, despite safety concerns, metformin use has been common and well tolerated in diabetic patients with heart failure.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H9"/>
			<id>173126</id>
			<summary>
				<section label="Predisposing factors" id="9">
					<fragment>Decreased tissue perfusion or hemodynamic instability due to infection or other causes.</fragment>
				</section>
			</summary>
			<category term="C0031001" scheme="gov.nih.nlm.semanticType.topp" label="perfusion"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H9"/>
			<id>173130</id>
			<summary>
				<section label="Predisposing factors" id="9">
					<fragment>As a result, a given serum creatinine can represent a substantially lower glomerular filtration rate (GFR) than seen in patients with normal muscle mass.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H9"/>
			<id>173131</id>
			<summary>
				<section label="Predisposing factors" id="9">
					<fragment>Rather than using serum creatinine alone, the GFR can be estimated in patients with a stable serum creatinine concentration.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H9"/>
			<id>173133</id>
			<summary>
				<section label="Predisposing factors" id="9">
					<fragment>In the United Kingdom where serum creatinine limits are 130 or 150 micromol/L (1.5 or 1.7 mg/dL), calculation of estimated GFR in over 30,000 patients with type 2 diabetes and analysis of the proportion of patients in whom creatinine and estimated GFR limits contraindicated metformin showed that the serum creatinine limits approximately corresponded to estimated GFR thresholds of 30 to 49 mL/min.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H9"/>
			<id>173136</id>
			<summary>
				<section label="Predisposing factors" id="9">
					<fragment>For a patient with an eGFR between 30 and 50 mL/min, we typically reduce the metformin dose by half.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H9"/>
			<id>173137</id>
			<summary>
				<section label="Predisposing factors" id="9">
					<fragment>In addition, we advise such patients to stop taking metformin if they have any illness, such as influenza, upper respiratory infection, or urinary tract infection.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H9"/>
			<id>173138</id>
			<summary>
				<section label="Predisposing factors" id="9">
					<fragment>Metformin should be discontinued in patients who develop one of the predisposing factors listed above.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="Metformin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H9"/>
			<id>173139</id>
			<summary>
				<section label="Predisposing factors" id="9">
					<fragment>In addition, patients who are about to receive intravenous iodinated contrast material (with potential for contrast-induced renal failure) or undergo a surgical procedure (with potential compromise of circulation) should have metformin held until stable renal function can be established (normal urine output, normal serum creatinine, and no physical exam evidence of fluid overload or circulatory compromise).</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0031809" scheme="gov.nih.nlm.semanticType.hlca" label="physical exam"/>
			<category term="C0278293" scheme="gov.nih.nlm.semanticType.topp" label="procedure"/>
			<category term="C0543467" scheme="gov.nih.nlm.semanticType.hlca" label="surgical"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H10"/>
			<id>173143</id>
			<summary>
				<section label="Contraindications in clinical practice" id="10">
					<fragment>A number of patients treated with metformin have one or more of the above contraindications (most often renal insufficiency or heart failure).</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H10"/>
			<id>173146</id>
			<summary>
				<section label="Contraindications in clinical practice" id="10">
					<fragment>This finding has led some but not all to recommend a reevaluation of the contraindications to metformin therapy, particularly in patients with stable, well-compensated heart failure or with estimated GFR above 30 mL/min.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H10"/>
			<id>173147</id>
			<summary>
				<section label="Contraindications in clinical practice" id="10">
					<fragment>Improved clinical outcomes with metformin have been reported in observational studies of patients with diabetes and heart failure.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H10"/>
			<id>173149</id>
			<summary>
				<section label="Contraindications in clinical practice" id="10">
					<fragment>In a systematic review of studies and evidence-based guidelines on the use of intravenous contrast in patients taking metformin, the only available data were from case reports and case series.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H10"/>
			<id>173150</id>
			<summary>
				<section label="Contraindications in clinical practice" id="10">
					<fragment>The majority of cases of metformin-related lactic acidosis occurred in patients with abnormal renal function who received intravenous contrast medium.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H10"/>
			<id>173151</id>
			<summary>
				<section label="Contraindications in clinical practice" id="10">
					<fragment>The risk of metformin-induced lactic acidosis in patients with normal renal function who receive intravenous contrast is unknown but appears to be rare.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H10"/>
			<id>173152</id>
			<summary>
				<section label="Contraindications in clinical practice" id="10">
					<fragment>Until more data are available, however, we prefer to hold metformin in patients who are about to receive intravenous iodinated contrast material (with potential for contrast-induced renal failure), irrespective of baseline renal function, until stable renal function can be established.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H10"/>
			<id>173153</id>
			<summary>
				<section label="Contraindications in clinical practice" id="10">
					<fragment>In summary, the risk of lactic acidosis in the overall population of patients with type 2 diabetes treated with metformin is low.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H10"/>
			<id>173154</id>
			<summary>
				<section label="Contraindications in clinical practice" id="10">
					<fragment>Although patients with one or more of the predisposing factors cited above are most at risk, the incidence of lactic acidosis in these patients is not known and may be low in patients with borderline risk factors, such as well-compensated heart failure.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H10"/>
			<id>173155</id>
			<summary>
				<section label="Contraindications in clinical practice" id="10">
					<fragment>This is an important issue because the benefits of metformin in the treatment of type 2 diabetes mellitus may outweigh the risk in such patients.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H11"/>
			<id>173156</id>
			<summary>
				<section label="Treatment" id="11">
					<fragment>The role of bicarbonate therapy in patients with lactic acidosis and shock or tissue hypoxia is not well established, except in severe metabolic acidosis, because of concern about possible worsening of intracellular acidosis.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H11"/>
			<id>173157</id>
			<summary>
				<section label="Treatment" id="11">
					<fragment>However, this may not apply to metformin-associated lactic acidosis since, in patients with concurrent renal failure, bicarbonate hemodialysis can both correct the acidosis and remove metformin.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H12"/>
			<id>173159</id>
			<summary>
				<section label="Drug interactions" id="12">
					<fragment>A potential drug interaction exists between metformin and cimetidine, as cimetidine may lower the renal clearance of metformin due to competitive inhibition of renal tubular secretion of metformin.</fragment>
				</section>
			</summary>
			<category term="C0008783" scheme="gov.nih.nlm.semanticType.phsu" label="cimetidine"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H12"/>
			<id>173160</id>
			<summary>
				<section label="Drug interactions" id="12">
					<fragment>This interaction could increase the risk of hypoglycemia in patients taking metformin plus a sulfonylurea or insulin.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H12"/>
			<id>173161</id>
			<summary>
				<section label="Drug interactions" id="12">
					<fragment>Other H2-blockers are less likely to affect the renal handing of metformin.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H12"/>
			<id>173163</id>
			<summary>
				<section label="Drug interactions" id="12">
					<fragment>The rationale for this recommendation is to avoid the potential for high plasma metformin concentrations (and lactic acidosis) if the patient develops contrast-induced acute renal failure.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H12"/>
			<id>173164</id>
			<summary>
				<section label="Drug interactions" id="12">
					<fragment>In a review of the 110 published cases of lactic acidosis associated with metformin, nine occurred in patients with contrast-induced renal failure.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H12"/>
			<id>173165</id>
			<summary>
				<section label="Drug interactions" id="12">
					<fragment>This risk for contrast-induced acute renal failure is greatest in diabetic patients with renal insufficiency;</fragment>
				</section>
			</summary>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H1209560"/>
			<id>173170</id>
			<summary>
				<section label="Cancer incidence" id="1209560">
					<fragment>In meta-analyses of predominantly case-control and cohort studies in patients with type 2 diabetes, use of metformin compared with nonuse or with use of other diabetes treatment was associated with a reduced risk of all cancers (RR 0.61, 95% CI 0.54-0.70), colorectal cancer (RR 0.64, 95% CI 0.54-0.76), and lower cancer mortality (RR 0.66, 95% CI 0.49-0.88).</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="C3252015" scheme="gov.nih.nlm.semanticType.phsu" label="RR"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H1209560"/>
			<id>173173</id>
			<summary>
				<section label="Cancer incidence" id="1209560">
					<fragment>In contrast to the observational data, a meta-analysis of randomized trials comparing metformin to a comparator (thiazolidinedione, sulfonylurea, DPP-IV inhibitor, or placebo) did not show a reduction in cancer incidence.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0032042" scheme="gov.nih.nlm.semanticType.topp" label="placebo"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
			<category term="C0048442" scheme="gov.nih.nlm.semanticType.orch" label="meta"/>
			<category term="C0669693" scheme="gov.nih.nlm.semanticType.orch" label="DPP"/>
			<category term="C2605394" scheme="gov.nih.nlm.semanticType.orch" label="thiazolidinedione"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H1209560"/>
			<id>173179</id>
			<summary>
				<section label="Cancer incidence" id="1209560">
					<fragment>A possible mechanism by which metformin may decrease cancer incidence is regulation of AMPK through LKB1.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H1209560"/>
			<id>173180</id>
			<summary>
				<section label="Cancer incidence" id="1209560">
					<fragment>LKB1 is a tumor suppressor and activation of AMPK through LKB1 may play a role in inhibiting cell growth.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H13"/>
			<id>173181</id>
			<summary>
				<section label="DOSING AND MONITORING" id="13">
					<fragment>Metformin is absorbed rapidly from the small intestine, with peak plasma concentrations attained in two hours.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="Metformin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H13"/>
			<id>173189</id>
			<summary>
				<section label="DOSING AND MONITORING" id="13">
					<fragment>Combination tablets of metformin and sulfonylureas, thiazolidinediones, or DPP-IV inhibitors are also available.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
			<category term="C0669693" scheme="gov.nih.nlm.semanticType.orch" label="DPP"/>
			<category term="C2605394" scheme="gov.nih.nlm.semanticType.orch" label="thiazolidinediones"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H13"/>
			<id>173190</id>
			<summary>
				<section label="DOSING AND MONITORING" id="13">
					<fragment>For patients taking metformin, we measure A1C every three to six months, serum creatinine annually, and hemoglobin, hematocrit, and red cell indices at diagnosis and at other times if the patient develops symptoms suggestive of anemia, neuropathy, or deteriorating renal function.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H15"/>
			<id>173192</id>
			<summary>
				<section label="Efficacy" id="15">
					<fragment>Metformin typically lowers A1C concentrations by approximately 1.5 percent, is not associated with weight gain, and is less likely to cause hypoglycemia than sulfonylureas and insulin.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="Metformin"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H15"/>
			<id>173193</id>
			<summary>
				<section label="Efficacy" id="15">
					<fragment>In the absence of specific contraindications, we suggest metformin as initial therapy in most patients with type 2 diabetes.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H15"/>
			<id>173194</id>
			<summary>
				<section label="Efficacy" id="15">
					<fragment>Insulin can also be considered a first-line therapy for all patients with type 2 diabetes, particularly patients presenting with A1C &gt;10 percent, fasting plasma glucose &gt;250 mg/dL (13.9 mmol/L), random glucose consistently &gt;300 mg/dL (16.7 mmol/L), or ketonuria.</fragment>
				</section>
			</summary>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="Insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H15"/>
			<id>173195</id>
			<summary>
				<section label="Efficacy" id="15">
					<fragment>We suggest initiating metformin at the time of diabetes diagnosis, along with consultation for lifestyle intervention.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1809#H16"/>
			<id>173201</id>
			<summary>
				<section label="Side effects" id="16">
					<fragment>Thus, metformin should not be administered to individuals with predisposing factors for developing lactic acidosis.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
	</feed>
	<feed>
		<title>Treatment of type 2 diabetes mellitus in the elderly patient</title>
		<category term="C0019860" scheme="gov.nih.nlm.semanticType.hlca" label="nursing homes"/>
		<category term="C0047590" scheme="gov.nih.nlm.semanticType.phsu" label="fit"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0292977" scheme="gov.nih.nlm.semanticType.phsu" label="falling"/>
		<category term="C0001637" scheme="gov.nih.nlm.semanticType.phsu" label="adrenergic"/>
		<category term="C0020616" scheme="gov.nih.nlm.semanticType.phsu" label="hypoglycemic"/>
		<category term="C0020616" scheme="gov.nih.nlm.semanticType.phsu" label="Hypoglycemic"/>
		<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
		<category term="C0019860" scheme="gov.nih.nlm.semanticType.hlca" label="nursing home"/>
		<category term="C0292977" scheme="gov.nih.nlm.semanticType.phsu" label="falls"/>
		<category term="C0441587" scheme="gov.nih.nlm.semanticType.hlca" label="placement"/>
		<category term="C1611640" scheme="gov.nih.nlm.semanticType.phsu" label="therapeutic agents"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="Insulin"/>
		<category term="C0012167" scheme="gov.nih.nlm.semanticType.topp" label="Diet, weight reduction"/>
		<category term="C1257928" scheme="gov.nih.nlm.semanticType.topp" label="Medical nutrition therapy"/>
		<category term="C2937349" scheme="gov.nih.nlm.semanticType.hlca" label="nutrition therapy"/>
		<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
		<category term="C1135809" scheme="gov.nih.nlm.semanticType.topp" label="caloric restriction"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0020616" scheme="gov.nih.nlm.semanticType.phsu" label="hypoglycemic"/>
		<category term="C0359086" scheme="gov.nih.nlm.semanticType.phsu" label="oral hypoglycemic"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
		<category term="C0246689" scheme="gov.nih.nlm.semanticType.phsu" label="repaglinide"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="Metformin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0278293" scheme="gov.nih.nlm.semanticType.topp" label="procedure"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C0008287" scheme="gov.nih.nlm.semanticType.phsu" label="chlorpropamide"/>
		<category term="C0017628" scheme="gov.nih.nlm.semanticType.phsu" label="glyburide"/>
		<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
		<category term="C0017628" scheme="gov.nih.nlm.semanticType.phsu" label="glyburide"/>
		<category term="C0017642" scheme="gov.nih.nlm.semanticType.phsu" label="glipizide"/>
		<category term="C0017245" scheme="gov.nih.nlm.semanticType.phsu" label="gemfibrozil"/>
		<category term="C2936462" scheme="gov.nih.nlm.semanticType.orch" label="fibric acid"/>
		<category term="C2974226" scheme="gov.nih.nlm.semanticType.orch" label="salicylates"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
		<category term="C0071097" scheme="gov.nih.nlm.semanticType.phsu" label="pioglitazone"/>
		<category term="C0289313" scheme="gov.nih.nlm.semanticType.phsu" label="rosiglitazone"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C2605394" scheme="gov.nih.nlm.semanticType.orch" label="thiazolidinediones"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C2605394" scheme="gov.nih.nlm.semanticType.orch" label="thiazolidinediones"/>
		<category term="C2605394" scheme="gov.nih.nlm.semanticType.orch" label="thiazolidinediones"/>
		<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
		<category term="C0023767" scheme="gov.nih.nlm.semanticType.imft" label="lipid"/>
		<category term="C0071097" scheme="gov.nih.nlm.semanticType.phsu" label="pioglitazone"/>
		<category term="C0289313" scheme="gov.nih.nlm.semanticType.phsu" label="rosiglitazone"/>
		<category term="C2605394" scheme="gov.nih.nlm.semanticType.orch" label="thiazolidinedione"/>
		<category term="C0071097" scheme="gov.nih.nlm.semanticType.phsu" label="pioglitazone"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
		<category term="C0246689" scheme="gov.nih.nlm.semanticType.phsu" label="Repaglinide"/>
		<category term="C0903898" scheme="gov.nih.nlm.semanticType.phsu" label="nateglinide"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
		<category term="C0246689" scheme="gov.nih.nlm.semanticType.phsu" label="repaglinide"/>
		<category term="C0903898" scheme="gov.nih.nlm.semanticType.phsu" label="nateglinide"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
		<category term="C0246689" scheme="gov.nih.nlm.semanticType.phsu" label="repaglinide"/>
		<category term="C0050393" scheme="gov.nih.nlm.semanticType.phsu" label="Acarbose"/>
		<category term="C0066535" scheme="gov.nih.nlm.semanticType.phsu" label="miglitol"/>
		<category term="C1979844" scheme="gov.nih.nlm.semanticType.aapp" label="alpha"/>
		<category term="C0050393" scheme="gov.nih.nlm.semanticType.phsu" label="Acarbose"/>
		<category term="C0066535" scheme="gov.nih.nlm.semanticType.phsu" label="miglitol"/>
		<category term="C0669693" scheme="gov.nih.nlm.semanticType.orch" label="DPP"/>
		<category term="C0669693" scheme="gov.nih.nlm.semanticType.orch" label="DPP"/>
		<category term="C0357164" scheme="gov.nih.nlm.semanticType.phsu" label="intravenous glucose"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C1562292" scheme="gov.nih.nlm.semanticType.horm" label="incretin"/>
		<category term="C2354520" scheme="gov.nih.nlm.semanticType.aapp" label="peptides"/>
		<category term="C0167117" scheme="gov.nih.nlm.semanticType.phsu" label="Exenatide"/>
		<category term="C0763866" scheme="gov.nih.nlm.semanticType.aapp" label="GLP"/>
		<category term="C1456408" scheme="gov.nih.nlm.semanticType.horm" label="liraglutide"/>
		<category term="C0763866" scheme="gov.nih.nlm.semanticType.aapp" label="GLP"/>
		<category term="C0763866" scheme="gov.nih.nlm.semanticType.aapp" label="GLP"/>
		<category term="C0167117" scheme="gov.nih.nlm.semanticType.phsu" label="exenatide"/>
		<category term="C0063684" scheme="gov.nih.nlm.semanticType.horm" label="amylin"/>
		<category term="C0537551" scheme="gov.nih.nlm.semanticType.horm" label="Pramlintide"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="add"/>
		<category term="C0020616" scheme="gov.nih.nlm.semanticType.phsu" label="hypoglycemic"/>
		<category term="C0304870" scheme="gov.nih.nlm.semanticType.horm" label="long-acting insulins"/>
		<category term="C0359086" scheme="gov.nih.nlm.semanticType.phsu" label="oral hypoglycemic"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulins"/>
		<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
		<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C1564509" scheme="gov.nih.nlm.semanticType.antb" label="pen"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="Insulin"/>
		<category term="C0588436" scheme="gov.nih.nlm.semanticType.topp" label="self monitoring"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0588436" scheme="gov.nih.nlm.semanticType.topp" label="self-monitoring"/>
		<category term="C0200149" scheme="gov.nih.nlm.semanticType.hlca" label="eye examinations"/>
		<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C3263684" scheme="gov.nih.nlm.semanticType.topp" label="screen"/>
		<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
		<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE) inhibitors"/>
		<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
		<category term="C3263684" scheme="gov.nih.nlm.semanticType.topp" label="screened"/>
		<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitor"/>
		<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
		<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
		<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
		<category term="C0150240" scheme="gov.nih.nlm.semanticType.topp" label="foot care"/>
		<category term="C0150600" scheme="gov.nih.nlm.semanticType.hlca" label="advice"/>
		<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0023767" scheme="gov.nih.nlm.semanticType.imft" label="lipid"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
		<category term="C0360714" scheme="gov.nih.nlm.semanticType.phsu" label="statin"/>
		<category term="C0625158" scheme="gov.nih.nlm.semanticType.phsu" label="cholesterol"/>
		<category term="C0003367" scheme="gov.nih.nlm.semanticType.phsu" label="lipid-lowering drugs"/>
		<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
		<category term="C0023767" scheme="gov.nih.nlm.semanticType.imft" label="lipid"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
		<category term="C0679699" scheme="gov.nih.nlm.semanticType.topp" label="secondary prevention"/>
		<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
		<category term="C0679699" scheme="gov.nih.nlm.semanticType.topp" label="secondary prevention"/>
		<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
		<category term="C0033144" scheme="gov.nih.nlm.semanticType.topp" label="primary prevention"/>
		<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0001701" scheme="gov.nih.nlm.semanticType.topp" label="aerobic exercises"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimens"/>
		<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
		<category term="C0292977" scheme="gov.nih.nlm.semanticType.phsu" label="falls"/>
		<category term="C0292977" scheme="gov.nih.nlm.semanticType.phsu" label="falls"/>
		<category term="C0292977" scheme="gov.nih.nlm.semanticType.phsu" label="falls"/>
		<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevents"/>
		<category term="C0292977" scheme="gov.nih.nlm.semanticType.phsu" label="falls"/>
		<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
		<category term="C0020616" scheme="gov.nih.nlm.semanticType.phsu" label="hypoglycemic"/>
		<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0292977" scheme="gov.nih.nlm.semanticType.phsu" label="falls"/>
		<category term="C0308403" scheme="gov.nih.nlm.semanticType.phsu" label="balanced"/>
		<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
		<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimens"/>
		<category term="C1611640" scheme="gov.nih.nlm.semanticType.phsu" label="therapeutic agents"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
		<category term="C0246689" scheme="gov.nih.nlm.semanticType.phsu" label="repaglinide"/>
		<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
		<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
		<id>1776</id>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H2"/>
			<id>171884</id>
			<summary>
				<section label="INDIVIDUALIZING MANAGEMENT" id="2">
					<fragment>Older adults with diabetes are a heterogeneous population that includes persons residing independently in communities, in assisted care facilities, or in nursing homes.</fragment>
				</section>
			</summary>
			<category term="C0019860" scheme="gov.nih.nlm.semanticType.hlca" label="nursing homes"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H2"/>
			<id>171885</id>
			<summary>
				<section label="INDIVIDUALIZING MANAGEMENT" id="2">
					<fragment>Thus older adults with diabetes can be fit and healthy or frail with many comorbidities and functional disabilities.</fragment>
				</section>
			</summary>
			<category term="C0047590" scheme="gov.nih.nlm.semanticType.phsu" label="fit"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H2"/>
			<id>171887</id>
			<summary>
				<section label="INDIVIDUALIZING MANAGEMENT" id="2">
					<fragment>However, in frail elderly patients with diabetes, avoidance of hypoglycemia, hypotension, and drug interactions due to polypharmacy are of even greater concern than in younger patients with diabetes.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H2"/>
			<id>171888</id>
			<summary>
				<section label="INDIVIDUALIZING MANAGEMENT" id="2">
					<fragment>In addition, management of coexisting medical conditions is important, as it influences their ability to perform self-management.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H3"/>
			<id>171890</id>
			<summary>
				<section label="Glycemic targets" id="3">
					<fragment>Hyperglycemia increases dehydration and impairs vision and cognition, all of which contribute to functional decline and an increased risk of falling in elderly diabetic patients.</fragment>
				</section>
			</summary>
			<category term="C0292977" scheme="gov.nih.nlm.semanticType.phsu" label="falling"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H3"/>
			<id>171895</id>
			<summary>
				<section label="Glycemic targets" id="3">
					<fragment>The results of the ACCORD trial suggest that a target A1C of 7.0 to 7.9 percent (achieving a median of 7.5 percent) may be safer than a lower target for patients with long-standing type 2 diabetes who are at high risk for cardiovascular disease.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H4"/>
			<id>171903</id>
			<summary>
				<section label="Avoiding hypoglycemia" id="4">
					<fragment>In addition, older adults may have more neuroglycopenic manifestations of hypoglycemia (dizziness, weakness, delirium, confusion) compared with adrenergic manifestations (tremors, sweating).</fragment>
				</section>
			</summary>
			<category term="C0001637" scheme="gov.nih.nlm.semanticType.phsu" label="adrenergic"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H4"/>
			<id>171904</id>
			<summary>
				<section label="Avoiding hypoglycemia" id="4">
					<fragment>These symptoms may be missed or misconstrued as primary neurological disease (such as a transient ischemic attack), leading to inappropriate reporting of hypoglycemic episodes by the patients.</fragment>
				</section>
			</summary>
			<category term="C0020616" scheme="gov.nih.nlm.semanticType.phsu" label="hypoglycemic"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H4"/>
			<id>171905</id>
			<summary>
				<section label="Avoiding hypoglycemia" id="4">
					<fragment>Hypoglycemic episodes in elderly individuals may also increase the risk of adverse cardiovascular events and cardiac autonomic dysfunction.</fragment>
				</section>
			</summary>
			<category term="C0020616" scheme="gov.nih.nlm.semanticType.phsu" label="Hypoglycemic"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H4"/>
			<id>171906</id>
			<summary>
				<section label="Avoiding hypoglycemia" id="4">
					<fragment>In addition, severe hypoglycemia requiring hospitalization has been associated with an increased risk of developing dementia that is higher in patients with repeated episodes, although the direction of causality, if any, is unknown.</fragment>
				</section>
			</summary>
			<category term="C0019993" scheme="gov.nih.nlm.semanticType.hlca" label="hospitalization"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H4"/>
			<id>171907</id>
			<summary>
				<section label="Avoiding hypoglycemia" id="4">
					<fragment>Even a mild episode of hypoglycemia may lead to adverse outcomes in frail elderly patients.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H4"/>
			<id>171908</id>
			<summary>
				<section label="Avoiding hypoglycemia" id="4">
					<fragment>As an example, episodes of dizziness or weakness increase the risk of falls and fracture leading to nursing home placement.</fragment>
				</section>
			</summary>
			<category term="C0019860" scheme="gov.nih.nlm.semanticType.hlca" label="nursing home"/>
			<category term="C0292977" scheme="gov.nih.nlm.semanticType.phsu" label="falls"/>
			<category term="C0441587" scheme="gov.nih.nlm.semanticType.hlca" label="placement"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H4"/>
			<id>171909</id>
			<summary>
				<section label="Avoiding hypoglycemia" id="4">
					<fragment>Given the risks, avoidance of hypoglycemia is an important consideration in choosing therapeutic agents and establishing glycemic goals in elderly adults.</fragment>
				</section>
			</summary>
			<category term="C1611640" scheme="gov.nih.nlm.semanticType.phsu" label="therapeutic agents"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H4"/>
			<id>171910</id>
			<summary>
				<section label="Avoiding hypoglycemia" id="4">
					<fragment>Insulin secretagogues such as sulfonylurea and meglitinides, as well all types of insulin, should be used with caution in the frail elderly.</fragment>
				</section>
			</summary>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="Insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H5"/>
			<id>171911</id>
			<summary>
				<section label="Lifestyle modification" id="5">
					<fragment>Diet, weight reduction, and exercise can all be used to improve glycemic control, although the majority of elderly patients with type 2 diabetes will require medication over the course of their diabetes.</fragment>
				</section>
			</summary>
			<category term="C0012167" scheme="gov.nih.nlm.semanticType.topp" label="Diet, weight reduction"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H5"/>
			<id>171912</id>
			<summary>
				<section label="Lifestyle modification" id="5">
					<fragment>Medical nutrition therapy (MNT) is the process by which the nutrition prescription is tailored for people with diabetes based upon medical, lifestyle, and personal factors and is an integral component of diabetes management and diabetes self-management education.</fragment>
				</section>
			</summary>
			<category term="C1257928" scheme="gov.nih.nlm.semanticType.topp" label="Medical nutrition therapy"/>
			<category term="C2937349" scheme="gov.nih.nlm.semanticType.hlca" label="nutrition therapy"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H5"/>
			<id>171913</id>
			<summary>
				<section label="Lifestyle modification" id="5">
					<fragment>In a randomized trial of medical nutrition intervention in adults &gt;=65 years of age, patients in the intervention group had significantly greater improvements in fasting plasma glucose (-18.9 versus -1.4 mg/dL) and A1C (-0.5 percentage points versus no change) than control patients.</fragment>
				</section>
			</summary>
			<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H5"/>
			<id>171916</id>
			<summary>
				<section label="Lifestyle modification" id="5">
					<fragment>Thus, all elderly patients with diabetes should receive a medical nutrition evaluation.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H5"/>
			<id>171917</id>
			<summary>
				<section label="Lifestyle modification" id="5">
					<fragment>The choice of diet has important clinical considerations: Obese older adults with diabetes may benefit from caloric restriction and an increase in physical activity with a weight loss goal of approximately 5 percent of body weight.</fragment>
				</section>
			</summary>
			<category term="C1135809" scheme="gov.nih.nlm.semanticType.topp" label="caloric restriction"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H5"/>
			<id>171919</id>
			<summary>
				<section label="Lifestyle modification" id="5">
					<fragment>Weight loss increases the risk of morbidity and mortality in older adults.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H6"/>
			<id>171921</id>
			<summary>
				<section label="Drug therapy" id="6">
					<fragment>There are few data specifically addressing drug therapy in elderly patients.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C2003848" scheme="gov.nih.nlm.semanticType.topp" label="drug therapy"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H6"/>
			<id>171923</id>
			<summary>
				<section label="Drug therapy" id="6">
					<fragment>All of the types of oral hypoglycemic drugs and insulin are safe in older patients, although each has some limitations.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0020616" scheme="gov.nih.nlm.semanticType.phsu" label="hypoglycemic"/>
			<category term="C0359086" scheme="gov.nih.nlm.semanticType.phsu" label="oral hypoglycemic"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H6"/>
			<id>171928</id>
			<summary>
				<section label="Drug therapy" id="6">
					<fragment>For elderly patients who do not have contraindications to metformin (eg, renal impairment or severe heart failure), we prefer to initiate therapy with metformin.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H6"/>
			<id>171930</id>
			<summary>
				<section label="Drug therapy" id="6">
					<fragment>In a patient with chronic kidney disease who is intolerant of sulfonylureas, repaglinide could be considered as initial therapy.</fragment>
				</section>
			</summary>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
			<category term="C0246689" scheme="gov.nih.nlm.semanticType.phsu" label="repaglinide"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H6"/>
			<id>171934</id>
			<summary>
				<section label="Drug therapy" id="6">
					<fragment>As an alternative, family members or caregivers may be required to help administer medication.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H6"/>
			<id>171935</id>
			<summary>
				<section label="Drug therapy" id="6">
					<fragment>Indications for a second agent and therapeutic options for patients who fail initial therapy with lifestyle intervention and metformin or a sulfonylurea are similar in the elderly and in younger patients ).</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H7"/>
			<id>171937</id>
			<summary>
				<section label="Metformin" id="7">
					<fragment>Metformin is an attractive agent to use in the elderly due to a low risk of hypoglycemia.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="Metformin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H7"/>
			<id>171938</id>
			<summary>
				<section label="Metformin" id="7">
					<fragment>However, it should be given with caution in older diabetic patients because of the risk of lactic acidosis.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H7"/>
			<id>171939</id>
			<summary>
				<section label="Metformin" id="7">
					<fragment>Elderly patients often have impaired renal function despite an apparently normal serum creatinine concentration.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H7"/>
			<id>171942</id>
			<summary>
				<section label="Metformin" id="7">
					<fragment>Weight loss and gastrointestinal side effects may also be limiting factors in older adults taking metformin.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H7"/>
			<id>171943</id>
			<summary>
				<section label="Metformin" id="7">
					<fragment>Therefore, metformin should be used with caution in older patients.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H7"/>
			<id>171945</id>
			<summary>
				<section label="Metformin" id="7">
					<fragment>Any elderly patient treated with metformin should be cautioned to stop taking the drug immediately if they become ill for any reason, or if they are to undergo a procedure requiring the use of iodinated contrast material.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0278293" scheme="gov.nih.nlm.semanticType.topp" label="procedure"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H8"/>
			<id>171948</id>
			<summary>
				<section label="Sulfonylurea drugs" id="8">
					<fragment>Thus, we avoid the use of long-acting sulfonylureas in elderly adults.</fragment>
				</section>
			</summary>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H8"/>
			<id>171951</id>
			<summary>
				<section label="Sulfonylurea drugs" id="8">
					<fragment>In one observational study, the frequency in patients over age 65 treated with either glyburide or chlorpropamide was similar (16.6 episodes per 1000 person-years).</fragment>
				</section>
			</summary>
			<category term="C0008287" scheme="gov.nih.nlm.semanticType.phsu" label="chlorpropamide"/>
			<category term="C0017628" scheme="gov.nih.nlm.semanticType.phsu" label="glyburide"/>
			<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H8"/>
			<id>171952</id>
			<summary>
				<section label="Sulfonylurea drugs" id="8">
					<fragment>In contrast, in another study of 52 elderly patients treated with glyburide or the glipizide gastrointestinal therapeutic system (GITS), no episodes of hypoglycemia occurred during a 23-hour fast.</fragment>
				</section>
			</summary>
			<category term="C0017628" scheme="gov.nih.nlm.semanticType.phsu" label="glyburide"/>
			<category term="C0017642" scheme="gov.nih.nlm.semanticType.phsu" label="glipizide"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H8"/>
			<id>171956</id>
			<summary>
				<section label="Sulfonylurea drugs" id="8">
					<fragment>During therapy with salicylates, sulfonamides, fibric acid derivatives (such as gemfibrozil), and warfarin.</fragment>
				</section>
			</summary>
			<category term="C0017245" scheme="gov.nih.nlm.semanticType.phsu" label="gemfibrozil"/>
			<category term="C2936462" scheme="gov.nih.nlm.semanticType.orch" label="fibric acid"/>
			<category term="C2974226" scheme="gov.nih.nlm.semanticType.orch" label="salicylates"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H8"/>
			<id>171958</id>
			<summary>
				<section label="Sulfonylurea drugs" id="8">
					<fragment>These issues may arise when there is a change in overall health status in older adults with diabetes.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H8"/>
			<id>171959</id>
			<summary>
				<section label="Sulfonylurea drugs" id="8">
					<fragment>In patients who are using sulfonylurea drugs, the presence and frequency of hypoglycemia should be evaluated at each visit.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H9"/>
			<id>171960</id>
			<summary>
				<section label="Thiazolidinediones" id="9">
					<fragment>The thiazolidinediones (rosiglitazone and pioglitazone) improve insulin resistance.</fragment>
				</section>
			</summary>
			<category term="C0071097" scheme="gov.nih.nlm.semanticType.phsu" label="pioglitazone"/>
			<category term="C0289313" scheme="gov.nih.nlm.semanticType.phsu" label="rosiglitazone"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="C2605394" scheme="gov.nih.nlm.semanticType.orch" label="thiazolidinediones"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H9"/>
			<id>171961</id>
			<summary>
				<section label="Thiazolidinediones" id="9">
					<fragment>They also may increase insulin secretion in response to glucose, at least in patients with impaired glucose tolerance.</fragment>
				</section>
			</summary>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H9"/>
			<id>171962</id>
			<summary>
				<section label="Thiazolidinediones" id="9">
					<fragment>The thiazolidinediones may be considered for some older patients, particularly those with lower initial A1C values, if there are specific contraindications to sulfonylureas or if they are not able or willing to consider insulin.</fragment>
				</section>
			</summary>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="C2605394" scheme="gov.nih.nlm.semanticType.orch" label="thiazolidinediones"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H9"/>
			<id>171963</id>
			<summary>
				<section label="Thiazolidinediones" id="9">
					<fragment>They can be given to patients who have impaired renal function, are well tolerated in older adults, and do not cause hypoglycemia.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H9"/>
			<id>171964</id>
			<summary>
				<section label="Thiazolidinediones" id="9">
					<fragment>However, thiazolidinediones should not be used in patients with class III or IV heart failure.</fragment>
				</section>
			</summary>
			<category term="C2605394" scheme="gov.nih.nlm.semanticType.orch" label="thiazolidinediones"/>
			<category term="C3501774" scheme="gov.nih.nlm.semanticType.phsu" label="III"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H9"/>
			<id>171966</id>
			<summary>
				<section label="Thiazolidinediones" id="9">
					<fragment>If a thiazolidinedione is to be used as therapy, pioglitazone is preferred because of the greater concern about atherogenic lipid profiles and a potential increased risk for cardiovascular events with rosiglitazone.</fragment>
				</section>
			</summary>
			<category term="C0023767" scheme="gov.nih.nlm.semanticType.imft" label="lipid"/>
			<category term="C0071097" scheme="gov.nih.nlm.semanticType.phsu" label="pioglitazone"/>
			<category term="C0289313" scheme="gov.nih.nlm.semanticType.phsu" label="rosiglitazone"/>
			<category term="C2605394" scheme="gov.nih.nlm.semanticType.orch" label="thiazolidinedione"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H9"/>
			<id>171969</id>
			<summary>
				<section label="Thiazolidinediones" id="9">
					<fragment>New concerns regarding increased risk for bladder cancer with pioglitazone, in addition to fluid retention and bone loss, have led to decreased enthusiasm for its use.</fragment>
				</section>
			</summary>
			<category term="C0071097" scheme="gov.nih.nlm.semanticType.phsu" label="pioglitazone"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H10"/>
			<id>171970</id>
			<summary>
				<section label="Meglitinides" id="10">
					<fragment>Repaglinide and nateglinide are short-acting glucose-lowering drugs that act similarly to the sulfonylureas and have similar or slightly less efficacy in decreasing glycemia.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
			<category term="C0246689" scheme="gov.nih.nlm.semanticType.phsu" label="Repaglinide"/>
			<category term="C0903898" scheme="gov.nih.nlm.semanticType.phsu" label="nateglinide"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H10"/>
			<id>171971</id>
			<summary>
				<section label="Meglitinides" id="10">
					<fragment>Meglitinides are pharmacologically distinct from sulfonylureas and may be used in patients who have allergy to sulfonylurea medications.</fragment>
				</section>
			</summary>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H10"/>
			<id>171974</id>
			<summary>
				<section label="Meglitinides" id="10">
					<fragment>Dose adjustments with this agent do not appear to be necessary in patients with renal insufficiency.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H10"/>
			<id>171975</id>
			<summary>
				<section label="Meglitinides" id="10">
					<fragment>In addition, repaglinide is somewhat more effective in lowering A1C than nateglinide.</fragment>
				</section>
			</summary>
			<category term="C0246689" scheme="gov.nih.nlm.semanticType.phsu" label="repaglinide"/>
			<category term="C0903898" scheme="gov.nih.nlm.semanticType.phsu" label="nateglinide"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H10"/>
			<id>171976</id>
			<summary>
				<section label="Meglitinides" id="10">
					<fragment>Thus, repaglinide could be considered as initial therapy in a patient with chronic kidney disease who is intolerant of metformin and sulfonylureas.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
			<category term="C0246689" scheme="gov.nih.nlm.semanticType.phsu" label="repaglinide"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H11"/>
			<id>171977</id>
			<summary>
				<section label="glucosidase inhibitors" id="11">
					<fragment>Acarbose and miglitol inhibit the gastrointestinal alpha-glucosidases that convert dietary starch and other complex carbohydrates into monosaccharides, thereby slowing the absorption of glucose, which results in a slower rise in postprandial blood glucose concentrations.</fragment>
				</section>
			</summary>
			<category term="C0050393" scheme="gov.nih.nlm.semanticType.phsu" label="Acarbose"/>
			<category term="C0066535" scheme="gov.nih.nlm.semanticType.phsu" label="miglitol"/>
			<category term="C1979844" scheme="gov.nih.nlm.semanticType.aapp" label="alpha"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H11"/>
			<id>171979</id>
			<summary>
				<section label="glucosidase inhibitors" id="11">
					<fragment>Acarbose and miglitol have not been widely tested in elderly diabetic patients, but are likely to be fairly safe and effective.</fragment>
				</section>
			</summary>
			<category term="C0050393" scheme="gov.nih.nlm.semanticType.phsu" label="Acarbose"/>
			<category term="C0066535" scheme="gov.nih.nlm.semanticType.phsu" label="miglitol"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H12"/>
			<id>171985</id>
			<summary>
				<section label="IV inhibitors" id="12">
					<fragment>DPP-IV inhibitors have no risk of hypoglycemia and are weight-neutral, when used as monotherapy, and therefore may be attractive agents to use in the elderly.</fragment>
				</section>
			</summary>
			<category term="C0669693" scheme="gov.nih.nlm.semanticType.orch" label="DPP"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H12"/>
			<id>171987</id>
			<summary>
				<section label="IV inhibitors" id="12">
					<fragment>The dose of DPP-IV inhibitors should be adjusted in patients with renal insufficiency.</fragment>
				</section>
			</summary>
			<category term="C0669693" scheme="gov.nih.nlm.semanticType.orch" label="DPP"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H13"/>
			<id>171988</id>
			<summary>
				<section label="1 therapies" id="13">
					<fragment>The role of gastrointestinal peptides in glucose homeostasis is illustrated by the incretin effect, in which oral glucose has a greater stimulatory effect on insulin secretion than intravenous glucose.</fragment>
				</section>
			</summary>
			<category term="C0357164" scheme="gov.nih.nlm.semanticType.phsu" label="intravenous glucose"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="C1562292" scheme="gov.nih.nlm.semanticType.horm" label="incretin"/>
			<category term="C2354520" scheme="gov.nih.nlm.semanticType.aapp" label="peptides"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H13"/>
			<id>171990</id>
			<summary>
				<section label="1 therapies" id="13">
					<fragment>Exenatide and liraglutide are GLP-1 analog agents available for use as monotherapy as an adjunct to diet and exercise or in combination with oral agents in adults with type 2 diabetes.</fragment>
				</section>
			</summary>
			<category term="C0167117" scheme="gov.nih.nlm.semanticType.phsu" label="Exenatide"/>
			<category term="C0763866" scheme="gov.nih.nlm.semanticType.aapp" label="GLP"/>
			<category term="C1456408" scheme="gov.nih.nlm.semanticType.horm" label="liraglutide"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H13"/>
			<id>171992</id>
			<summary>
				<section label="1 therapies" id="13">
					<fragment>There is no risk of hypoglycemia with the use of GLP-1 analogs alone.</fragment>
				</section>
			</summary>
			<category term="C0763866" scheme="gov.nih.nlm.semanticType.aapp" label="GLP"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H13"/>
			<id>171995</id>
			<summary>
				<section label="1 therapies" id="13">
					<fragment>There have been postmarketing reports of acute pancreatitis and deterioration in renal function in patients taking GLP-1 therapies.</fragment>
				</section>
			</summary>
			<category term="C0763866" scheme="gov.nih.nlm.semanticType.aapp" label="GLP"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H13"/>
			<id>171997</id>
			<summary>
				<section label="1 therapies" id="13">
					<fragment>Due to concerns about renal toxicity, exenatide should not be used in patients with a creatinine clearance below 30 mL/min.</fragment>
				</section>
			</summary>
			<category term="C0167117" scheme="gov.nih.nlm.semanticType.phsu" label="exenatide"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H14"/>
			<id>171998</id>
			<summary>
				<section label="Pramlintide" id="14">
					<fragment>Pramlintide is a synthetic analog of amylin that is administered by mealtime subcutaneous injection with insulin.</fragment>
				</section>
			</summary>
			<category term="C0063684" scheme="gov.nih.nlm.semanticType.horm" label="amylin"/>
			<category term="C0537551" scheme="gov.nih.nlm.semanticType.horm" label="Pramlintide"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H15"/>
			<id>172002</id>
			<summary>
				<section label="Insulin" id="15">
					<fragment>With the availability of long-acting insulins, it has become easier to use once daily long-acting insulin as monotherapy or add once daily insulin to oral hypoglycemic medications in older patients who have suboptimal glycemic control.</fragment>
				</section>
			</summary>
			<category term="C0002860" scheme="gov.nih.nlm.semanticType.horm" label="add"/>
			<category term="C0020616" scheme="gov.nih.nlm.semanticType.phsu" label="hypoglycemic"/>
			<category term="C0304870" scheme="gov.nih.nlm.semanticType.horm" label="long-acting insulins"/>
			<category term="C0359086" scheme="gov.nih.nlm.semanticType.phsu" label="oral hypoglycemic"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulins"/>
			<category term="C1528990" scheme="gov.nih.nlm.semanticType.orch" label="acting"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H15"/>
			<id>172003</id>
			<summary>
				<section label="Insulin" id="15">
					<fragment>Patients may wrongly assume that their symptoms of fatigue are due to "old age" rather than hyperglycemia.</fragment>
				</section>
			</summary>
			<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H15"/>
			<id>172005</id>
			<summary>
				<section label="Insulin" id="15">
					<fragment>Before beginning insulin therapy, it is important to evaluate whether or not the patient is physically and cognitively capable of using an insulin pen or drawing up and giving the appropriate dose of insulin (using syringes and vials), monitoring blood glucose, and recognizing and treating hypoglycemia.</fragment>
				</section>
			</summary>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="C1564509" scheme="gov.nih.nlm.semanticType.antb" label="pen"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H15"/>
			<id>172006</id>
			<summary>
				<section label="Insulin" id="15">
					<fragment>For elderly patients taking a fixed daily dose of insulin and who are capable of giving the insulin shot but not of drawing it up, a pharmacist or family member may prepare a week's supply of insulin in syringes and leave them in the refrigerator.</fragment>
				</section>
			</summary>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H15"/>
			<id>172008</id>
			<summary>
				<section label="Insulin" id="15">
					<fragment>Insulin metabolism is altered in patients with chronic renal failure, so that less insulin is needed when the glomerular filtration rate is below 50 mL/min.</fragment>
				</section>
			</summary>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="Insulin"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H16"/>
			<id>172013</id>
			<summary>
				<section label="Monitoring of blood glucose" id="16">
					<fragment>The effectiveness of self monitoring of blood glucose (SMBG) in terms of improving glycemic control in patients with type 2 diabetes is less clear than for type 1 diabetes.</fragment>
				</section>
			</summary>
			<category term="C0588436" scheme="gov.nih.nlm.semanticType.topp" label="self monitoring"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H16"/>
			<id>172014</id>
			<summary>
				<section label="Monitoring of blood glucose" id="16">
					<fragment>SMBG may be helpful in elderly patients with type 2 diabetes who take medications that can cause hypoglycemia (eg, insulin).</fragment>
				</section>
			</summary>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H16"/>
			<id>172016</id>
			<summary>
				<section label="Monitoring of blood glucose" id="16">
					<fragment>However, self-monitoring of glucose may not be necessary at all, or only in unusual circumstances, for elderly patients with type 2 diabetes who are diet-treated or who are treated with oral agents not associated with hypoglycemia.</fragment>
				</section>
			</summary>
			<category term="C0588436" scheme="gov.nih.nlm.semanticType.topp" label="self-monitoring"/>
			<category term="4" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H17"/>
			<id>172018</id>
			<summary>
				<section label="SCREENING FOR MICROVASCULAR COMPLICATIONS" id="17">
					<fragment>Retinopathy, nephropathy, and foot problems are all important complications of diabetes mellitus in elderly patients.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H17"/>
			<id>172019</id>
			<summary>
				<section label="SCREENING FOR MICROVASCULAR COMPLICATIONS" id="17">
					<fragment>Monitoring recommendations for elderly patients with diabetes are similar to those in younger patients.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H18"/>
			<id>172021</id>
			<summary>
				<section label="Retinopathy" id="18">
					<fragment>Regular eye examinations are extremely important for elderly diabetic patients because poor vision can lead to social isolation, an increased risk of accidents, and impaired ability to measure blood glucose and draw up insulin doses.</fragment>
				</section>
			</summary>
			<category term="C0200149" scheme="gov.nih.nlm.semanticType.hlca" label="eye examinations"/>
			<category term="C0640640" scheme="gov.nih.nlm.semanticType.orch" label="doses"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H18"/>
			<id>172023</id>
			<summary>
				<section label="Retinopathy" id="18">
					<fragment>The purpose is to screen not only for diabetic retinopathy but also for cataracts and glaucoma, which are more common in elderly diabetic compared with nondiabetic subjects.</fragment>
				</section>
			</summary>
			<category term="C3263684" scheme="gov.nih.nlm.semanticType.topp" label="screen"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H18"/>
			<id>172024</id>
			<summary>
				<section label="Retinopathy" id="18">
					<fragment>Cataracts are over twice as common in people over age 65 years with diabetes compared with similarly aged nondiabetic subjects (38.4 percent versus 16.6 percent), while glaucoma is almost three times more common (11.2 percent versus 3.8 percent).</fragment>
				</section>
			</summary>
			<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H19"/>
			<id>172025</id>
			<summary>
				<section label="Nephropathy" id="19">
					<fragment>The availability of effective therapy for diabetic nephropathy with angiotensin-converting enzyme (ACE) inhibitors has led to the recommendation that all patients with diabetes be screened for increased urinary albumin excretion annually.</fragment>
				</section>
			</summary>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE) inhibitors"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="C3263684" scheme="gov.nih.nlm.semanticType.topp" label="screened"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H19"/>
			<id>172027</id>
			<summary>
				<section label="Nephropathy" id="19">
					<fragment>For elderly patients who are already taking an ACE inhibitor or ACE receptor blocker, it may not be necessary or helpful to continue testing for increased urinary albumin excretion on an annual basis.</fragment>
				</section>
			</summary>
			<category term="C0003015" scheme="gov.nih.nlm.semanticType.phsu" label="ACE inhibitor"/>
			<category term="C2703199" scheme="gov.nih.nlm.semanticType.phsu" label="ACE"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H20"/>
			<id>172028</id>
			<summary>
				<section label="Foot problems" id="20">
					<fragment>Foot problems are an important cause of morbidity in patients with diabetes, and the risk of them is much higher in older patients.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H20"/>
			<id>172030</id>
			<summary>
				<section label="Foot problems" id="20">
					<fragment>It is estimated, for example, that the prevalence of diabetic neuropathy in patients with type 2 diabetes is 32 percent overall and more than 50 percent in patients over age 60 years.</fragment>
				</section>
			</summary>
			<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H20"/>
			<id>172031</id>
			<summary>
				<section label="Foot problems" id="20">
					<fragment>In addition to the increasing prevalence of neuropathy with age, more than 30 percent of older diabetic patients cannot see or reach their feet, and may therefore be unable to perform routine foot inspections.</fragment>
				</section>
			</summary>
			<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H20"/>
			<id>172032</id>
			<summary>
				<section label="Foot problems" id="20">
					<fragment>We recommend that elderly diabetic patients have their feet examined at every visit;</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H20"/>
			<id>172036</id>
			<summary>
				<section label="Foot problems" id="20">
					<fragment>It is also important that prophylactic advice on foot care be given to any patient whose feet are at high risk.</fragment>
				</section>
			</summary>
			<category term="C0150240" scheme="gov.nih.nlm.semanticType.topp" label="foot care"/>
			<category term="C0150600" scheme="gov.nih.nlm.semanticType.hlca" label="advice"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H21"/>
			<id>172038</id>
			<summary>
				<section label="CARDIOVASCULAR RISK REDUCTION" id="21">
					<fragment>It is therefore not surprising that coronary heart disease is by far the leading cause of death in elderly patients with diabetes, and that the effect of most interventions is more pronounced in them.</fragment>
				</section>
			</summary>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H22"/>
			<id>172044</id>
			<summary>
				<section label="Smoking cessation" id="22">
					<fragment>Smoking in patients with diabetes mellitus is an independent risk factor for all-cause mortality, due largely to cardiovascular disease.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H23"/>
			<id>172046</id>
			<summary>
				<section label="Treatment of hypertension" id="23">
					<fragment>Treatment of hypertension in elderly patients is clearly beneficial, including patients over age 80.</fragment>
				</section>
			</summary>
			<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H23"/>
			<id>172047</id>
			<summary>
				<section label="Treatment of hypertension" id="23">
					<fragment>Recommended therapeutic goals and drug options for patients with diabetes and the elderly are reviewed in detail elsewhere.</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H24"/>
			<id>172048</id>
			<summary>
				<section label="Treatment of dyslipidemia" id="24">
					<fragment>Several abnormalities in lipid metabolism may contribute to the increase in atherosclerosis associated with diabetes.</fragment>
				</section>
			</summary>
			<category term="C0023767" scheme="gov.nih.nlm.semanticType.imft" label="lipid"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H24"/>
			<id>172050</id>
			<summary>
				<section label="Treatment of dyslipidemia" id="24">
					<fragment>In addition, the relative reduction of cardiovascular disease with serum LDL reduction is similar in elderly and younger patients with diabetes.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H24"/>
			<id>172051</id>
			<summary>
				<section label="Treatment of dyslipidemia" id="24">
					<fragment>We recommend use of a statin drug (unless contraindicated) to lower cholesterol in all elderly diabetics with a persistent LDL cholesterol value above 100 mg/dL (2.6 mmol/L), with a goal of reducing LDL below 100 mg/dL (2.6 mmol/L).</fragment>
				</section>
			</summary>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drug"/>
			<category term="C0360714" scheme="gov.nih.nlm.semanticType.phsu" label="statin"/>
			<category term="C0625158" scheme="gov.nih.nlm.semanticType.phsu" label="cholesterol"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H24"/>
			<id>172052</id>
			<summary>
				<section label="Treatment of dyslipidemia" id="24">
					<fragment>In patients with diabetes who already have cardiovascular disease, a goal LDL of 70 to 80 mg/dL (1.8 to 2.1 mmol/L) is warranted, particularly in very high-risk patients.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H24"/>
			<id>172054</id>
			<summary>
				<section label="Treatment of dyslipidemia" id="24">
					<fragment>More detailed information on the use of lipid-lowering drugs for secondary prevention of CHD is found elsewhere.</fragment>
				</section>
			</summary>
			<category term="C0003367" scheme="gov.nih.nlm.semanticType.phsu" label="lipid-lowering drugs"/>
			<category term="C0013227" scheme="gov.nih.nlm.semanticType.phsu" label="drugs"/>
			<category term="C0023767" scheme="gov.nih.nlm.semanticType.imft" label="lipid"/>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
			<category term="C0679699" scheme="gov.nih.nlm.semanticType.topp" label="secondary prevention"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H25"/>
			<id>172056</id>
			<summary>
				<section label="Aspirin" id="25">
					<fragment>The value of daily aspirin therapy in patients with known macrovascular disease (secondary prevention) is widely accepted.</fragment>
				</section>
			</summary>
			<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
			<category term="C0679699" scheme="gov.nih.nlm.semanticType.topp" label="secondary prevention"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H25"/>
			<id>172058</id>
			<summary>
				<section label="Aspirin" id="25">
					<fragment>The role of aspirin for the primary prevention of cardiovascular events in patients with diabetes is less certain.</fragment>
				</section>
			</summary>
			<category term="C0004057" scheme="gov.nih.nlm.semanticType.phsu" label="aspirin"/>
			<category term="C0033144" scheme="gov.nih.nlm.semanticType.topp" label="primary prevention"/>
			<category term="C0199176" scheme="gov.nih.nlm.semanticType.topp" label="prevention"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H26"/>
			<id>172060</id>
			<summary>
				<section label="Exercise" id="26">
					<fragment>Exercise is beneficial to help maintain physical function, reduce cardiac risk, and improve insulin sensitivity in patients with diabetes.</fragment>
				</section>
			</summary>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H26"/>
			<id>172062</id>
			<summary>
				<section label="Exercise" id="26">
					<fragment>Studies of frail elderly people have shown that weight training should be included in addition to aerobic exercises.</fragment>
				</section>
			</summary>
			<category term="C0001701" scheme="gov.nih.nlm.semanticType.topp" label="aerobic exercises"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H28"/>
			<id>172064</id>
			<summary>
				<section label="Cognitive impairment" id="28">
					<fragment>Diabetes is associated with increased risk of dementia.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H28"/>
			<id>172065</id>
			<summary>
				<section label="Cognitive impairment" id="28">
					<fragment>Many older patients with dementia remain undiagnosed, particularly in the early stages.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H28"/>
			<id>172066</id>
			<summary>
				<section label="Cognitive impairment" id="28">
					<fragment>Elderly patients with diabetes and cognitive dysfunction may have difficulty performing self-management and following complicated treatment regimens.</fragment>
				</section>
			</summary>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimens"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H28"/>
			<id>172067</id>
			<summary>
				<section label="Cognitive impairment" id="28">
					<fragment>Cognitive function should be assessed in elderly diabetic patients when there is: Nonadherence with therapy.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H29"/>
			<id>172070</id>
			<summary>
				<section label="Depression" id="29">
					<fragment>Depression occurs at a higher rate in older patients with diabetes compared with age-matched controls.</fragment>
				</section>
			</summary>
			<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H29"/>
			<id>172071</id>
			<summary>
				<section label="Depression" id="29">
					<fragment>Depression is frequently undiagnosed and remains untreated in this high risk population.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H29"/>
			<id>172072</id>
			<summary>
				<section label="Depression" id="29">
					<fragment>Depression has been associated with poor glycemic control and with accelerated rates of coronary heart disease in diabetic patients.</fragment>
				</section>
			</summary>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H31"/>
			<id>172078</id>
			<summary>
				<section label="Falls" id="31">
					<fragment>The increased risk of falls in older adults with diabetes is multifactorial.</fragment>
				</section>
			</summary>
			<category term="C0292977" scheme="gov.nih.nlm.semanticType.phsu" label="falls"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H31"/>
			<id>172079</id>
			<summary>
				<section label="Falls" id="31">
					<fragment>Presence of peripheral and/or autonomic neuropathy, reduced renal function, muscle weakness, functional disability, loss of vision, polypharmacy, comorbidities like osteoarthritis, and even mild hypoglycemia may contribute to falls in frail older adults.</fragment>
				</section>
			</summary>
			<category term="C0292977" scheme="gov.nih.nlm.semanticType.phsu" label="falls"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H31"/>
			<id>172080</id>
			<summary>
				<section label="Falls" id="31">
					<fragment>While good glycemic control prevents progression of some diabetes complications and therefore may decrease the risk of falls, hypoglycemia that occurs as a result of intensive glycemic control may increase the risk of falls.</fragment>
				</section>
			</summary>
			<category term="C0292977" scheme="gov.nih.nlm.semanticType.phsu" label="falls"/>
			<category term="C0309872" scheme="gov.nih.nlm.semanticType.phsu" label="prevents"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H31"/>
			<id>172081</id>
			<summary>
				<section label="Falls" id="31">
					<fragment>In a prospective observational study of 446 elderly adults with diabetes (mean age 74 years), intensive glycemic control (A1C &lt;=6 versus &gt;8 percent) was associated with an increased risk of falls in insulin users (odds ratio 4.4, 95% CI 1.3-14.5) but not in those treated with oral agents (OR 1.3, 95% CI 0.7-2.5).</fragment>
				</section>
			</summary>
			<category term="C0292977" scheme="gov.nih.nlm.semanticType.phsu" label="falls"/>
			<category term="C0910022" scheme="gov.nih.nlm.semanticType.topp" label="age"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="C2354505" scheme="gov.nih.nlm.semanticType.orch" label="CI"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H31"/>
			<id>172082</id>
			<summary>
				<section label="Falls" id="31">
					<fragment>Potential reasons for the discrepancy include a greater duration or severity of diabetes or a greater number of hypoglycemic episodes in patients treated with insulin versus oral agents, possibilities which were not rigorously explored in this observational study.</fragment>
				</section>
			</summary>
			<category term="C0020616" scheme="gov.nih.nlm.semanticType.phsu" label="hypoglycemic"/>
			<category term="C0308902" scheme="gov.nih.nlm.semanticType.phsu" label="duration"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="6" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H31"/>
			<id>172083</id>
			<summary>
				<section label="Falls" id="31">
					<fragment>Nevertheless, the benefits of improved glycemic control to reduce diabetes-related complications (and decrease risk of falls) must be balanced with the possible increased risk of falls with intensive insulin therapy.</fragment>
				</section>
			</summary>
			<category term="C0292977" scheme="gov.nih.nlm.semanticType.phsu" label="falls"/>
			<category term="C0308403" scheme="gov.nih.nlm.semanticType.phsu" label="balanced"/>
			<category term="C0915897" scheme="gov.nih.nlm.semanticType.phsu" label="insulin"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H32"/>
			<id>172085</id>
			<summary>
				<section label="Urinary incontinence" id="32">
					<fragment>Diabetes increases a woman's risk of developing urinary incontinence.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H32"/>
			<id>172086</id>
			<summary>
				<section label="Urinary incontinence" id="32">
					<fragment>Risk factors include urinary tract infection, vaginal infection, autonomic neuropathy (resulting in either neurogenic bladder or fecal impaction) and polyuria due to hyperglycemia.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H32"/>
			<id>172087</id>
			<summary>
				<section label="Urinary incontinence" id="32">
					<fragment>Although there is no direct evidence to suggest deleterious effect of incontinence on diabetes control, identification and treatment are recommended to improve quality of life in women.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H33"/>
			<id>172090</id>
			<summary>
				<section label="Nursing home patients" id="33">
					<fragment>Exercise as tolerated in any form continues to be important for all patients.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H33"/>
			<id>172092</id>
			<summary>
				<section label="Nursing home patients" id="33">
					<fragment>Treatment regimens should be chosen to achieve maximal glycemic control possible, with a focus on avoidance of hypoglycemia and control of hyperglycemic symptoms.</fragment>
				</section>
			</summary>
			<category term="C0386586" scheme="gov.nih.nlm.semanticType.topp" label="regimens"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H34"/>
			<id>172097</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="34">
					<fragment>Thus, avoidance of hypoglycemia is an important consideration in establishing goals and choosing therapeutic agents in elderly adults.</fragment>
				</section>
			</summary>
			<category term="C1611640" scheme="gov.nih.nlm.semanticType.phsu" label="therapeutic agents"/>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H34"/>
			<id>172098</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="34">
					<fragment>Elderly patients with diabetes should receive individualized counseling regarding lifestyle modification, including a medical nutrition evaluation.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H34"/>
			<id>172099</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="34">
					<fragment>The nutrition prescription is tailored for elderly people with diabetes based upon medical, lifestyle, and personal factors.</fragment>
				</section>
			</summary>
			<category term="1" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H34"/>
			<id>172100</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="34">
					<fragment>In the absence of specific contraindications, we suggest metformin as initial therapy for elderly patients with diabetes.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="3" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H34"/>
			<id>172102</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="34">
					<fragment>In patients who are intolerant of or are not candidates for metformin or sulfonylureas, repaglinide is a reasonable alternative, particularly in a patient with chronic kidney disease at risk for hypoglycemia.</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylureas"/>
			<category term="C0246689" scheme="gov.nih.nlm.semanticType.phsu" label="repaglinide"/>
			<category term="5" scheme="org.openInfobutton.score"/>
		</entry>
		<entry>
			<link href="http://www.uptodate.com/contents/1776#H34"/>
			<id>172108</id>
			<summary>
				<section label="SUMMARY AND RECOMMENDATIONS" id="34">
					<fragment>Indications for a second agent and therapeutic options for patients who fail initial therapy with lifestyle intervention and metformin or a sulfonylurea are similar in the elderly and in younger patients ).</fragment>
				</section>
			</summary>
			<category term="C0025598" scheme="gov.nih.nlm.semanticType.phsu" label="metformin"/>
			<category term="C0038766" scheme="gov.nih.nlm.semanticType.phsu" label="sulfonylurea"/>
			<category term="2" scheme="org.openInfobutton.score"/>
		</entry>
	</feed>
</aggregateKnowledgeResponse>
